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ABSTRACT 
In the present day societies chemicals play vital roles in the 
well-being and effective functioning of the people. But chemicals, 
including drugs implies not only the desired benefits but also 
adverse effects and we are compelled to compromise between 
costs and benefits. The extent to which human population is 
exposed to different types of environmental agents, chemicals and 
drugs is alarming. 
Human cytogenetics began in the mid 1950s with the 
development of human tissue culture technique. The emergence 
of the discipline was very much facilitated by the facts: (i) that 
human peripheral blood T lymphocytes could be readily, stimulated 
to undergo mitosis in short term culture; (ii) that these cells were 
easily available in large quantity from a few drops of blood 
obtained from virtually any individual; and (iii) that stimulated 
lymphocytes were ideal cells from the point of view of producing 
well spread metaphase chromosomes. 
The birth of human cytogenetics resulted in the fast and to 
the point assessment of the effects of mutagens at chromosome 
level. Modern human cytogenetics of course is not confined to 
the study of human chromosomes in lymphocytes only but a wide 
variety of cells have been subject to analysis in case of studies on 
human genotoxicity. 
Human peripheral blood lymphocyte is an extremely sensitive 
indicator in both in vitro and in vivo tests" of induced chromosomal 
changes. There are various classes of chromosomal changes that 
can be induced by exposure to chemical substances. These changes 
are categorised as structural and numerical chromosomal 
alterations and sister chromatid exchanges. Cell cycle kinetics 
analysis is another sensitive method for detecting delay or 
stimulation in human lymphocyte cultures due to any genotoxic 
substance. 
Hormones play an important role in the growth, metabolic 
regulations and control of many vital functions. Several steroidal 
hormones and their synthetic derivatives are being used 
therapeutically. Sex steroids are used as medicine for human for a 
large variety of conditions viz. in the treatment of dysmenorrhoea, 
endometriosis dysfunctional uterine bleeding, climacterics and in 
the prevention of postmenopausal osteoporosis. Several 
corticosteroids have been reported to possess anti-inflammatory, 
anaesthetic, anabolic, angiostatic, antiangiogenic, cardioactive and 
antidiabetic activities. 
Keeping in view, the practical applications of these steroidal 
drugs a genotoxicity study through the battery of in vitro and in 
vivo assays had been attempted to see the effect of these steroids 
on human lymphocyte chromosomes. The influence of these drugs 
were also evaluated in the presence of metabolic activation system 
(S^ mix). Some adverse/side effects were also recorded from the 
drug users to correlate, if any, the severe symptoms with the 
genotoxicity of the drug. 
The parameters used in the present study included 
chromosomal aberrations (CAs), sister chromatid exchange (SCE) 
analysis and cell growth kinetics assay in the absence as well as in 
the presence of exogenous metabolic activation system (S^ mix). 
In the in vivo study two types of controls, i.e. normal and healthy 
people and patients before taking steroidal drugs were taken for 
comparison of the data. Blood was collected from the patients 
who were using the drug for atleast one to three months. The 
student 't' test (paired) was applied for chromosomal aberrations 
and sister chromatid exchanges. The 2x3 chi-square test was used 
for cell growth kinetics studies. The level of significance was 
compared at p < 0.05 for all the parameters. Lymphocytes were 
exposed to all drugs for three different durations (i.e. 24, 48 and 
72 h) and for three different dose concentrations. 
In the in vitro study, among progestins, medroxyprogesterone 
acetate caused CAs at 25 and 50 j^g/ml concentrations. At 25 jug/ 
ml the values of CAs were 19.50%, 21.00% and 27.67% for 24, 
48 and 72 h. of incubations respectively, which were highly 
significant at p < 0.05 compared to normal control value. At 25 
(ig/ml concentration also the drug caused significant increase in 
the frequency of CAs which were 21.00%, 21.67% and 32.33% at 
24, 48 and 72 h. of incubations respectively. In the presence of 
metabolic activation (S^ mix) also, the values were 10.00%, 22.50% 
and 33.50% at 10, 25 and 50 |Lig/ml of concentrations respectively. 
The maximum frequency of SCE per cell was found to be 
4.50+1.24 at 50 j^ g of concentrations which is highly significant 
when compared with the mean SCE value of normal control 
(1.72+0.14). In the presence of metabolic activation the values of 
SCE frequencies were 4.22+0.39 and 6.20+1.32 at 25 and 50 fig/ 
ml concentrations respectively which were highly significant. In 
the cell growth kinetics study the drug significantly affected the 
replication index (RI). At 25 fig/ml and 50 jug/ml the RI were 
1.53 and 1.56 respectively while it was 1.73 for the normal control. 
At 10 ng/ml the drug did not affect any parameters significantly 
at any duration. 
Hydroxyprogesterone caproate was unable to cause any 
damage to the genetic material at all concentrations and at all 
durations while megestrol acetate induced maximum increase in 
the frequencies of CAs and SCEs at 25 jiig/ml concentration only. 
At 10 and 50 |ig/ml the drug did not affect the result significantly. 
The decrease in the chromosomal aberrations at highest dose 
concentration may be attributed to the toxic effect of the drug at 
this concentration on the mitotic index. The results show similar 
pattern for SCE and cell growth kinetics analysis also. In the 
presence of metabolic activation also the results have same trend. 
Among corticosteroids evaluated in the present work 
Triamcinolone induced CAs and SCEs and affected RI in the 
presence of metabolic activation (S^ mix) only. The values were 
13.00% and 18.50% at 50 and 100 ^g/ml of concentrations 
respectively with S^  mix. These values were significant compared 
to the normal control (4.50%) at p < 0.05. The value of SCE 
frequencies were 3.96+0.19 and 4.40+0.21 at 50 and 100 jug/ml 
concentrations respectively which were significant compared to 
normal control (1.56+0.12). At 100 jxg/ml concentration 
triamcinolone depleted RI significantly which was 1.56 compared 
to normal control 1.65. The differences in the in vitro study without 
metabolic activation and with metabolic activation and in vivo 
studies can be explained on the basis of the fact that some 
chemicals and drugs are not mutagenic and clastogenic by 
themselves but require metabolic activation. It is probable that 
the products of triamcinolone metabolism could be clastogenic. 
Another corticosteroidal drug prednisolone was unable to 
cause CAs at any concentration and time duration. The maximum 
frequency of CAs at 20 )ig/ml was 3.67% for 72 h of time duration 
and it was 5.00% at both 40 and 75 jag/ml of concentration. RI 
was also unaffected at all concentrations and time durations. In 
the presence of metabolic activation also no significant result was 
obtained. Betamethasone was the only steroidal drug among three 
corticosteroids which was able to affect the genetic material 
significantly both without and with metabolic activation system 
(S^ mix). At 25 i^g/ml concentration it induced highest CAs at 72 
h duration (26.00%) and at 50 |ig/ml the value of CAs was 29.33% 
at 24 h duration which was highly significant compared to normal 
control value (2.33%). The drug did not show significant result at 
48 and 72 h duration for 50 i^g/ml concentrations, which may be 
attributed to the cell killing effect of the drug at high concentrations 
and longer time durations. 
For in vivo study blood was collected from the persons using 
the above steroidal drugs for one to three months continuously. 
The results obtained in the study show more or less similar pattern 
as obtained in the in vitro study. But in most of the cases the 
values are markedly less than the in vitro study. The differences 
may be due to the inherent capability of the human body systems 
to repair the genetic damage and metabolise any genotoxic 
chemical to less genotoxic form or harmless form. 
Very small sample study has been done for recording adverse/ 
side effects among the patients continuously exposed to the test 
steroidal drugs for atleast 1 to 3 months. It was found that few 
adverse effects are severe among some drug users while others 
are mild and few drug users did not experience any side effects. 
Vomiting, headache, hypersensitivity, sweating, fatigue, 
drowsiness, rash etc. were severe among the progestin users. 
Corticosteroidal drugs caused severe dizziness, depression, acne, 
delayed wound healing and coughing among the patients. 
Any genetic damage occurring in germ cells of a person taking 
these drugs would only be manifested in his or her offspring either 
in the form of single gene mutations or chromosome abnormalities 
leading to teratogenesis or carcinogenesis. Even if a recessive 
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mutation or balanced chromosome abnormality is not expressed 
in the first generation, it could possibly manifest several generations 
later, due to fetal germ or somatic cell mutations. 
It is, therefore, advisable to be careful of the potential hazards 
of these drugs to which we are continuously exposed to day in 
and out in modern life. This demands the lowest possible use of 
effective and acceptable doses of these drugs so as to minimise 
any potential risk. Otherwise they may become capable of attaching 
the genetic material directly in their unmetabolised as well as 
metabolised state. 
Studies conducted in vivo assume greater importance as they 
present real evidence per se of the hazardous effects undergoing 
by the cells. Their long term effect may further exacerbate the 
genotoxic effect in the life span of the organism itself and may 
assume serious damage to life itself. 
Therefore, extreme care should be taken of the potential 
hazards of possible genotoxic steroidal drugs, especially if they 
are used for longer periods of time. 
CYTOGENETIC AND CLINICAL STUDIES OF 
CERTAIN STEROIDS ON HUMAN 
CHROMOSOMES 
SUBMITTED FOR THE AWARD OF THE DEGREE OF 
JBottor of $]bilo£iDpt)P 
IN 
I! i < ZOOLOGY 
(GENETICS): 
y J. 
§\"4 
iV^ 
BY 
G. G. HAMMAD AHMAD SHADAB 
SECTION OF GENETICS 
DEPARTMENT OF ZOOLOGY 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH (U.P.)INDIA 
2000 
T5403 
• • i External : 400920/21-300/301 
^^°°" \ Internal : 300/301 
D E P A R T M E N T O F Z O O L O G Y 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH—202 002 
INDIA 
Sections : 
1. AGRICULTURAL NEMATOLOGY D. No. I / Z D 
2. ENTOMOLOGY 
' 4'. GENE'JICI""*''' * ''°^^'=^'^"''' Dated 3 / . /O,..2^.GP.©.... 
5. PARASITOLOGY 
CERTIFICATE 
I feel great pleasure in forwarding the thesis entitled, "Cytogenetic 
and clinical studies of certain steroids on human 
chromosomes" submitted by Mr. G.G. Hammad Ahmad 
Shadab of the Section of Genetics, Department of Zoology for 
the award of the degree of Doctor of Philosophy (Zoology, 
Genetics) of the Aligarh Muslim University, Aligarh. This is to 
certify that the subject matter of the thesis as presented by Mr. 
Shadab is the actual record of work done by him under my 
supervision and guidance and the same does not form the part of 
any other course or degree presented to or taken by him. 
Dr. Mohamd'nad Afzal 
CONTENTS 
CHAPTER SECTIONS PAGE NO. 
Acknowledgement i 
List of Tables ii 
List of Figures v 
INTRODUCTION 1 - 72 
HUMAN CYTOGENETICS AND GENOTOXICITY 2 
ANALYSIS OF CELLS AND CLASSIFICATION OF ENDPOINTS 6 
CHROMOSOMAL CHANGES 16 
Structural aberrations 16 
Chromosome-type aberrations 17 
Chromatid-type aberrations 17 
SISTER CHROMATID EXCHANGE (SCE): 20 
SCE AND GENOTOXICITY/CARCINOGENICITY STUDIES 22 
THE KINETICS OF REPAIR OF DNA 24 
Numerical alterations 26 
Sister Chromatid Exchange 27 
MECHANISMS OF FORMATION OF CHROMOSOMAL CHANGES 2 8 
(i) Structural chromosomal alterations 28 
(ii) Numerical chromosomal changes 30 
(iii) Sister chromatid exchange 31 
MUTATAGENESIS AND CARCINOGENICITY 3 2 
TYPE OF CARCINOGENESIS 3 4 
BIOCHEMICAL MECHANISMS OF MUTAGENESIS 3 7 
CORRELATION OF MUTAGENESIS AND CARCINOGENESIS 3 9 
MUTAGENICITY AND CARCINOGENICITY TESTING SYSTEMS 43 
AMES TESTING SYSTEM 45 
HERITABLE CYTOGENETIC DAMAGE 46 
SHORT-TERM CYTOGENETIC TESTS 47 
DRUG TOXICITY 53 
STEROIDAL DRUGS: USES AND APPLICATIONS 5 8 
STEROID HORMONES AND CARCINOGENESIS 61 
STEROID HORMONES, EMBRYOTOXICITY AND 
TERATOGENECITY *^  65 
STEROID HORMONES AND MUTAGENICITY/ 
GENOTOXICmr/CLASTOGENICITY 68 
OBJECTIVES AND LIMITATIONS OF THE PRESENT WORK 70 
MATERIALS AND METHODS 73-107 
DESCRIPTION OF TEST CHEMICALS 74 
DESCRIPTION OF CONTROL CHEMICALS 84 
ASSAY SYSTEM USED 8 7 
PREPARATION OF S, LIVER/MICROSOME FRACTION 8 9 
EVALUATION OF CHROMOSOMAL ABERRATION 
IN VITRO AND IN VIVO 92 
SISTER CHROMATID EXCHANGE ANALYSIS 101 
CELL CYCLE KINETICS 105 
STATISTICAL ANALYSIS 105 
CLINICAL STUDIES 107 
RESULTS 108-166 
I PROGESTINS 108 
MEDROXYPROGESTERONE ACETATE 108 
HYDROXYPROGESTERONECAPROATE 111 
MEGESTROL ACETATE 114 
II CORTICOSTEROIDS 117 
TRIAMCINOLONE 117 
PREDNISOLONE 119 
- BETAMETHASONE 121 
IN VrVO STUDY 124 
ADVERSE/SIDE EFFECTS OF THE STEROIDAL DRUGS 
TABLES 
DISCUSSION 
(A) GENERAL CONSIDERATION 
(B) ADVERSE /SIDE EFFECTS OF STEROIDAL DRUGS 
(C) CYTOGENETIC EFFECTS OF STEROIDAL DRUGS 
IN VITRO AND IN VIVO 
I- Progestins 
II- Corticosteroids 
BIBLIOGRAPHY 
APPENDIX 
PUBLICATIONS 
128 
131-166 
167-227 
167 
176 
190 
190 
215 
228-258 
ACKNOWLEDGEMENT 
I would like to express my sincere thanks to Dr. Mohammad 
Afzal, Reader, Section of Genetics, Department of Zoology, 
Aligarh Muslim University, Aligarh, for the supervision of the work 
and cooperation to complete this work. 
I am also grateful to Professor Jameel Ahmad Khan, 
Chairman, Department of Zoology for providing necessary 
facilities for the work carried out by me. 
Words are also worth-mentioning to Dr. Md. Asim Azfer, 
Lecturer, Section of Genetics, Department of Zoology, for his 
valuable suggestions, positive comments, continuous help, 
incessant encouragement and inspirations rendered to me. 
My sincere thanks are due to Mr. Md. Iqbal Ahmad Khan 
and Mr. Afsahul Hoda, my lab colleagues and Dr. Khalid 
Saifullah, for their help and cooperation. 
I wish to acknowledge with sincere thanks the helpfulness 
and enthusiastic support of my parents, teachers and brothers, 
Mr. Azad, Mr. Shamshad and Mr. Irshad and friends Mr. 
Mazhar A. Siddiqui, Mr. Tariq Ahmad Khan and Mr. Fazlur 
Rahman. 
G.G. HAMMAD AHMAD SHADAB 
11 
LIST OF TABLES 
TABLE NO. TITLE PAGE NO. 
1. Classification of Drug Induced Toxic Reactions 56 
2. Chromosomal aberrations in human lymphocytes after 131 
Medroxyprogesterone acetate treatment. 
3. Chromosomal aberrations in human lymphocytes after 132 
Medroxyprogesterone acetate treatment with and without metabolic 
activation. 
4. Sister Chromatid Exchage (SCE) in human lymphocytes after 133 
Medroxyprogesterone acetate exposure in vitro. 
5. Sister Chromatid Exchage (SCE) in human lymphocytes after 133 
Medroxyprogesterone acetate exposure with metabolic activation 
(S9 mix). 
6. Analysis of Cell growth kinetics after Medroxyprogesterone acetate 134 
exposure in vitro. 
7. Analysis of Cell growth kinetics after Medroxyprogesterone acetate with 134 
metabolic activation (S9 mix). 
8. Chromosomal aberrations in human lymphocytes after 135 
Hydroxyprogesterone caproate treatment. 
9. Chromosomal aberrations in human lymphocytes after 136 
Hydroxyprogesterone caproate treatment with and without metabolic 
activation. 
10. Sister Chromatid Exchage (SCE) in human lymphocytes after 137 
Hydroxyprogesterone caproate exposure in vitro. 
11. Sister Chromatid Exchage (SCE) in human lymphocytes after 137 
Hydroxyprogesterone caproate exposure with metabolic activation 
(S9 mix). 
12. Analysis of Cell growth kinetics after Hydroxyprogesterone caproate 13 8 
exposure in vitro. 
13. Analysis of Cell growth kinetics after Hydroxyprogesterone caproate 13 8 
with metabolic activation (S9 mix). 
14. Chromosomal aberrations in human lymphocytes after Megestrol acetate 139 
treatment. 
15. Chromosomal aberrations in human lymphocytes after Megestrol acetate 140 
treatment with and without metabolic activation. 
16. Sister Chromatid Exchage (SCE) in human lymphocytes after Megestrol 141 
acetate exposure in vitro. 
17. Sister Chromatid Exchage (SCE) in human lymphocytes after Megestrol 141 
acetate exposure with metabolic activation (S9 mix). 
18. Analysis of Cell growth kinetics after Megestrol acetate exposure in vitro. 142 
Ill 
19. Analysis of Cell growth kinetics after Megestrol acetate with metabolic 142 
activation (S9 mix). 
20. Chromosomal aberrations in human lymphocytes after Triamcinolone 143 
treatment. 
21. Chromosomal aberrations in human lymphocytes after Triamcinolone 144 
treatment with and without metabolic activation. 
22. Sister Chromatid Exchage (SCE) in human lymphocytes after 145 
Triamcinolone exposure in vitro. 
23. Sister Chromatid Exchage (SCE) in human lymphocytes after 145 
Triamcinolone exposure with metabolic activation (S9 mix). 
24. Analysis of Cell growth kinetics after Triamcinolone exposure in vitro. 146 
25. Analysis of Cell growth kinetics after Triamcinolone with metabolic 146 
activation (S9 mix). 
26. Chromosomal aberrations in human lymphocytes after Prednisolone 147 
treatment. 
27. Chromosomal aberrations in human lymphocytes after Prednisolone 148 
treatment with and without metabolic activation. 
28. Sister Chromatid Exchage (SCE) in human lymphocytes after 149 
Prednisolone exposure in vitro. 
29. Sister Chromatid Exchage (SCE) in human lymphocytes after 149 
Prednisolone exposure with metabolic activation (S9 mix). 
30. Analysis of Cell growth kinetics after Prednisolone exposure in vitro. 150 
31. Analysis of Cell growth kinetics after Prednisolone with metabolic 150 
activation (S9 mix). 
32. Chromosomal aberrations in human lymphocytes after Betamethasone 151 
treatment. 
33. Chromosomal aberrations in human lymphocytes after Betamethasone 152 
treatment with and without metabolic activation. 
34. Sister Chromatid Exchage (SCE) in human lymphocytes after 153 
Betamethasone exposure in vitro. 
35. Sister Chromatid Exchage (SCE) in human lymphocytes after 153 
Betamethasone exposure with metabolic activation (S9 mix). 
36. Analysis of CeJJ growth kinetics after Betamethasone exposure in vitro. 154 
37. Analysis of Cell growth kinetics after Betamethasone with metabolic 154 
activation (S9 mix). 
38. Chromosomal aberrations in human lymphocytes of the patients exposed 155 
to Medroxyprogesterone acetate. 
39. Sister Chromatid Exchage (SCE) in human lymphocytes of the patients 155 
exposed to Medroxyprogesterone acetate. 
40. Analysis of CelJ growth kinetics in human lymphocytes of the patients 155 
exposed to Medroxyprogesterone acetate. 
41. Chromosomal aberrations in human lymphocytes of the patients exposed 156 
to Hydroxyprogesterone caproate. 
IV 
42. Sister Chromatid Exchage (SCE) in human lymphocytes of the patients 156 
exposed to Hydroxyprogesterone caproate. 
43. Analysis of Cell growth kinetics in human lymphocytes of the patients 156 
exposed to Hydroxyprogesterone caproate. 
44. Chromosomal aberrations in human lymphocytes ofthe patients exposed 157 
to Megestrol acetate. 
45. Sister Chromatid Exchage (SCE) in human lymphocytes of the patients 157 
exposed to Megestrol acetate. 
46. Analysis of Cell growth kinetics in human lymphocytes of the patients 157 
exposed to Megestrol acetate. 
47. Chromosomal aberrations in human lymphocytes ofthe patients exposed 158 
to Triamcinolone. 
48. Sister Chromatid Exchage (SCE) in human lymphocytes ofthe patients 158 
exposed to Triamcinolone. 
49. Analysis of Cell growth kinetics in human lymphocytes ofthe patients 158 
exposed to Triamcinolone. 
50. Chromosomal aberrations in human lymphocytes ofthe patients exposed 159 
to Prednisolone. 
51. Sister Chromatid Exchage (SCE) in human lymphocytes ofthe patients 159 
exposed to Prednisolone. 
52. Analysis of Cell growth kinetics in human lymphocytes ofthe patients 159 
exposed to Prednisolone. 
53. Chromosomal aberrations in human lymphocytes ofthe patients exposed 160 
to Betamethasone. 
54. Sister Chromatid Exchage (SCE) in human lymphocytes ofthe patients 160 
exposed to Betamethasone. 
55. Analysis ofCell growth kinetics in human lymphocytes ofthe patients 160 
exposed to Betamethasone. 
56. Adverse / Side effects observed in the patients exposed to 161 
Medroxyprogesterone acetate for 1 to 3 months (n = 7) 
57. Adverse / Side effects observed in the patients ejqjosed to 162 
Hydroxyprogesterone caproate for 1 to 3 months (n = 8) 
58. Adverse / Side effects observed in the patients exposed to Megestrol 163 
acetate for 1 to 3 months (n = 8) 
59. Adverse / Side effects observed in the patients exposed to Triamcinolone 164 
for 1 to 3 months (n = 8) 
60 Adverse / Side effects observed in the patients exposed to Prednisolone 165 
for 1 to 3 months (n = 7) 
61. Adverse / Side effects observed in the patients exposed to Betamethasone 166 
for 1 to 3 months (n = 7) 
LIST OF FIGURES 
Aberrations induced by Medroxyprogesterone Acetate 
Fig. A. Cell with chromatid g ^ and chromatid break. 
Fig. B. Cell showing diploidy. 
Fig. C. Cell showing sister chromatid excnahges. 
Aberrations induced by Megestrol Acetate 
Fig. D. Cell showing extreme chromosome shortening. 
Fig. E. Cell with chromatid break and chromatid gap. 
Aberrations when treated with Triamcinolone 
Fig. F. Cell showing chromatid break, chromatid gap and termial deletions. 
Fig. G. Cell with breaks in chromatid. 
Some of the anomalies when treated with Betamethasone 
Fig. H. Cell with diploidy. 
Fig. I. Cell showing g^s and breaks in cliromatids. 
Fig. J. Cell with terminal deletion, chromatid breaks, gaps and chromosome break. 
Aberrations induced by Medroxyprogesterone Acetate in vivo 
Fig. K. Cell showing endoreduplication. 
Fig. L. Cell showing chromatid gaps, deletions and chromatid separation. 
Aberrations when treated with Betamethasone in vivo 
Fig. M. Cell showing chromatid separation and abnormal chromosomes. 
Fig. N. Cell showing chromatid gap. 
Fig. O. Cell with sister chromatid excnahges. 
INTEODUCTION 
INTRODUCTION 
O^Uuman Cytogenetics as a discipline in its own right 
was established around 50 years ago. It emerged directly as a 
consequence of the development of techniques that enabled us to 
clearly visualise chromosomes in human somatic cells and the 
demonstration, using these techniques, that a number of prenatal 
and postnatal chromosomal abnormalities in man were a 
consequence of chromosome anomalies. The emergence of the 
discipline was very much facilitated by the facts : (i) that human 
peripheral blood T lymphocytes could be readily stimulated to 
undergo mitosis in short term culture; (ii) that these cells were 
easily available in large quantity from a few drops of blood 
obtained from virtually any individual; and (iii) that stimulated 
lymphocytes were ideal cells from the point of view of producing 
well spread metaphase chromosomes. In addition to being able to 
analyse chromosomes in cells taken more or less directly from an 
individual who has for example been exposed to a mutagen, or 
who has a neoplasm, the techniques of cell culture enable us to 
expose normal human cells in vitro to mutagens and carcinogens 
and allow us to study the consequences of such exposure on 
chromosome structure and behaviour in these cells. The birth of 
cytogenetics resulted in the fast and to the point assessment of 
the effects of mutagens at chromosomal level. 
HUMAN CYTOGENETICS AND GENOTOXICITY 
In many ways chemicals are a basic factor in the well-being 
and effective functioning of present day societies. The quality of 
life at both the social and individual levels would be severely 
restricted if we had to live without petroleum products, plastics, 
synthetic drugs, synthetic textiles, packed food etc. in solid and 
liquid form using many synthetic chemicals in them. 
As in the case of drugs, the use of other chemicals implies 
not only the desired benefits but also adverse effects. We are 
compelled to compromise between costs and benefits. When the 
desired and the adverse effects of the use of chemicals are weighed, 
it is pertinent to ask whether we really need all the more than 3000 
new chemicals synthesised annually and whether all the 60,000-
70,000 chemicals used daily in industrialized societies are truly 
essential, some people have even wondered how long our 
ecosystem can survive and how long the biosystem, man included, 
can tolerate the doubling of the consumption of chemicals that 
occurs every seven years. 
Monitoring the impact and assessment of hazards on human 
health from exposure to environmental agents of all types 
concomitant with periodical monitoring to confirm that control 
measures are working effectively or not are key aspects of the 
world scientific community. Without objective data on effects, 
attempts to assign causes can only be speculative. Speculation 
does not provide a reliable basis for remedial action and the 
control of health hazards. Knowledge of the presence and identity 
of mutagenic agents in the environment and the extent of exposure 
to them is therefore extremely important in interpreting and using 
the results obtained from cytogenetic studies for genetic effects. 
Efforts concerned with the assessment of human exposures and 
effects on health are needed. 
The extent to which human population is exposed to different 
types of environmental agents, chemicals and drugs is alarming. 
The scientific community has been working globally on this very 
hazard of the mutagens, to which people are forced to be exposed 
intentionally or unintentionally. 
Modem cytogenetics of course is not confined to the study 
of human chromosomes in lymphocytes and a wide variety of 
cells have been subject to analysis and particularly so, and in the 
case of studies on human genotoxicity. 
Studies on exposed individual, and on cultured cells have 
shown that the human peripheral blood lymphocyte is an extremely 
sensitive indicator of both in vivo (Evans et al., 1979; Evans, 
1982) and in vitro (Evans, 1962; Buckton, et al., 1973) test of 
induced chromosomal changes. These changes in chromosome 
structure offer readily scored morphological evidence of damage 
to the genetic material. Although problems exist in the extrapolation 
from in vitro results to the in vivo situation, the lymphocyte offers 
several advantages as a test system viz. easy availability of large 
numbers of human cells : a few mis of peripheral blood can be 
easily and repeatedly obtained from an individual and each ml of 
blood can contain 1-3x10^ of small lymphocytes. 
The lymphocytes are distributed throughout the body, 
circulate in all tissues and a proportion of them are long-lived. 
Virtually all the peripheral blood lymphocytes are a synchronised 
cell population in the same G^  or G, stage or the mitotic interphase, 
and in healthy individuals, these cells are only infrequently involved 
in mitotic proliferation in vivo. 
A proportion of the lymphocytes can be stimulated by 
mitogens to undergo mitosis in culture; they are easy to culture 
and thus provide a ready source of dividing cells for the scoring 
of chromosome aberrations. There are excellent techniques 
available for making chromosome preparations from lymphocytes 
and the cells have a low spontaneous chromosome aberration 
frequency (Buckton et al., 1973). 
Although small lymphocytes of peripheral blood are in a 
resting G^  stage, the cells comprise a mixed population in terms 
of their surface properties and function. The two major categories 
are referred to as T' (thymus-derived) and 'B' (bone-marrow 
derived) cells; the former respond to antigens and secrete 
immunoglobulins. Although there is some variation, T cells 
normally comprise around 70% of the total peripheral lymphocytes 
and there are various T cells subsets defined by various 
monoclonal antibodies, two major groups being referred to as 
inducer/helper cells (OKT 4) and suppressor/cytotoxic cells (OKT 
5/8). There is some evidence for a quantitative difference in the 
response of B and T cells to mutagens and perhaps also for 
different T cell subsets (Evans, 1984). 
The lymphocytes observed in the first waves of mitotic 
division in PHA-stimulated culture are largely T lymphocytes. Since 
these cells are closely concerned with an individual's immune 
response, where a chromosome analysis following an in vitro 
exposure to an immunological stimulus, or to drugs that may not 
themselves be mutagenic but which alter the lymphocyte population 
structure, may influence the frequencies of chromosome 
aberrations detected. 
ANALYSIS OF CELLS AND CLASSIFICATION OF ENDPOINTS 
There are many schemes available for the classification of 
chromosome aberration types, and comprehensive description 
can be found in Savage (1975) and Bloom (1981). The following 
section includes descriptions of the aberrations most commonly 
observed in control samples or samples from individuals 
exposed to radiation or chemical agents. 
Terminal and interstitial deletions 
CD 
Fig. 1 ChromosoTne-tjipe deletions 
It is not possible to distinguish between chromosome-type 
terminal deletions and non-sister union isochromatid deletions, 
and so, in cases of radiation exposure, when induced aberrations 
are of the chromosome-type, it is appropriate to classify all paired 
acentric fragments as terminal deletions. 
Asymmetrical interchanges (usually dicentrics) 
T J replication II Jj 
Fig. 2 Dicentric and acentric fragments 
Fig. 3 Tricentric and acentric fragments 
The small interstitial deletions appearing as paired dots are 
classified as "minutes". The larger interstitial deletions in which 
there is a clear space in the centre of the ring are usually classified 
as acentric rings. The distinction is not particularly clear-cut, and, 
in general, is merely an indication of the different sizes of interstitial 
deletions. Acentric fragments associated with inter- or intra-
changes are not classified as terminal deletions. 
It is assumed that a dicentric, analysed at the first in vitro 
metaphase will be accompanied by an acentric fragment and a 
tricentric by 2 acentric fragments. A cell with a dicentric and two 
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acentric fragments is, by convention, classified as a dicentric with 
its accompanying fragment and a terminal deletion. The two 
acentric fragments could be the result of incomplete rejoining 
during the formation of the dicentric. However, although this cannot 
be ascertained, it has been shown experimentally that its probability 
of occurrence is rather low (< 10%) (Schmid and Bauchinger, 
1980). 
Asymmetrical interchanges, i.e., dicentrics, can be analysed 
with greater efficiency than any other aberration type (> 95%), 
and it is their frequency that is generally used for estimations of 
radiation dose. For such determinations, a tricentric, for example, 
is assumed to be equivalent to 2 dicentrics. 
Asymmetrical intrachange (centric ring) 
J2 -SI - p S ^ 
Fig. 4 Centric ring 
In asymmetrical intrachanges as in interchanges, a centric 
ring is accompanied by an acentric fragment, and the same 
classification scheme applies to these as for dicentrics ((2), above). 
Symmetrical interchanges (reciprocal translocations) 
Fig. 5 Reciprocal translocation. 
Symmetrical interchanges are particularly difficult to observe 
in conventionally-stained preparations, unless the exchanged pieces 
produce 2 chromosomes, very different from the normal 
karyotype. However, it is suggested that obvious symmetrical 
interchanges should be recorded, but giving less weight to their 
frequency than to that of most other aberration types. 
Symmetrical interchanges (peri - and paracentric inversions) 
Fig. 6 Pericentric inveresion 
^ - / - / - / 
Fig. 7 Paracentric inversion 
It is not usually possible to observe these symmetrical 
intrachanges in conventionally-stained preparations, unless a 
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pericentric inversion produces a chromosome that is distinctly 
different from the normal karyotype. Any obvious symmetrical 
intrachanges should be recorded, but less weight given to their 
frequency than to that of most other aberration types. 
Chromatid-type aberrations are generally classified in the 
same way as chromosome-type aberrations; the apparent unit of 
involvement in a chromatid-type aberration is, in most cases, the 
single chromatid, and not the whole chromosome, as seen for 
chromosome-type aberrations. 
(1) Terminal deletions 
Fig. 8 Terminal deletions 
A terminal deletion is a distinct displacement of the 
chromatid fragment distal to the lesion, or, if there is no 
displacement, the width of the non-staining region between the 
centric and acentric regions is greater than the width of a 
chromatid. The latter definition is used to distinguish between 
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terminal deletions and achromatic lesions or "gaps". 
(2) Interstitial deletions 
•l i -fl ^ 
Fig. 9 Interstitial deletion 
Chromatid-type interstitial deletions are not as readily 
observable as their chromosome-type counterpart, partly because 
the small deleted fragment is often separated from the deleted 
chromosome, and is not observed. 
(3) Achromatic lesions ("gaps") 
Fig. 10 Achromatic lesions 
Achromatic lesions or gaps are non-staining or very lightly 
stained regions of chromosomes, present in one chromatid (single) 
or, in both sister chromatids, at apparently identical loci (double). 
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If the non-staining region is of a width less than that of a chromatid, 
the event is recorded as an achromatic lesion. This is clearly only 
a working definition. It is generally suggested that achromatic 
lesions should be recorded, but always separately from chromatid 
deletions. Their frequency should not be included in the totals for 
aberrations per cell, since their significance and relationship to 
other "true" aberration types is not clear at present. 
(4) Isochromatid deletions 
H K h li 
n M n I I 
sister union non-union non-union non-union 
distal proximal proximal and 
distal 
Fig. 11 Isochromatid deletions 
Isochromatid deletions appear as exceptions to the class of 
chromatid-type aberrations, since they involve both chromatids, 
apparently with "brakes at the same position on both. However, 
in suitable material they can be shown to be induced by radiation 
in the S and G^  phases of the cell cycle, as is the case for other 
chromatid-type aberrations. 
There are several possible types, depending on the nature 
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of the sister unions. If sister union occurs, it is possible to 
distinguish isochromatid aberrations from chromosome-type 
terminal deletions. 
Fig. 12 Asymmetrical chromatid interchange 
In mammalian cells, however, sister union is a rare event, 
and most of the isochromatid deletions are of the non-union 
proximal and distal type. The acentric fragment is most often not 
associated with the deleted centric part of the chromosome. The 
convention for analysis (discussed for chromosome-type terminal 
deletions, above) is that, for radiation exposures, paired acentric 
fragments are recorded as chromosome-type terminal deletions, 
but, for chemical exposures or control samples, they are most 
appropriately recorded as isochromatid deletions. 
(5) Asymmetrical interchanges (interarm interchanges, 
asymmetrical chromatid exchanges) 
Asymmetrical interchanges are the chromatid-type equivalent 
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to chromosome-type dicentrics. 
(6) Symmetrical interchanges (symmetrical chromatid 
exchanges). 
itf H^ 
usual orientation 
Fig. 13 Symmetrical chromatid interchange 
Symmetrical interchanges are the chromatid-type equivalent 
of chromosome-type reciprocal translocations. In the case of 
chromatid-type symmetrical exchanges, somatic pairing maintains 
an association between the chromosomes involved in the exchange, 
and thus they can be readily observed in the absence of any 
chromosome-banding procedures. 
Asymmetrical Symmetrical 
Fig. 14 Chromatid interchanges 
(7) Asymmetrical and symmetrical intrachanges (interarm 
intrachanges). 
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There are 2 forms of symmetrical and asymmetrical interarm 
intrachanges but, when analysing metaphase cells, only one of 
each is distinguishable. The symmetrical intrachange can be 
observed in somatic pairing. 
(8) Triradials 
Fig. 15 Triradials 
A triradial (3-armed configuration) can be described as the 
interaction between one chromosome having an isochromatid 
deletion and a second having a chromatid deletion. Many types of 
triradials can be formed but, in mammalian cells, where the 
frequency of sister union is low, the 2 illustrated are the most 
common. 
It is important to note that the different types of chromosome 
aberration should be recorded separately. The results for any 
sample should be presented as the aberration frequency per cell 
for each aberration type,or frequency of aberrant cells for each 
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aberration type. 
CHROMOSOMAL CHANGES 
There are various classes of chromosomal changes that can 
be induced by exposure to chemical substances. These changes 
are categorised as structural and numerical chromosomal 
alterations and sister chromatid exchanges. The mechanism of 
induction of each class is described so that short and medium-
term assays can be designed to account for mechanistic 
considerations. The various endpoints are related with the tumour 
formation and carcinogenicity. 
The inherent merits of the broad range of in-vitro and in-
vivo assays for detecting induced chromosomal changes and the 
usefulness of the assays in detecting carcinogens and for 
describing dose-response curves at low doses can be set to be 
assessed with a knowledge of the different types of chromosomal 
changes and their cellular consequences. 
STRUCTURAL ABERRATIONS 
The broadest classification of structural chromosomal 
aberrations is based on whether they are formed before or after 
semiconservative DNA replication. 
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Chromosome-type aberrations : Chromosomal type aberrations 
are produced by errors in DNA repair in unreplicated DNA,i.e. in 
cells in G, or S in DNA regions that have not yet been replicated. 
When observed at metaphase (or interphase), chromosome type 
aberrations involve a change in both chromatids of the 
chromosomes. 
Chromatid-type aberrations : Chromatid type aberrations are 
produced by errors in DNA repair in cells in Gj or S phase in 
DNA regions that have already replicated at the time of exposure 
or by errors in DNA replication on a damaged DNA template. 
Errors in DNA repair leading to chromosomal aberrations 
generally occur after exposure to mutagenic chemicals ionizing 
radiation or truly radiomimetic chemicals (e.g. bleomycin, 
neocarzinostatin and streptonigrin). When observed at metaphase, 
chromatid type aberrations involve only one of the two sister 
chromatids, with the exception of isochromatid fragments or 
deletions that involve both chromatids. Isochromatid deletions 
are thus difficult to distinguish from chromosome type terminal 
deletions. They can be classified, if needed, into chromatid type 
or chromosome type on the basis of the other, clearly 
distinguishable types observed in a particular study. For the 
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purposes of the present discussion, it is important to note that 
after cell division and a subsequent round of DNA replication, 
chromatid-type aberrations can be converted into the so-called 
derived-chromosome-type aberrations. The probability of this 
occurrence varies for different types of aberration depending on 
the likelihood of lethality at the intervening cell division resulting 
from loss of an acentric chromosomal fragment. 
Within each major group of chromosome-type and 
chromatid-type aberrations is a range of different types of 
aberration, broadly defined as deletions and exchanges. Large 
terminal or interstitial chromosomal type deletions observable 
under the light microscope are almost always lethal to the cells as 
a result of loss of the acentric fragment at the first or second cell 
division, after its formation. It can be reasonably argued, however, 
that the mechanism of formation and general shape of the dose-
response curve for small deletions that cause transmissible 
mutations is similar to that for larger (microscopically observable) 
interstitial deletions. A similar argument holds for chromatid-type 
terminal and interstitial deletions, with the exception that, since 
the deletions involve only one of the two chromatids, only one 
daughter cell is viable, namely the one receiving the undamaged 
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chromatid. 
Exchange aberrations can be intrachromosomal or 
interchromosomal, each class including transmissible (stable) and 
non-transmissible (unstable) types. Intrachromosomal exchanges 
can produce inversions involving the centromere (pericentric) or 
within a chromosome arm (paracentric) which are transmissible, 
and centric and acentric rings that are most frequently non-
transmissible because of loss of acentric chromosomal material 
at division (i.e. the acentric ring itself or the acentric fragment 
accompanying a centric ring). Acentric rings are the same as the 
interstitial deletions described above. 
Interchromosomal exchange can produce reciprocal 
translocations that are transmissible and the dicentrics (with an 
accompanying acentric fragment) that are almost always non 
transmissible. A reciprocal chromatid type translocation between 
homologous chromosomes is mitotic crossing over, which, in one-
quarter of the chromosomal segregation patterns at mitosis, leads 
to the production of homozygosity for heterozygous loci for genes 
located distal to the translocations. This mechanism is relevant to 
producing homozygosity of recessive mutant tumour suppressor 
genes in cells that were originally heterozygous at these loci. 
20 
Chromosome type reciprocal translocations are transmitted to both 
daughter cells and do not cause loss of heterozygosity, whereas 
chromatid-type reciprocal translocations have a one-quarter 
probability of being present in a daughter cell. This is an important 
consideration for predicting potentially adverse outcomes 
attributable to chromosomal changes. 
The analysis of reciprocal translocations and inversions has 
until recently been difficult, relying on one or another version of 
chromosome banding. The recent development of whole 
chromosome painting probes (Tucker et al, 1993), chromosome 
arm specific probes (Lucas et al., 1996) and even total karyotype 
differentiation (Speicher et al., 1996) have made the analysis much 
easier. These transmissible aberrations can be analysed in human 
and mouse cells, and rat chromosome, probes are becoming 
available. 
SISTER CHROMATID EXCHANGE (SCE) 
Sister Chromatid Exchange (SCE) results from the breakage 
and rejoining of DNA at apparently homologous sites on the two 
chromatids of a single chromosome. In comparison to 
chromosomal aberration method, SCE analysis is more sensitive 
and nonspecific for the chemical in question. They were first 
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visualised by Taylor et al. (1957) who used treated thymidine to 
differentially label the DNA of replicating cells and autoradiography 
to distinguish the silver grain pattern on the two sister chromatids. 
Latt (1973) and Perry and Wolff (1974) made this technique more 
simple. In principle, SCEs can be observed in any cells that has 
completed two, or the first of two, replication cycles in the 
presence of BrdU. The most common procedure for human 
lymphocytes is to grow the cells in BrdU for two replication cycles 
(Preston, 1999). 
SCEs are most efficiently induced by substances that form 
covalent adducts with the DNA, or interfere with DNA precursor 
metabolism or repair (Perry and Evans, 1975; Wolff, 1977; Perry, 
1980; Carrano and Thompson, 1981; Latt et al., 1981). It is well 
documented that SCEs are produced during DNA replication 
(Wolff e/ al., 1974) and that the polarity of DNA is maintained in 
the process of exchange (Taylor, 1958; Wolff and Perry, 1975). 
Baseline SCE frequencies are increased in some human diseases 
such as Bloom's syndrome (Chaganti et al., 1974) and multiple 
sclerosis (Sutherland etal., 1980; Vijayalaxmi etal., 1983). Cells 
from patients with the inherited disease Xeroderma pigmentosum 
are hypersensitive to the induction of SCEs by ultraviolet radiation 
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and alkylating agents (Wolffs/ al, 1975; Wolff, 1977). 
SCE AND GENOTOXICITY/CARCINOGENICITY STUDIES 
An SCE represents the breakage of 4 strands of DNA 
(2 double helices), a switch of the strands from one to the other 
arm of the same chromosome, and the rejoining of the strands in 
their new locations. The question is whether the breakage and 
rejoining events occur without producing any modification in the 
genetic code. There is evidence suggesting that this exchange 
process might not always be error-free. In particular, a 
considerable amount of information has been gathered concerning 
the relationship between induced SCEs and other genetic effects 
in \ivo and in vitro. 
Because the technique for enumerating SCEs is relatively 
simple, this assay has been used quite extensively in genetic 
toxicology studies. It has been amply demonstrated that the 
frequency of SCE is dramatically increased when the cells or 
animals including human beings, are exposed to known mutagens 
or carcinogens (Perry and Evans, 1975; Latt et al., 1981; Lambert 
et al., 1982). Moreover in earlier experiments using Chinese 
hamster cells in culture, it was found that the induction of SCE 
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was linearly related to the increase in single-gene mutations (HPRT 
Locus), when the cells were exposed to several substances each 
of which differed in the type of lesion produced in DNA (Carrano 
et al., 1978; Carrano and Thompson, 1982). The ratio of induced 
SCE to induced mutation differed for each of the agents, 
suggesting that each type of lesion formed is processed differently 
by the cell favouring either the formation of SCEs or mutations. 
It is possible that the same lesion is capable of producing both an 
SCE and a mutation and/or that the lesions that form mutations 
are a subset of those that form SCEs. The induction of mutations 
has been shown to be correlated with the induction of SCEs in 
mice for one chemical, ethylnitrosourea (Jones et al., 1985). In 
the same study, the induction of SCEs in mouse spleuocytes after 
intraperitoneal administration of the chemical it was found that a 
linear relation is existing between SCEs and proportional to the 
increase in mutations at the HPRT locus. It suggests that the 
mutation-SCE relation is not unique to in vitro studies. 
The results of early studies on rabbits demonstrated that it 
was possible to measure an increase in SCEs in peripheral blood 
lymphocytes for many months following repeated low-level 
exposure to mitocin C in vivo (Stetka et ai, 1978). Increased 
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SCEs in human beings have been observed in cigarette smokers 
(Lambert et al, 1978; Carrano, 1982) and in individuals undergoing 
chemotherapy (Lambert et al, 1978; Musilova et al, 1979; Gillian 
Clare et al., 1982). The results of these studies suggest that a 
subpopulation of lymphocytes with high SCE frequency may be 
present for long periods after termination of exposure. These cells 
may represent persistent damage in long-lived lymphocytes or a 
sensitive sub-population (Carrano and Moore, 1982). If this is 
true, they may offer a more appropriate approach to the 
quantification of persistent damage in vivo. 
THE KINETICS OF REPAIR OF DNA 
An aberration is a rare occurrence in comparison with the 
amount of induced DNA damage, most of which is efficiently 
repaired. The kinetics of repair of different types of DNA damage 
affects the types of structural alterations produced, as discussed 
below. 
One class of chromosomal change that requires separate 
attention is gaps or chromatic lesions. These changes appear as 
unstained regions of a chromosome, where no obvious break or 
displacement is observed microscopically. The gaps have variously 
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been attributed to damaged DNA regions that have unwound or 
decondensed and to sides of DNA repair and have been considered 
harbingers of cell death. Their frequency can clearly be increased 
by exposure to radiation and chemicals, but their further 
significance is unclear. When gaps are observed at the first 
metaphase after treatment, they are generally not seen at 
subsequent metaphases, as would be predicted if gaps are sites 
of decondensation or repair or indicate imminent cell death. The 
idea that they represent sites of damage is perhaps supported by 
the observation that the number of chromosomal breaks in treated 
cells that are induced to undergo premature chromosome 
condensation is very much higher than that observed in metaphase 
cells. A gap could be seen as a break if premature chromosome 
condensation separated pieces of chromosomes that would 
normally repair absent condensation. There is no agreement on 
how to distinguish deletions from gaps or how to interpret data 
on gaps, especially when they are the only chromosomal change 
observed in an assay. The United Kingdom Environmental Mutagen 
Society subcommittee on guidelines for mutagenicity testing (Scott 
et al., 1983) provides what is perhaps the most reasonable 
approach. An observation of gaps alone indicates the potential 
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for true chromosomal aberrations but is insufficient for a firm 
conclusion to be drawn. Additional studies are recommended to 
establish the conditions that might lead to the formation of 
unequivocal structural aberrations. 
Numerical Alterations 
An increase (hyperploidy) or decrease (hypoploidy) in the 
number of chromosomes can result from incorrect segregation of 
chromosomes at anaphase and failure of the chromosomes to leave 
the metaphase plate in anaphase so that they are not included in 
either of daughter nuclei. In addition, partial chromosomal 
aneuploidy can arise from chromosomal deletions and from certain 
segregants of chromatid exchange aberrations. Increasing 
knowledge about the mechanisms of chromosome movement 
during mitosis has allowed identification of a number of steps at 
which induced changes can lead to aneuploidy (Preston, 1996). 
Traditionally aneuploidy has been assessed by counting 
chromosomes at metaphase. More recently, fluorescence 
hybridization techniques have been added. For example, the 
proportion of micronuclei containing whole chromosomes can be 
assessed by using a probe that can detect the kinetochore 
(Eastmond and Tucker, 1989). This approach can, of course. 
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detect only aneuploidy that results from logging chromosomes. 
Whole-chromosome painting probes or preferably artificial 
bacterial chromosome probes that provide more discrete signals, 
can be used for the detection of aneuploidy in interphase cells 
(Kim et al., 1995, Bell et al, 1996). 
Changes in ploidy (duplication of whole chromosome 
complement) are also induced generally as a result of inhibition 
of cytokinesis or failure of all chromosomes to segregate. The 
outcome can be either polyploidy or endoreduplication. The latter 
is a specific version of polyploidy in which replicated 
chromosomes maintain a parallel association along their lengths 
even at C metaphase (Therman et al, 1983), specific assays are 
not available for detecting changes in ploidy, but they should be 
noted when observed in the course of other assays for 
chromosomal alterations. 
Sister Chromatid Exchange 
Sister chromatid exchange is apparently reciprocal exchange 
between the two chromatids of a chromosome generally. It is most 
observed by differential staining of the two chromatids after two 
rounds of replication in the presence of a nucleotide analogue, 
most frequently bromodeoxyuridine (BrdU). It is possible to 
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establish if a sister chromatid exchange is produced in the first or 
second replication in the presence of BrdU. In induced polyploid 
or endoreduplicated cells the appearance of sister chromatid 
exchange in only one of the homologous chromosomes (single) 
indicates that it was produced in the second S phase, whereas its 
presence in both homologous (twin) suggests it was formed in 
the first S phase (Wolff and Afzal, 1996). This observation can 
have important implications for interpretation of the results. 
The analysis and classification of sister chromatid exchanges 
in all of the cell types so far used is relatively straight forward, 
each label switch representing and SCE. 
MECHANISMS OF FORMATION OF CHROMOSOMAL CHANGES 
(i) Structural Chromosomal Alterations 
Chromosomal aberrations induced by ionizing radiation are 
formed most frequently by errors of DNA repairs such that 
chromosomal aberrations are produced in cells in G^  or Gj quite 
rapidly after exposure and before DNA replication. Delay in G, 
as a result of cell cycle check-points enhances the probability of 
DNA repair before replication. A few truly radiomimetic chemicals 
(e.g. bleomycin, streptonigrin, neocarcinostatin and 8-ethoxy 
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caffeine) operate similarly, namely by inducing DNA strand breaks 
or oxidative, DNA base damage. The repair errors arise from mis-
ligation of double-strand breaks or interaction of coincidentally 
repairing regions during nucleotide excision repair of damaged 
bases. The molecular basis of these processes has been extensively 
studied, and comprehensive reviews are available on nucleotide 
excision repair (Wood, 1995; Sancar, 1996), oxidative damage 
repair (Demple and Harrison, 1994) as well as DNA strand break 
repair (Jackson, 1996). Thus the overall fidelity and kinetics of 
DNA repair influence the sensitivity of cells to the induction of 
chromosomal aberrations produced by misrepair. 
Most clastogenic chemicls (e.g. alkylating agents and cross-
linking agents) produce aberrations almost exclusively by errors 
of DNA replication on an adducted template. This does not 
represent an inability to produce aberrations by repair errors but 
rather a low probability, since coincidentally repairing regions must 
be available to interact, and this coincidence is rare, given the 
relatively slow overall rate of repair of DNA damage induced by 
most chemicals. If the probability of obtaining such coincident 
repair is greatly enhanced by using a DNA repair inhibitor such as 
cytosine arabinoside, chromosome type aberrations are formed 
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in cells in G, treated with chemicals that are commonly described 
as S phase-dependent (Preston and Gooch, 1981). Thus it is 
essential in any cytogenetic assay for so called S phase-dependent 
chemicals to ensure that the cells observed at metaphase have 
passed through S phase between treatment and sampling. If the 
induced frequency of all aberration classes is required, cells should 
be sampled for metaphase analysis at their first mitosis after a 
single treatment. Since several types of aberration produce cell 
lethality and/or loss of an acentric fragment at division, observation 
at the second or subsequent mitosis after treatment leads to a 
lower aberration frequency than that induced. 
The frequency of chromatid aberrations produced by DNA 
replication errors is influenced most strongly by factors such as 
the treatment dose to the cell, the phase of the cell cycle, DNA 
repair kinetics, DNA replication fidelity and maintenance of cell 
cycle check-points. Thus, different cell types can have different 
sensitivity to chromosomal aberration induction as a consequence 
of differences in these factors. 
(ii) Numerical Chromosomal Changes : 
Numerical changes can arise from errors in chromosomal 
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segregation. The apparent complexity of the control and the 
mechanics of the mitotic process means that alteration of a number 
of components can result in failure to segregate the sister 
chromatids to separate daughter cells or in a failure to segregate a 
chromosome to either pole (Bickel and Orr-Weaver, 1996). The 
mechanisms underlying chromosomal loss are pertinent to those 
involved in the formation of centromere-containing micronuclei. 
A limited set of chemicals has been demonstrated to cause 
aneuploidy through interaction with components of chromosome 
movement. These include benomyl, griseofulvin, nocodazole, 
colchicine, colcemid, vinblastin and taxol. These chemicals affect 
tubulin polymerization or spindle microtubule stability. Todate, 
other mechanisms of aneuploidy induction have not been clearly 
identified (Preston, 1999). 
(iii) Sister Chromatid Exchange : 
Sister chromatid exchange (SCE) is produced during DNA 
synthesis and is presumed to be a consequence of errors in the 
replication process itself, perhaps at the site of stalled replication 
complexes (Painter, 1980, Heartlein et al., 1983). It is, in fact, 
this mode of action that makes assays for sister chromatid 
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exchange less than ideal for detecting effects due directly to a 
chemical (Tennant et al., 1987). The creation of intracellular 
conditions that slow DNA replication, for example, could induce 
sister chromatid exchange. 
As SCE is presumed to be reciprocal exchanges between 
the two chromatids, differential staining of the sister chromatids 
is necessary in order to observe the exchanges. Two rounds of 
replication in BrdU are usually used to obtain the substrate for 
differential staining. Thus an assay design must allow for a maximal 
proportion of cells to be in their second post treatment metaphase. 
MUTAGENESIS AND CARCINOGENICITY 
Mutation occurs through a change in the genotype of a cell, 
which is passed on when the cell divides. When it is induced by 
chemical agents it is due to covalent modification of the DNA. 
Spontaneous mutations can occur in the absence of any external 
predisposing factor, but the probability of such mutation can be 
greatly increased by ionising radiation or by various kinds of 
chemical. Changing a single base in DNA may produce effects on 
the cell ranging from none at all to rapid death, depending on 
whether the gene sequence affected is undergoing transcription 
and translation, and, if so, whether the resulting change in the 
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peptic sequence for which it codes is functionally important or 
trivial. Certain kinds of mutation result in carcinogenesis, because 
the affected protein is somehow involved in growth regulation. 
The current view is that cancer arises when the function of 'proto-
oncogenes' (which are probably normal growth-regulator genes) 
is altered by mutation. This can result in the expression of a protein 
that is not normally formed by the cell, or of a modified version 
of a normally expressed protein. Alteration of the so-called tumour 
suppressor genes could also be involved; these genes are believed 
to code for products which inhibit the transcription of oncogenes. 
It usually requires more than one mutation in a cell to initiate the 
changes which result in maligancy. It may at first sight seem 
vanishingly improbable that random changes among the thousands 
of base pairs in a DNA strand will hit on the right combination to 
alter a particular protooncogene without irreparably damaging the 
genome. However, since this change has to occur in only one of 
millions of cells in order to produce a tumour, the probability is 
much higher than it appears. The nature of these oncogene 
products which transform cells from a normal to a malignant 
growth pattern is currently under very energetic study. Some 
oncogenes have been found to code for modified growth factors 
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or growth-factor receptors, or for elements of the intracellular 
transduction mechanism by which growth factors regulate cell 
proliferation. Growth factors are polypeptide mediators which 
stimulate division of certain types of cell; examples are epidermal 
growth factor (EGF) and platelet derived growth factor (PGDF). 
The receptors for these growth factors regulate a number of cellular 
processes. Though there are many details to be filled in, and 
doubtless many more oncogenes than have yet been identified, 
the complex connection between the introduction of a mutagenic 
chemical and the development of a cancer is now beginning to be 
understood. 
TYPES OF CARCINOGENESIS 
Chemical carcinogens are chemical substances which cause 
cancer. The term is sometimes restricted to those substances which 
interact directly with DNA. However, various substances act at a 
later stage to increase the likelihood that mutagenesis will result in 
the production of a tumour, and could also be considered to be 
carcinogenic. Here we classify carcinogens by the scheme put 
forward by Weisburger and Williams, 1984; Lutz and Maier, 1988, 
by which carcinogens can be divided into: 
* Genotoxic carcinogens (i.e. mutagens, as discussed above). 
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These are also termed 'initiators' and can be further divided 
into: 
- Primary carcinogens, which act on DNA directly. 
- Secondary carcinogens, which must be converted to a 
reactive metabolite before they affect the DNA. Most of 
the important chemical carcinogens fall into this category. 
Epigenetic carcinogens (i.e. agents that do not themselves 
cause genetic damage, but increase the likelihood that such 
damage will cause cancer). There are several different types 
of epigenetic carcinogen, the most important being: 
- Promoters. These are substances which are not carcinogenic 
by themselves, but increase the likelihood of tumour 
development from genetically damaged cells; they can thus 
produce cancers when given after the genotoxic agent. 
Examples include phorbol esters, bile acids, saccharin and 
so on. 
- Co-carcinogens. These are substances which are not 
carcinogenic by themselves but enhance the effect of 
genotoxic agents when given simultaneously; examples are 
phorbol esters, various aromatic and aliphatic hydrocarbons 
and so on. Some chemicals have both genotoxic and 
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promoter co-carcinogenic activity. 
- Hormoens. Tumours may be hormone dependent, the most 
important examples being oestrogen-dependent breast 
cancers and androgen-dependent prostatic cancers. In 
humans, endometrial hyperplasia induced by excessive 
oestrogen can give rise to cancer. This is probably due to a 
change in the DNA which is given expression when the cells 
proliferate. 
The development of a cancer is a complex, multi-stage 
process. Alteration of the DNA is the first step, but many later 
steps, at present only poorly understood, are also necessary. The 
actual initiation may require only a brief exposure to an 
environmental carcinogen. It is possible that each individual has 
some cells which have undergone the initiating event and that the 
burden of initiated cells increases steadily with age. Promotion is 
thought to be rare and in some circumstances may be the limiting 
event in the development of cancer. In animal experiments it has 
been shown to be important in determining the site of the tumour. 
Cigarette smoke not only contains a number of potentially 
carcinogenic aromatic hydrocarbons, but can be shown 
experimentally to have promoter activity. Urban polluted air 
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contains some substances which have potential carcinogenic, 
cocarcinogenic and promoter actions. 
BIOCHEMICAL MECHANISMS OF MUTAGENESIS 
It is by chemical modification of the bases in DNA, 
particularly guanine, that most chemical carcinogens act. There 
are two sites on the guanine molecule to which groups can easily 
be covalently attached in the presence of reactive metabolites of 
chemical carcinogens, namely the O^  and N^ positions. Substitution 
at the Og position of guanine is the most likely to produce a 
permanent mutagenic effect, since N, substitutions are usually 
quickly repaired by the normal DNA repair mechanisms-involving 
excision and replacement of the altered base. Substitution at O^ i 
more likely to produce a stable misreading of the code which 
perpetuated when the DNA is replicated. 
The accessibility of bases in DNA to chemical attack is 
greater when the DNA is in the process of replication (i.e. during 
cell division). The likelihood of genetic damage by many mutagens 
is related to the frequency of cell division. This means that the 
developing focus is particularly susceptible, and thus many 
mutagens and carcinogens are also teratogenic. This is also 
important in relation to mutagenesis of germ cells, particularly in 
is 
is 
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the female, because in humans the production of primary oocytes 
occurs by a rapid succession of mitotic divisions when the female 
baby is in utero in fact very early in embryogenesis. Each of these 
primary oocytes then undergoes only two further divisions-much 
later in life-at the time of ovulation. It is thus during early pregnancy 
that germ cells of the developing female embryo are most likely to 
undergo mutagenesis; this will not affect the developing embryo 
itself but is likely to become manifest in successive generations. 
In the male, germ cell divisions occur throughout life, and 
sensitivity to mutagens is continuously present. Some mutagens 
(e.g. ionising radiations) can affect DNA whether or not it is 
replicating, so that even the female germ cells are sensitive 
throughout reproductive life. Chemical mutagens are only one of 
many types of agent responsible for germ cell mutation, and the 
effects range from infertility, if the mutation is incompatible with 
life, to effects that actually confer a biological advantage. Between 
these extremes lie many forms of inherited disease. 
The importance of few drugs, in comparison to other 
chemicals such as pollutants and food additives, as a causative 
factor in mutagenesis has been established, and such 
epidemiological evidence as exists does suggest that they are of 
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major significance in causing cancer. 
Even if chemical modification of a base does persist in the 
form of a mutation, this may have no discernible effect on the 
organism. For example, it may be on a part of the genome that is 
not expressed, or it may cause a single amino acid substitution in 
a region of a protein molecule that has no effect on the function 
of the protein. It may, on the other hand, have a drastic effect, by 
affecting an enzyme or other functional protein in a major way 
(e.g. in the thalassaemic or sickle cell traits, which lead to the 
production of abnormal haemoglobins and result in serious illness. 
CORRELATION OF MUTAGENESIS AND CARCINOGENESIS 
The implications for carcinogenesis and mutagenesis of 
increased rates of chromosomal aberrations in lymphocytes in the 
subjects exposed to genotoxic agents are still under discussion. 
For many years it has been recognized that most of the strongly 
mutagenic agents, such as ionizing radiations, UV lights, and 
chemicals are also carcinogenic, that is, induce cancers. In recent 
years, sensitive techniques have been developed to test chemicals 
and other agents for mutagenicity and carcinogenicity. 
Carcinogenicity tests are usually done with rodents, most 
frequently newborn mice. These studies involve feeding or injecting 
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the substance being tested and subsequent examination of the 
animal for tumour formation. The mutagenicity tests have often 
been done in similar fashion. However, because mutation is a low 
frequency event and because maintaining large populations of 
animals such as mice is an expensive undertaking, such animal 
tests have usually been quite insensitive, that is, low levels of 
mutagenicity would seldom have been detected. 
Ames and his associates in 1975 developed some sensitive 
techniques by which large number of chemicals and other agents 
can be screened for mutagenicity. Their procedures are rapid and 
inexpensive. Ames' procedures involve the use of specially 
constructed strains of Salmonella typhimurium that carry 
auxotrophic mutations of various types : transitions, transversions 
and frame shift. The reversion of these auxotrophic mutants to 
prototrophy, either spontaneous or induced with various agents, 
can easily be monitored by placing a known number of mutant 
cells in a petriplate containing medium supplemented with a trace 
of the growth factor required by the auxotroph which is enough 
to support a few cell divisions, but not enough to allow the 
formation of visible colonies and hence counting the number of 
colonies produced by prototrophic revertants after an appropriate 
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period of incubation i.e. when some growth is required to detect 
the effects of mutagens that are only mutagenic to replicating DNA. 
The frequency of reversion induced by a particular substance can 
be compared directly with the spontaneous reversion frequency 
to obtain an estimate of its mutagenicity. Its ability to induce 
different types of mutations can be assessed by using a set of 
test strains that carry different types of mutations - one strain 
with a transition, one with a frameshift mutation and so forth. The 
procedures developed by Ames and colleagues are very sensitive 
and facilitate the detection of even weak mutagens. 
Over a period of several years during which hundreds of 
different chemicals were tested. Ames and his colleagues have 
observed a correlation of greater than 90 percent between the 
mutagenicity and the carcinogenicity of the substances tested. 
Initially, several potent carcinogens were found to be non mutagenic 
to the tester strains. Subsequently, many of these carcinogens, 
although non mutagenic per se, were found to be metabolized to 
strongly mutagenic derivatives in eukaryotic cells. Ames and his 
associates therefore added rat liver microsomal fraction to their 
assay systems in an attempt to detect the mutagenicity of metabolic 
derivatives of substances being tested. Coupling of the rat liver 
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microsomal activation system to the microbial mutagenicity tests 
expanded the utility of the system considerably. Nitrates, for 
example, are not mutagenic or carcinogenic themselves. However, 
in in vivo conditions, in eukaryotic cells, nitrates are converted 
via a series of enzyme-catalyzed reactions to nitrosamines, which 
are highly mutagenic and carcinogenic. 
Ames' Salmonella mutagenicity tests demonstrated the 
presence of frameshift mutagens in several different components 
of chemically fractionated cigarette smoke condensates. In some 
cases, activation by the liver microsomal preparation was required 
for mutagenicity, in other cases activation was not required. 
The observed correlation between mutagenicity and 
carcinogenicity is consistent with the theory that cancer is caused 
by somatic mutations. Most geniticists would agree that somatic 
mutations can cause cancer. This has received strong support from 
the discovery of cellular oncogenes and the demonstration that 
the oncogene responsible for human bladder carcinoma resulted 
from a single base pair change in its normal cellular counterpart 
(Reddy et a/., 1982). The common feature of all of the many 
diffierent types of cancer is that the malignant cells, whatever 
their types, continue to divide when their normal counterparts 
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would no longer be undergoing cell division. That is, all cancers 
exhibit a loss of normal control of cell division, with the resultant 
formation of tumors, cell division is undoubtedly, at least in part, 
under genetic control. Thus, mutation in a gene is involved in the 
control of cell division. Like a mutation in any other gene, it can 
cause a loss of function and thus a loss of the normal control of 
cell division. One can also easily envision epigenetic causes of 
cancer, that is, changes in the states of differentiation, rather 
than permanent changes in the genetic material per se (Mc Gregor 
etal., 1999) 
Genotoxic effects are induced at varying doses or levels, 
apparently and at the present state of the art, without any no effect 
threshold . Therefore, with low levels of potentially electrophilic 
chemicals in human environments, the hazards of raised incidence 
of cancer and heritable damages possibly of embryonal nature 
will be predominating over those of other kinds of toxicity, and 
hence may be characterized by a dose threshold below which the 
risk is zero. 
MUTAGENICITY AND CARCINOGENICITY TESTING SYSTEMS 
There is an extensive literature describing the different types 
of testing systems for the analysis of mutagenicity and 
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carcinogenicity in mammalian cells following treatment with 
chemical agents. These results have been obtained by using a large 
number of different protocols for the assays, some of which are 
adequate, some of which are not acceptable to achieve maximum 
sensitivity of the assay and yet some others that are sufficiently 
inappropriate to give false negatives. The most frequently used 
cells for in vitro cytogenetic assays are transformed cell lines such 
as Chinese hamster ovary (CHO) and V 79, largely because they 
are easy to grow in culture, have low chromosome numbers, and 
yield high frequencies of analysable metaphases. The 
disadvantages are that they are transformed cells frequently with 
a variable karyotype, they are treated as asynchronous populations, 
and generally have a considerable heterogeneity of cell cycle times. 
For mutagenicity and carcinogenicity testing, sensitive 
techniques have been developed in recent years to test chemicals 
and other agents. Carcinogenicity tests are usually done with 
rodents, most frequently newborn mice. These studies involve 
feeding or injecting the substance being tested and subsequent 
examination of the animal for tumor formation. But ultimately this 
assay system is found to be expensive and usually quite insensitive 
comparatively. Such long term tests are always expensive and time 
45 
consuming. There is another problem of predicting whether humans 
will respond to the carcinogens in the same way as the animals 
(Farmer, 1982). 
It can be advantageous to use short term tests (STTs) for 
genotoxic chemicals e.g. short term human lymphocyte cultures 
for chromosome aberration assays. These will have a stable 
karyotype, are reasonable synchronous populations at least for 
the first cell cycle, following mitogenetic stimulation, and exhibit 
less heterogeneity of cell cycle time. It is quite feasible to utilize 
human lymphocytes for the assay. These tests systems are 
however increasing day by day because of accumulating evidence 
in support of the somatic theory of carcinogenesis (Strauss, 1981; 
Crawford, 1985; Ames et al., 1987). and because of the new 
technologies developing fast to achieve the goal in less time and 
high accuracy. 
-AMES TESTING SYSTEM 
Among the various bacterial manifestations of DNA damage, 
Ames chose mutagenesis as the basis of his pioneering work to 
develop a test for potential carcinogen (Davoret, 1979). The 
Salmonella mutagenicity test (Ames et al., 1975) along with other 
short-term assays (Hollstein et al , 1979), is being extensively used 
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to survey a variety of substances in our environment for mutagenic 
activities. The test measures back mutation in several specially 
constructed mutants of Salmonella. 
The test has been adopted for use in detecting chemicals 
and drugs which are potential mutagen/carcinogen by adding 
homogenates of rat liver enzymes (S^ mix) directly to the petriplates 
as an approximation of mammalian metabolism introduced into 
the in vitro test (Ames et ai, 1973 b). Several histidine requiring 
mutants in the standard set of Salmonella tester strains have GC 
base pairs at the critical site for reversion (Isono and Yorno, 1974). 
Chromosome damage indicates a biological effect on 
the genome, the implications of which for carcinogenesis and 
mutagenesis are still unknown. It is generally believed that increased 
rates of chromosomal aberration in organism may indicate an 
increased cancer risk for the individual (Fomi, 1984). 
HERITABLE CYTOGENETIC DAMAGE 
Human cytogenetics began in the mid 1950s with the 
development of human tissue culture technique (Hsu 1952; Tjio 
and Levan 1956; and Moorhead et al, 1960). The improvement 
of this technique which analyses the numerical chromosome 
aberration (Lejuene et al., 1963) in human beings, initiated a new 
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branch of human genetics called clinical cytogenetics. The work 
done on chromosome analysis in adults, newborns and abortuses, 
permits an estimate of the load of chromosome mutations in man. 
The mutations are often called "spontaneous" mutations. It 
was supposed that part of these new mutations are induced by 
exogenous agents, including drugs and chemicls (Luers, 1955a; 
Rohrborn 1965). However, for a long time, the geneticists have 
underestimated the role of chemically induced germ cell mutations. 
It was due to the knowledge of epidemiological evidences that 
few genetic diseases were the results of exposure to chemical 
mutagens, the role of mutagen came into picture. The direct 
evidence of induced germ cell mutations, the selection of various 
stages of prenatal development and the outcome of chemically 
induced mutations were experimentally examined using 2,3,5-
triethyleneimonobenzoquinone-1,4 (Trenimon) (Easier et al., 1976) 
and mitocin C (Easier 1980). About 43% of zygotes showed 
induced chromosome aberrations. 
SHORT-TERM CYTOGENETIC TESTS 
It is advantageous and quite feasible to use short-term 
lymphocyte cultures for chromosome aberration assays. These 
will have a stable karyotype; are reasonable synchronous 
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populations at least for the first cell cycle following mitogenic 
stimulation, and exhibit less heterogeneity of cell cycle time. It 
has become quite feasible by use of cytogenetic methods to detect 
mutagenic potentialities of chemicals at biologically significant 
levels and in so doing to consider the complexity of human 
exposure patterns with various interacting factors and modifying 
responses. 
Some of the recommended methods for the in vitro 
cytogenetic tests are structural Chromosome Aberrations, (CAs) 
Sister Chromatic Exchanges (SCEs), Micronuclei Test (MNT), 
Cell Kinetics etc. 
For over 50 years now we have known that if cells are 
exposed to physical mutagens, such as ionizing radiations, we 
can observe mutational events. Many of the mutations are 
manifested as cytogenetic changes visible at the chromosome level. 
After the realization that chemical agents also can be mutagens, 
chromosomal aberrations were taken to be induced by these agents 
too (D'Amato, 1992). These early works were performed on the 
biological material that was most favoured for genetic or 
cytological analysis. These materials are still used to determine 
whether or not a compound is a mutagen but more often today 
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mammalian cells in culture are used for this purpose. 
After human lymphocytes are exposed to mutagen or test 
chemical, the mutation induced can be classified as either gene 
mutations, or gross chromosome aberrations. The chromosome 
aberrations are the result of effects that occur anywhere in the 
genome. Therefore, because of the difference in size between a 
genome and a gene, the cytogenetic effects manifested as gross 
chromosomal aberrations occur at a much greater frequency than 
do mutations observed at a single locus. Thus it is possible to 
observe effects of mutagens in relatively small numbers of cells, 
and consequently, chromosome aberration tests have provided a 
very sensitive method for determining whether or not an 
environmental agent can interact with the genetic material. 
With most chemical mutagens (Evans and Scott, 1969) and 
even with some physical mutagens such as ultraviolet radiation 
(Griggs and Bender, 1973), only chromatid aberrations are 
produced, that is these agents produce lesions in chromosomal 
DNA that, if unrepaired, will remain in the chromosome and form 
an aberration when that chromosome replicates in S. Thus lesions 
produced in G, and S can produce chromatid aberrations 
observable at the first metaphase after treatment, whereas lesions 
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produced in G^ chromosomes do not give rise to aberrations until 
the cell passes through some successive S phase. Agents that 
produce such lesions are designated S-dependent agents and differ 
from x-rays and the occasional chemical agents that can produce 
double-strand breaks in DNA and can thus form aberrations at 
any stage of the cell cycle. The technology was later extended to 
exposed humans in whom chromosome aberrations induced in 
peripheral blood lymphocytes could be observed (Gooch et al., 
1964; Bender and Gooch, 1967). The human peripheral blood 
lymphocyte is a particularly felicitous cell for such studies because 
it can be obtained noninvasively and because it is an extremely 
long-lived cell (Buckton et al., 1967 b) in which all of the 
chromosomes are in G^ , i.e. are in noncycling cells containing G,-
like unreplicated chromosomes so that only chromosome and not 
chromatid-aberrations will be induced so that phenomena caused 
by cell-stage sensitivity are minimized. 
Induced chromosome aberrations in human lymphocytes 
were well-developed by the mid-1970s (Evans and O'Riordan 1975) 
Recommended methodology, classification and scoring of 
structural aberrations and statistical methods have been described 
(Fomi, 1979; Evans 1982). Chromosome aberrations consist of 
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breakage and rearrangements of chromosome visualized in the 
metaphase plate. Chromosome aberrations are most sensitive to 
agents that can directly break DNA duplex. However, since most 
chemical mutagens which cause chromatid type damage, one 'S' 
phase dependent, the highest yield of aberration is likely to be 
seen in the first division of the metaphases. 
Sister Chromatid Exchanges (SCEs) involve breakage of 
double stranded DNA in both chromatids followed by an exchange 
of whole DNA duplexes. The SCEs, like chromosome aberrations, 
induced by S-dependent agents, are formed by unpaired lesions 
that are present when the cell passes through S-phase and the 
chromosome replicates. This is the most sensitive method to detect 
the mutagenic property of the chemical and to determine which of 
the metabolites of a premutagenic and precarcinogenic agent might 
be the most likely ones to interact with DNA and cause its effect 
(Perry and Evans, 1975; Latt et al., 1981). 
An additional check on the potential of the mutagen to 
produce an effect on the cells can be made by analysing the 
proportion of mitotic cells in their first, second or subsequent 
metaphase for each treatment group and calculating a proliferation 
index (PI). 
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Cell cycle kinetics analysis is based on the differential 
staining technique of sister chromatids. It is a sensitive method 
for detecting delay or stimulation in human lymphocyte cultures. 
Potential of the mutagenic agent to produce and effect on the 
cells is evaluated by analysing the proportion of mitotic cells in 
their first, second and third replication cycles (Mj, M^ and M3 
respectively) (Tice et al., 1976; Crossen and Morgan, 1977; 
Morimoto and Wolff, 1980). 
The rate at which mitosis occurs is measured by the mitotic 
index or proliferation index or replication index. A statistical 
difference between the test compound treated and control groups 
indicates the ability of the chemical to introduce cell cycle delay 
or cytotoxicity. In some instances this type of information can be 
important for indicating that metabolic activation in the test 
compound had occurred even though it was not clastogenic. Thus, 
the index gives an idea about the stimulation of lymphocytes to 
divide and the mitotic activity in culture (Melarango and Smith, 
1984; Sinha et al., 1984). Any change in mitotic index following 
drug exposure compared to concurrent control, provides 
information on mitostimulative or mitodepressive activity of the 
drug. 
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DRUG TOXICITY 
All drugs have properties that can be harmful to people taking 
them (drug toxicity). These may be so undesirable that they greatly 
limit the therapeutic usefulness of a given drug. Table summarizes 
a scheme for the classification of drug-induced toxicities. It is 
based partly on a scheme proposed by Rosenheim, but an effort 
has been made to deal more completely with the fundamental 
mechanisms involved. Note that there are two major subdivisions 
under the category "Primary Toxic Effects." The first is related 
to the therapeutic or pharmacologic properties of the drug, whereas 
the second deals with adverse or toxic effects unrelated to the 
pharmacologic properties. Respiratory depression as a result of 
phenobarbital overdose is a familiar example of the first 
subdivision, whereas such effects as megaloblastic anemia, ginvival 
hyperplasia, and osteomalacia as induced by phenytoin or valproic 
acid-induced liver damage are examples of the second subdivision. 
The hypokalemia associated with thiazide diuretic therapy is 
classed as an "indirect consequence of a primary drug action." 
The latter is a subcategory of an "exaggerated pharmacologic 
effect," since thiazides do enhance potassium excretion by the 
kidneys. Frank renal or hepatic injury can hardly be considered 
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as an "exaggerated pharmacologic effect." They are examples of 
the second category of toxic effects, unrelated to the 
pharmacologic effects of the drug. 
Pharmacologic effects other than those intended for the 
therapeutic purpose are included in the category of "undesirable 
side-effects." Examples of these include dry mouth and blurred 
vision, which accompany therapeutic use of mscarinic blocking 
drugs, the constipation that occurs with codeine analgesia, or the 
sedation or drowsiness observed with classic antihistaminic drugs. 
The term "side-effect" carried the connotation that the reaction 
or effect is relatively mild. In the scheme of Table 104,2, drug -
induced liver, kidney, or bone marrow damage would not be 
classified as "undesirable side-effects." Instead, such reactions 
are examples of "primary toxic effects." 
The category called "idiosyncratic reaction" can be very 
confusing. Some authors regard these reaction simply as being 
rare (low-incidence), irrespective of the underlying mechanism. 
Others regard them as low-incidence reactions that occur by an 
unknown mechanism. Goldestein et al. Restrict the term to drug 
reactions involving a genetically determined trait in an individual. 
Most authorities agree that the mere incidence of a reaction should 
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not constitute a basis for its definition, but others are reluctant to 
restrict the term to reactions having an in heited basis. Such a 
restriction would exclude noninherited reactions classed as 
"idiosyncratic", but which have a well-defined basis. For cally-
based reactions as one subtype of "idiosyncratic reactions." but 
allows for the inclusion of other sub-types. The subject is still 
contraversial, and the reader should be aware that "drug 
idiosyncrasy" means different things to different authors. 
Zbinden classified toxic reactions into three kinds of change 
functional; biochemical; and structural. Each of these can be 
divided into multiple subcategories. Functional toxicity was 
defined as "due to the pharmacologic effects not necessary for 
the desired action, although they may for another patient in 
different circumstances constitute an important therapeutic effect." 
This definition appears to correspond to that for undesirable 
side-effects in Table 1. The term "functional" implies a change in 
the function of an organ system, and these undesirable side-effects 
are usually reversible on discontinuation of the drug. 
"Biochemical toxicity," as defined by Zbinden, is due to 
changes in biochemical reactions associated with various organs 
wit|iOj^ i^7lderic,e,^ 6f gross organ damage. Shifts in hormonal, 
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balance, changes in acid-base balance, changes in electrolytes, or 
alterations in blood clotting, if a adverse, are examples of 
biochemical toxicity. These reactions are also reversible up to a point 
on discontinuation of the drug. In Table 1 such reactions might be 
classified as "primary toxic effects" or as "undesirable side-effects," 
depending on the underlying mechanism. 
Obviously, "structural toxicity," as used by Zbinden, involves 
an actual change in the structure of an organ or tissue, these 
structural changes in turn may bring about biochemical and/or 
fimctional changes, e.g., drug-induced cataracts, or liver or kidney 
injury, which would be classified as primary toxic effects" in 
Table 1. 
Table 1 : Classification of Drug-Induced Toxic Reactions 
I. Primary toxic Effects 
A. Exaggerated pharmocologic effect 
1. Occurs with drug overdose 
2. Occurs with therapeutic doses if individual is hyper-
reactive (hyper-susceptible, intolerant) to drug. 
3. Indirect consequence of primary drug action. 
B. Adverse effect unrelated to pharmacologic therapeutic 
effect. 
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1. Occurs with drug overdosage 
2. Occurs with therapeutic doses. 
3. Occurs with therapeutic doses if individual is hyper-
reactive (hyper-susceptible, intolerant) to drug. 
II. Undesirable Side-effects 
A. Undesirable pharmacologic effect that accopmanies the 
primary drug action 
1. Occurs with therapeutic doses 
III. Alergic Reactions 
A. Effect based on immunologic reaction (antigen antibody 
reaction). 
1. Occurs in sensitized individual 
2. Occurs with therapeutic or subtherapeutic doses 
IV. Idiosyncratic Reactions 
A. Unexpected or unpredictable reaction, dissimilar from 
known pharmacologic or adverse effects attributable 
to the drug 
1. Depends on the personal characteristics of the 
individual 
2. Occurs in a small number of individuals 
3. May be attributable to the genetic status of the 
individual 
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V. Physical Dependence 
A. Altered physiologic state resulting in abstinence 
syndrome when drug in discontinued 
STEROIDAL DRUGS : USES AND APPLICATIONS 
The steroids form a group of structurally related 
compounds which are widely distributed in animals and plants. 
Included in the steroids are sterols (from which the name steroid 
is derived), vitamin D, the bile acids, a number of sex hormones, 
the adrenal cortex hormones, some carcinogenic hydrocarbons, 
certain sapogenins, etc. The structures of the steroids are based 
on the 1,2-cyclopentenoperhydrophenanthrene skeleton. In 
mammals five important groups of steroidal hormones occur : 
progestestagens, glucocorticoids and mineralocorticoids with 21, 
androgens with 19 and estrogens with 18 carbon atoms. Hormones 
are substances which are secreted by the ductless glands, and 
only minute amounts are necessary to produce the various 
physiological reactions in the body. As a group, hormones do not 
resemble one another chemically, and then classification is based 
on their physiological activity. The sex hormones belong to the 
steroid class of compounds, and are produced in the gonads 
(testes in the male, and overies in the female). 
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Naturally occurring as well as synthetic steroids have since 
long been used for various purposes. Several steroids have been 
reported to possess anti-inflammatory (Bottralik, 1988), 
anaesthetic (Evelyne et al., 1988), anabolic (Fennessey et al., 
1988), angiostatic (Larrian, 1989), antiangiogenic (Judah et al., 
1989), cardioactive (Karel and Thomas, 1987) and antidiabetic 
activities. 
Sex steroidal hormones produced by gonads and adrenals 
are necessary for conception, embryonic maturation, and 
development of primary and secondary sexual characteristics at 
puberty. The gonadal hormones are used therapeutically in 
replacement therapy and, in case of estrogen, for contraception 
and osteoporosis. The adrenal cortex produces two major classes 
of steroid hormones : the adrenocorticosteroids (glucocorticoids 
and mineralocorticoids) and the adrenal androgens. Hormones of 
the adrenal cortex are used in replacement therapy, in the treatment 
and management of inflammatory diseases such as reheumatoid 
arthritis, in the treatment of severe allergic conditions, and in the 
treatment of some cancers. 
Steroid hormones diffuse across the cell membrane and bind 
with high affinity to specific nuclear receptor proteins. Affinity 
60 
for the receptor varies with the particular hormone. The attachment 
of steroid receptor complex to the genome is required for a 
response. The activated steroid receptor complex interacts with 
DNA to indicate hormone specific RNA synthesis resulting in the 
synthesis of specific proteins that mediate a number of 
physiological functions. 
Certain steroids have also been reported to control energy 
metabolism throughout pregnancy (Baird et ai, 1985), steroid 
alkaloid formulations have been used for skin disorder treatment 
(Chain et ai, 1984). Also, there are some steroidal compounds 
which increase resistance against drugs and toxic agents 
(Kourounakis, 1986). Sex hormonal steroids are used in human 
medicine for a large variety of conditions, apart from their uses 
as oral contraceptive agents viz. in the treatment of dysmenorrhoea, 
endometriosis and dysfunctional urine bleedings and climacterics 
Their use in the prevention of postmenopausal osteoporosis, is 
also there. Progestines have been used in the management of 
threatened abortion and to prevent premature labour. 
The natural steroids are rapidly metabolised and eliminated. 
Estradiol-17p and progesterone have half lives of 20 minutes, and 
testosterones have of 11 minutes (Sandberg and Slaunwhite, 1958). 
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Some conversions occur peripherally, but the major site of 
metabolism is in the liver. Elimination of glucoromide/or sulphate 
conjugates of metabolites occurs via the urine or the bile. The 
main urinary metabolites of Estradiol 17 (3 and Estrone one the 
conjugates of estriol, 2-hydroxy-esterone, esterone, 16a-
hydroxyestrone and estradiol. The main urinary metabolite of 
progesterone is the fully reduced compound, pregnanediol 
(Klopper and Millie, 1956). 
Synthetic steroids may be metabolised in humans by the 
same mechanisms as are the natural compounds. The main 
metabolites of norethynodrel ethynodiol diacetate and norgestrel 
are the 3a and 3p alcohols (Cook et al, 1973). The products are 
eliminated as the glucuronides and sulphates (Layne, 1963). 
STEROID HORMONES AND CARCINOGENESIS 
Several steroids have been reported to be mutagenic and 
carcinogenic on the basis of short term tests (Dunkel et al, 1985). 
There is high risk of development of cancer with the use of 
steroids, several steroids have been reported to possess 
tumourogenic and carcinogenic activities (Kay, 1981). Various 
steroids have been shown to play an active role in human 
carcinogenesis (Lipsett, 1986). Specially the steroidal hormones 
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and their derivatives have been demonstrated to be mutagenic and 
carcinogenic in the bacterial as well as in the animal testing system 
(Kay, 1981; Metzler, 1984). 
Contraceptive steroids have been assessed for toxicological 
and carcinogenic hazards (Heywood, 1986). Tissue steroids have 
been found to play a role in regulating aromatase activities in breast 
and endometrial cancer (James et al., 1986; Colditz et al., 1995). 
Estrogenic hormones have been shown to possess the 
tumourogenic activity and are assumed to serve as regulators of 
tumourous growth. These hormones probably maintain the 
neoplastic state of the cells in a variety of well characterised 
experimental animal tumour systems (Katzene Ilenbogen, 1986). 
Growth promoting effect on hepatocarcinoma has also been 
demonstrated to be mediated by estrogen receptor in the mated 
rats (Kohigashi et al., 1986). Moreover, the stereochemical 
complementarity of DNA and reproductive steroid hormones have 
been found to correlate with biological activity (Lawrence et al., 
1986). 
Since adrenal steroids influence so many cellular functions, 
it would seem likely that influences on the incidence of cancer in 
glucocorticoid deficiency or excess syndromes might be observed. 
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This might seem particularly probable since steroids inhibit the 
immune system which may be important in the prevention of certain 
cancer. There are complex interrelationships between a number 
of hormones and cancer (Bernstein et al, 1992). Further, elevations 
of glucocorticoids are present in malignancy (Deshpande et al, 
1961 \ Doe et al., 1969) and stress of a severe illness . There are 
infact data suggesting the facilitation of tumour survival of 
metastasis by adrenal steroid stimulations (Sutow et al, 1965), 
and steroid pretreatment of the host is most effective in fostering 
take and growth of transplanted tumours (Moore et al., 1960). 
Glucocorticoids have been shown in vitro to enhance the 
production of certain tumour viruses (Moruhenn et al, 1973). 
Also, in transplant recipients receiving steroids and other 
immunosuppressive agents, there is an increased incidence of 
lymphoid cell malignancies (Pierce et al., 1972). As far as 
correlation of steroid hormone and cancer is concerned the 
following points of possible mechanisms are speculative for 
neoplastic growth : 
(1) Steroid hormones may increase the binding of chemical 
carcinogens to cellular constituents e.g. by influencing metabolic 
activation system. 
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(2) Steroid hormones may activate oncogenic virus production 
e.g. mammary tumour virus in mice. 
(3) Exposure to hormones may resuh in lesions (preneoplastic) 
which provide an environment for the survival of cells with 
abnormal growth potentials. 
(4) These hormones may be immunosuppressive and could thus 
influence tumour occurrence and growth. 
(5) They may influence the rate of progression of preneoplastic 
cells to neoplastic cells. 
(6) They may preferentially stimulate proliferation of abnormal 
cell populations. 
(7) They may stimulate the DNA synthesis and mitosis essential 
for fixation of the transformed state. 
(8) Steroid hormones, by stimulating the proliferation of normal 
cells with a definitive number of cell divisions, may exhaust the 
normal cell population and thus eliminate their inhibitory influence 
over the proliferation of abnormal cells (Nandi, 1978). 
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STEROID HORMONES AND EMBRYOTOXICITY/TERATOGENICrrY 
Several steroidal hormones cause embryotoxicity and 
foetotoxicity in several species, and such effects are usually dose-
related. Some estrogens also produce teratogenic effects and 
impaired fertility in exposed offspring. Certain progestins, 
testosterone and testesterone derivatives have a virilizing effect 
on the foetus. 
In human, birth defects have been observed in foetuses after 
maternal ingestion of various drugs. However, only in a limited 
number of cases is it possible to ascribe a particular defect to a 
specific drug. If an adverse effect is to be produced, exposure 
must occur during the relevant susceptible period of embryogensis; 
and in interpreting the results of a study, the influence of the drug 
must be distinguished from any effects of the condition for which 
the drug was administered (Vessey et al., 1989; Wingfield, 1991). 
Non-neoplastic alterations in the genital tract are commonly 
found in female children born to women who received 
diethylstiibestool during pregnancy. These changes include vaginal 
adenosis, cervical ectrophion and transverse fibrous ridges on 
the cervix or in the vagina. In addition there is some evidence of 
alterations in the structure of the fundus of the uterus. Changes in 
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the male genital tract include epididymal cysts, testicular 
abnormalities and alterations in the seminal fluid (Wingfield, 1991). 
Neonatal mice provide a useful model for studying the long-term 
effects of prenatal exposure of humans to diethylstilbestrol and 
sex steroids (Forsberg, 1976; Kohrman, 1978). Both mice and 
rats are bom with incompletely developed genital tracts, in a stage 
similar to that in the first trimester in humans. In mice, the first 
few days after birth constitute a critical period during which 
injection of sex steroids or diethylstilbestrol may induce 
irreversible changes in the genital tract. Some of these responses, 
such as vaginal adenosis (Forsberg, 1979) and epididymal cysts 
(McLachlan et al, 1975,1982, resemble those seen in human after 
exposure to diethyl stilbestrol (Gill et al., 1977; Herbst, 1971). 
Masculanization of the external genitalia in female foetuses 
has been observed after their exposure in uterus to large doses 
of progestational agents. Similar changes have been reported after 
exposure to combinations of these compounds with estrogens 
(Colditz et al., 1995). Advancement of skeletal maturation has 
also been noted. Milder degrees of masculinazation have been 
reported with progestational compounds that have a lesser degree 
of androgenic activity, such as medroxyprogesterone acetate 
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(Burstein and Wasserman, 1964). 
Chromosome abnormalities (principally triploidy and 
tetr'aploidy) in foetuses have been reported to be more common 
following the use of oral contraceptives by their mothers (Carr, 
1970; Alberman et al, 1976; Harlap et al, 1979; McGourty, C. 
1989). It has been suggested that more congenital abnormalities 
occur in infants born to women who became pregnant while 
actually taking oral contraceptives. The defects described include 
the VACTERL syndrome (a pattern of multiple anomalies: 
vertebral, anal, cardiac, tracheal, esophageal, renal, limb (Nora 
and Nora, 1975; Nora et al, 1978), cardiovascular abnormalities 
(Heinomen et al., 1977; Rothman and Louik, 1978) and limb 
reduction defects (Janerich et al., 1974). A VACTERL syndrome 
was seen in a child of a mother given hormone therapy at the 
beginning of pregnancy (Kaufman, 1973). Higher risks of multiple 
births and abortions, among other side effects accompanying use 
of clomiphene and clomiphine citrate, are well documented. In 
humans neural tube defects have been reported in the 11 children 
of 10 women given clomiphene to induce ovulation. (Sandler, 1973; 
Field and Kerr, 1974; 1976; Barrett et al 1981). 
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STEROID HORMONES AND MUTAGENICITY/ 
GENOTOXICITY/CLASTOGENICITY 
Steroid hormones like estrogens were identified as mitotic 
inhibitors by Rao and Engelberg (1967) who suggested that the 
structural specificity is required for mitotic inhibition. Lycette et 
al. (1970) observed significant increase of hyperploid cells in 
cultured human synovial cells treated with high concentration of 
estradiol. Estradiol binds to isolated DNA (Blackburn et al., 1974) 
and induces fragmentation in isolated DNA (Yamafuji et al, 1971). 
The hormone is negative in Ames test and does not induce point 
mutations in mammalian cells in vitro (Lang and Redmann, 1979; 
Drevon etal, 1981). In human, embryonal fibroblasts and kidney 
epithelial cells, estradiol was reported to induce structural 
chromosomal aberrations (Serova and Kerkis, 1974). 
Some of the commonly used steroidal oral contraceptive 
(DCs) have been found to be mutagenic in plant chromosomes 
(Hakeem and Amer, 1965; Kabariti and Mazrooei, 1984). The drug 
'Ovral 50' was found to be genotoxic in mammals such as mice 
and dogs (Williams et al., 1968). Badr and Badr (1974) 
demonstrated a high incidence of dominant lethal mutations in 
female mice. The OCs were not mutagenic in Drosphila 
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melanogaster (Paradi, 1981). Chromosomal abnormalities were 
found in spontaneous abortions in women who became pregnant 
after stopping the intake of OC pills. Carr (1967) and Goh (1967) 
reported an increased number of chromnosomal breaks and 
rearrangements in lymphocyte cultures of woman taking OCs. This 
report was confirmed by McQuarrie et al. (1978) and Littlefield 
et al. (1971). An increased frequency of chromosomal aberration 
and micronucleus was reported using a combination of drugs 
containing estrogen ethinyl estradiol and progestin northisterone 
acetate (Shyama et al., 1991). 
Murthy and Prema (1983) observed a significantly increased 
frequency of SCE in OC users. Simultaneous addition of estradiol, 
progesterone and human chorionic gonadotropins increased the 
SCE frequency in human lymphocyte culture, but their separate 
administration did not induce SCEs (Sharma and Das, 1986). 
The mutagenicity of hydrocortisone both with and without 
metabolic activation (S^ mix) in the inhibition of the bacterial lawn 
formation could not produce significant result (Maron and Ames, 
1983). Dexamethasone has been found to induce chromosomal 
aberrations and sister chromatid exchanges in human lymphocytes 
in vivo but not in vitro (Singh et al., 1994; Ahmad et al., 2000), 
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whereas, other corticosteroid hydrocortisone induced 
chromosomal aberrations and sister chromatid exchanges in hiraian 
lymphocytes in vitro (Bali et al., 1990; Shadab et al., 1999). 
OBJECTIVES AND LIMITATIONS OF THE PRESENT WORK 
With the list of xenobiotics increasing day by day, mankind 
is exposed to a sea of chemicals not encountered since his 
evolutionary decent or basic biochemical adaptation. Since these 
chemicals are integral to human survival and well-being, their 
growing use can't be stopped except through alternatives. It is, 
therefore, extremely important to determine the toxicity of these 
chemicals, if any, and suggest safe therapeutic limits for curing 
the diseases. 
Among the pharmacological application of steroids, 
antitumour, anti-inflammatory and antineuplastic activities are 
reported (Tait and Burstein, 1961; Killie, 1971). Corticosteroid is 
reported to be antiinflammatory and immunosuppressive, 
antibacterial, antimicrobial and antiviral (Haynes, 1974). 
Glucocorticoids have been known to have important effects on 
the nervous system and large doses or glucocorticoids stimulate 
excessive production of acid and pepsin in the stomach and even 
cause peptic ulcer. 
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The cytogenetic effects of steroids have been mainly studied 
for their teratogenic (Joshi, 1983), carcinogenic (La Vecchia et 
al., 1996; Rosenfield et al., 1983) mutagenic and clastogenic 
(Dhillon and Dhillon, 1996; Wheeler, 1986) potentialities. However, 
detailed study on the effects of hormonal steroids on human 
lymphocyte chromosomes has been seriously taken in our 
laboratory in the past (Azfer and Afzal, 1994). While our 
laboratory earlier has reported a study on estrogens, present study 
is related to three progestogens and three corticosteroids, not 
studied earlier. 
The work has been conducted with a view to study the 
following objectives : 
(1) To study the effect of steroids through the human lymphocyte 
culture in vitro. 
(2) To study the genotoxic impact of steroids on human 
chromosomes. 
(3) To evaluate the chromosomal damage paralleled with the 
metabolic activation (S^ mix). 
(4) To score the frequency of sister-chromatid exchange (SCE) 
with and without steroid. 
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(5) The SCE has been recorded also in case of the metabolic 
activation following S^  mix. 
(6) The effect on growth kinetics of lymphocyte cell cycle was 
ascertained in the presence as well as absence of S^  mix. 
(7) In vivo exposure among patients on steroid therapy was 
followed to record clinical symptoms through physicians and 
compiled by us. 
(8) Detailed in vivo cytogenetic study could not be performed 
due to lack of infrastructure and logistic problems in 
monitoring enough number of patients in non-medical setup 
of the department of Zoology. 
RIAL 
METHOD. 
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MATERIALS AND METHODS 
Vxytogenetic abnormalities can essentially be studied in any 
cycling cell population, or in any cell population that can be 
stimulated by a mitogenic agent to cycle. In animals there are, 
several cell types that fit these criteria, but for humans there are 
to all intents and purposes, only two types that are practically 
suitable. These are the bone marrow cells, which are a cycling 
population, and peripheral lymphocytes, which are normally 
noncycling, but can be stimulated to enter the cell cycle by culturing 
in vitro with a mitogen such as phytohemagglutinin (PHA). Because 
of the ease of obtaining blood samples in contrast to taking bone 
marrow samples, the majority of studies on the induction of 
chromosome aberrations in humans have been done with the 
lymphocyte assay. 
In the present work cytogenetic effects of six steroids on 
human peripheral blood lymphocytes in vitro and in vivo have 
been studied. Blood donors were healthy and of 20-35 years age 
group. They were of both the sexes for corticosteroids and only 
females for progestins and similar socioeconomic status. It was 
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especially confirmed that all the donors are not occupationally 
exposed to any possible mutagen or clastogen. The genetic end 
points were the most readily-available and widely-used observations 
for evaluating somatic mutations in human beings. These are 
chromosomal aberrations (CAs), sister chromatid exchanges 
(SCE) and cell cycle kinetics assays. All the end points were 
assessed in the presence as well as absence of the exogenous 
metabolic activation system (S^ mix). Few drug users were 
examined for recording adverse effects and it was tried to find 
out correlation, if any of the severe adverse effects and genotoxic 
potential of the drugs. Statistical analysis was performed to ensure 
and find out significant values. 
DESCRIPTION OF TEST CHEMICALS 
Two types of steroids were selected for the cytogenetic 
evaluation in the present investigation. Of these three steroids 
namely Medroxyprogesterone acetate, Hydroxyprogesterone 
caproate, and Megestrol acetate were progesterones while the other 
three namely Betamethasone, Prednisolone and Triamcinolone were 
corticosteroids. Some important properties of these steroids are 
as follows : 
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[A] PROGESTERONES 
1. Hydroxyprogcsterone Caproate 
(Cj^ H^oO,, Mol.wt. 428.61) 
<-OCOCH2(CH2)3CH3 
Preparation : Hydroxyprogcsterone is esterified by heating with 
caproic anhydride in the presence of p-toluencsulfonic acid under 
an atmosphere of nitrogen. 
Description : White or creamy white crystalline powder which is 
odor less or has a slight odor; melts between 120 and 124°. 
Solubility : Insoluble in water; solubility is Ig in about 20 ml 
ether or 800 mL benzene. 
Uses : Show actions and uses of the progestins, except that it 
does not prevent ovulation. It is several times more potent than 
progesterone, and its duration of action is longer, but its onset of 
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action is also slower. A single injection of a solution of 
hydroxyprogesterone caproate in oil will exert progestational 
effects for 1 to 2 wk. 
It is not converted to progesterone or hydroxyprogesterone 
within the body. When used to regulate an irregular estrous cycle, 
it is usually combined with an estrogen. 
In addition to a potential to cause the usual side effects of 
progestins, this drug occasionally causes hypersensitivity, 
coughing or dyspnea. In rare instances it may cause virilization of 
the female fetus. It is used intramuscularly and cyclically with 
estradiol valerate for amenorrhea, to induce a secretary 
endometrium and desquamation, for uterine carcinoma and in 
several other diseases. 
2. Medroxyprogesterone Acetate 
(Cj^ Hj^ O ,^ Mol. Wt. 386.53) 
^ OCOCH3 
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Preparation : It is prepared from 17 a-hydroxyprogesterone by 
first forming the 3,21-bisethylene acetal with ethylene glycol, then 
treating with peracetic acid to give a mixture of the 5a,6a-and 
5(3, 6p-epoxides. With methyl magnesium iodide the a-epoxide 
isomer yields the 5a-hydroxy-6p-methyl derivative which 
dehydrates and epimerizes with hydrogen chloride in chloroform 
to the A4-6a-methyl compound, medroxyprogesterone. Acylation 
with acetic anhydride and p-toluenesulfonic acid in acetic acid 
gives medroxyprogesterone acetate. 
Description : White to off-white, odorless, crystalline powder; 
melts at about 205**; stable in air. 
Solubility : Insoluble in water; freely soluble in chloroform; soluble 
in acetone or dioxane; sparingly soluble in ether. 
Uses : Its oral efficacy is an advantage over progesterone. There 
is no clinical evidence todate confirming the supposed efficacy in 
threatened or habitual abortions. 
Furthermore, the drug is teratogenic during the first 4 months 
of pregnancy and hence should not be used for threatened 
abortion. The longer duration action of intramuscular drug makes 
it popular in son e^ bountries. It is effective as a contraceptive 
\ \ 
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when given IM at the recommended dose to the women every 3 
months. Gonadotropin secretion is inhibited, which prevents 
follicular maturation and ovulation and results in endometrial 
thinning. It has been found to be beneficial in some cases of Sleep 
apnea. Aqueous suspensions administered intramuscularly have 
a duration of action for weeks and months. It is administered 
orally for secondary amenorrhea and functional uterine bleeding 
and for endometriosis as an adjunct to cyclical therapy with the 
estrogen. It is used intramuscularly for endometriosis and 
endometral carcinoma and as deep intramuscular one for 
contraception. 
3. Megestrol Acetate 
C^HjjO ,^ Mol. Wt. - 384.51 
^OCOCHs 
Description : White or almost white, crystalline powder, odorless 
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tasteless; melts at about 215°. 
Solubility : Insoluble in water; sparingly soluble in alcohol; slightly 
soluble in ether; very soluble in chloroform. 
Uses : It is very potent in inhibiting ovulation, and is employed as 
an oral contraceptive. For such use it is supplemented with an 
estrogen, generally ethinyl estradiol. It is also used for palliative 
treatment of inoperable advanced carcinoma of the breast or 
endometrium, as an adjunct to other therapy. It has no estrogenic 
or androgenic properties of its own. Side effects include nausea 
and vomiting, headache, tiredness, breast discomfort and weight 
gain. It is used in endometrial carcinoma, breast cancer and as an 
oral contraceptive. 
[Bl CORTICOSTEROIDS : 
1. Betamethasone 
CjjH^FO ,^ Mol.Wt. - 392.47 
80 
Preparation : Betamethasone is prepared from 16-
dehydropregnenolone by treatment with methyl magnesium iodide 
to insert the 16 p-methyl group, catalytic reduction of the remaining 
double bond, enol acylation at position 20 and reaction with 
peracetic acid followed by hydrolysis to the 16p-methyl-17a-
hydroxy compound. Bromination and acetoxylation gives the 3-
p-hydroxy-21-acetoxy derivative which is oxidized to the 3-oxo 
compound with chromic acid. Dibromination at positions 1 and 4 
followed by dehydrobromination with dimethylformamide to the 
1,4-diene, then incubation with Pestalotia foedans (or a similar 
organism) results in the lla-hydroxy derivative. Esterification at 
the 11-position with ethyl chloroformate, elimination of the ester 
function with acetic acid to form the 1,4,9(1 l)-triene, treatment 
with N-bromoacetamide and perchloric acid gives the 9a-bromo-
lip-hydroxy compound. Abstraction of HBr with potassium 
acetate affords the 9p, llp-epoxy derivative which by treatment 
with HF in a halogenated hydrocarbon yields the 9a-fluoro-lip-
hydroxy analog,, betamethasone. 
Description : White to practically white, odorless crystalline 
powder; melts at about 240° with some decomposition. 
Solubility : 1 g in 5300 mL water, 65 mL alcohol or 325 mL 
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chloroform; very slightly soluble in ether. 
Uses : An extremely potent glucocorticoid with actions, uses and 
side effects typical of this class of steroids. Its activity is 20 to 
30 times that of Cortisol. However, it only rarely induces sodium 
and water retention and potassium loss such as accompany 
treatment with cortisone and many other adrenal corticoids; on 
occasion, it even may increase sodium excretion and induce 
diuresis. In the usual doses, the incidence of characteristic adrenal 
corticoid untoward effects such as anorexia, protracted weight 
loss, vertigo, headache and muscle weakness is quite low. The 
plasma half-life in about 6.5 h and the biological half life 36 to 54 h. 
2. Prednisolone 
C^ iHjgO ,^ Mol. Wt. 360.45 
Preparation : From hydrocortisone by a microbiological process 
using Corynebacterium simplex which selectively dehydrogenates 
Cortisol at the 1 and 2 positions. 
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Description : White to practically white odorless, crystalline 
powder; melts at about 235° with some decomposition. 
Solubility : 1 g in 30 mL alcohol or 180 mL chloroform very 
slightly soluble in water. 
Uses : A glucocorticoid with the actions, uses and side effects 
typical of drugs of this class. It is 4 times as potent as, but 
relatively somewhat weaker than, hydrocortisone as a 
mineralocorticoid although sodium retention and potassium 
depletion can occur. The plasma half life is said to be about 3 h 
and the biological half-life is 18 to 36 h. However, its 
pharmacokinetics is dose dependent because of nonlinear protein 
binding. With high doses the plasma-half life may approach 1.7 h. 
Except for its higher solubility, it may be considered equivalent to 
prednisone; it is the biologically active metabolite of prednisone. 
3. Triamcinolone 
CjjHj^ FOg, Mol. Wt. 394.44 
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Preparation : From hydrocortisone acetate via the 3,20-bisketal 
by treatment with thionyl chloride, refluxing with potassium 
hydroxide and acetylation to give 21-acetoxy-4,9,ll(16)-
pregnatriene-3,20-dione. Oxidation with osmium tetroxide to the 
16a, 17a-dihydroxy derivative and subsequent insertion of the 
9a-fluoro and llp-hydroxy groups as indicated for 
Betamethasone, gives a product lacking only a double bond at the 
1-position. This latter step is accomplished by incubation with 
Nocardia corallina, followed by saponification of the acetate to 
yield triamcinolone. Alternatively, the compound can be made from 
Fludrocortisone by enzymatically inserting the 16a-hydroxyl group 
and dehydrogenating as above at the 1,2-position. 
Description : Fine, white or practically white, crystalline powder 
having not more than a slight odor; its polymorphic forms and/or 
solvates melt between 248° and 250°, 260° and 263° or 269° and 
271°. 
Solubility : 1 gm in about 5000 mL water,70 mL propylene glycol 
or less than 20 mL dimethyl sulfoxide, slightly soluble in alcohol 
or chloroform. 
Uses : A glucocorticoid with actions, uses and side-effects typical 
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of drug of this class. It is 7 to 13 times more potent than 
hydrocortisone. It has been claimed that therapeutic doses of this 
drug are nearly devoid of mineralocorticoid and other side effects 
of hydrocortisone but the mineralocorticoid actions vary from 
patient to patient. 
It appears that the drug may induce naturesis, negative 
sodium balance with weight loss in most patients along with 
headache, dizziness and fatigue and sodium retention with weight 
gain, moon face etc. among others. Nearly every side effect seen 
with hydrocortisone has been observed with this drug, but the 
relative frequencies are less; however, it does not increases appetite 
and thus differs from other glucocorticoids. By the oral route, 
more of it survives the first pass through the liver than does 
hydrocortisone, and blood levels are somewhat more predictable. 
The plasma half-life is about 5 h and the biological half-life is 18 
to 36 h. The volume of distribution is 1.4 to 2.1 L/kg depending 
upon the dose. 
DESCRIPTION OF CONTROL CHEMICALS 
A single culture or few cultures should serve as solvent 
control, with the solvent concentration being that of the highest 
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used in the test compound group. Positive controls are included 
to establish the ability of the analysts to correctly ascertain 
aberrations, to determine the variations from test to test, and 
perhaps most importantly, to establish the sensitivity of a particular 
test. It is a common practice to have a high dose of an established 
clastogen for the positive control, so that a high frequency of 
aberrations is induced. This is considered to be a general practice, 
since it is extremely simple for any analyst to pickout the positive 
controls and the aberration frequency is usually too high and 
sometimes it is difficult to analyse accurately the aberrant cells as 
individual variations among the investigatorsi and test variations 
occur occasionally. The most appropriate positive controls are 
either weak clastogens or low concentrations of effective 
clastogens. The concentration of the positive control compound 
should be one that induces an aberration frequency which is 
statistically speaking significantly higher than in that the solvent 
control, i.e., having a p value of 0.05-0.10. The aberration 
frequency induced by the test compound can then be tested against 
the solvent and against the positive control values to determine 
whether or not it can be considered clastogenic. 
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I. NEGATIVE CONTROL (Dimethyl Sulphoxidc; DMSO) 
KsC-
H3C 
S = 0 (C,H,SO) 
In the present investigation the test chemicals are steroids, 
hence insoluble in water and these can be dissolved in other 
solvents. Therefore, the organic compound, dimethyl sulfoxide 
(DMSO), which is being successively employed as a solvent for 
most of the organic chemicals, was used as the solvent for the 
test chemicals. It has been reported to be non-toxic to animals 
and humans (Preston; 1987). This solvent control or negative 
control provided the baseline for the comparison of the data to 
see the significant effects. 
II POSITIVE CONTROL (Cyclophosphamide; CP) 
Cyclophosphamide is a drug used to treat some cancers, 
often in combination with other cytotoxic drugs. It also has 
immunosuppressive properties and is used in prolonging the 
survival of tissue transplants and in other conditions requiring 
reduced immune response. Cyclophosphamide has also cytotoxic 
effects i.e. damages or destroys cells and is used to treat various 
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types of cancer, with and without the use of radiotherapy. 
Cytotoxic drugs destroys cancer cells by inhibiting cell division 
i.e. they are antimitotic but they also affect normal cells, 
particularly in bone marrow, skin, stomach, living and fetal tissues. 
Cyclophosphamide is the most versatile therapeutic drug which 
possesses the broadest spectrum and antitumor activity of 
alkylating agents (Brock, 1967). 
It is known to have strong mutagenic effects which have 
been proved many times on different cells. Cyclophosphamide 
acts by forming DNA-crosslinks by the reaction of chloroethyl 
moieties of CP with adjacent nucleotide bases. Due to its potent 
mutagenic and clastogenic nature, it is widely used as positive 
control in in vitro assays. 
ASSAY SYSTEM USED 
Studies on exposed individuals, and on cultured cells, have 
shown that the human peripheral blood lymphocyte is an extremely 
sensitive indicator of both in vivo (Evans et al., 1979; Evans, 
1982) and in vitro (Evans, 1970; Buckton and Evans, 1973) induced 
chromosome structural change. These changes in chromosome 
structure offer readily scored morphological evidence of damage 
to the genetic material. Although problems exist in the extrapolation 
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from in vitro results to the in vivo situation, the lymphocyte offers 
several advantages as a test system -
Easy availability of large numbers of human cells: a few mis 
of peripheral blood can be easily and repeatedly obtained 
from an individual and each 1 ml of blood can contain 1-
3x10^ small lymphocytes. 
The lymphocytes are distributed throughout the body, they 
circulate in all tissues and a proportion are long-lived. 
Virtually all the peripheral blood lymphocytes are a 
synchronised cell population in the same G^  or G, stage of 
mitotic interphase, and, in healthy individuals, these cells are 
only infrequently involved in mitotic proliferation in vivo. 
A proportion of the lymphocytes can be stimulated by 
mitogens to undergo mitosis in culture; they are easy to culture 
and thus provide a ready source of dividing cells for the 
scoring of chromosome aberrations. 
There are chromosomes preparations from lymphocytes and 
the cells have a low spontaneous chromosome aberration 
frequency (Buckton and Evans, 1973). 
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Most commonly the cytogenetic studies being carried out 
involve the study of metaphase chromosomes. Because, at 
metaphase, chromosomes are thick, short and chromatids are 
separate and easily visible. Thus the evaluation of chromosomal 
damage at metaphase helps to study a greater number of dividing 
figures and gives more precise and detailed picture of the 
clastogenic agents than the anaphase and telophase analysis. In 
the present investigation three progesterones and three 
corticosteroids have been selected for cytogenetic evaluation in 
human peripheral blood lymphocytes chromosomes. The 
parameters are chromosomal aberrations, sister chromatid 
exchange analysis and cell growth kinetics assay in the presence 
as well as in the absence of exogenous metabolic activation system. 
PREPARATION OF S, LIVER/MICROSOME FRACTION 
Some genotoxic chemicals can produce their effects directly, 
whereas others require metabolic conversion to become 
mutagenically active intermediates. Several systems for obtaining 
metabolic activation have been reported for cells grown in vitro, 
however for toxicity to lymphocytes, special precautions have to 
be taken. A general method, such as that described by Madle and 
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Obe (1980), involves incubating the test-agent with an extract of 
liver microsomes (S )^ with the cells in the culture medium without 
serum. The S^  fraction was prepared as follows : 
(i) Induction of Rat Liver Enzymes : 
The S^  fraction was freshly prepared by the methods 
recommended by Ames et al (1975) and Maron and Ames (1983). 
Swiss albino rats (Wisterstrains) obtained from disease free small 
animal house, Haryana Agricultural University, Hissar, India, each 
weighing about 200 gm, were given 0.1% (1 mg/mL) of 
phenobarbitone in drinking water for one week for induction of 
liver enzymatic activities. 
(ii) Removal of livers from the rats : 
The rats were sacrificed through cervical decapitation. In 
order to ensure the sterility of S^  preparation, the livers were 
removed aseptically using sterile surgical tools under laminar flow 
hood. The care was taken not to cut into the oesophagus or the 
intestine which could otherwise cause the contamination of liver 
homogenate. The removed livers were immediately placed in chilled 
0.15 MKCl. 
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(iii) Preparation of liver homogenate fraction (S, fraction) 
The whole procedure was carried out at 0-4°C using 
sterilized solutions and glassware which had been cooled. The 
livers were washed in fresh chilled KCl several times so as to 
remove the traces of haemoglobin which inhibits enzyme activity. 
The washed livers were transferred to a beaker containing three 
volumes of 0.15 M KCl (3 ml/gm wet liver) and after mixing with 
sterile scissors these were homogenized within a tissue 
homogenizer. The homogenate was centrifuged in refrigerated 
centrifuge for 10 minutes at 9000 rotation per minute (rpm). The 
supernatant (S^ fraction) was decanted and saved in 1 ml aliquots 
in polypropylene storage vials, and stored in liquid nitrogen till 
further use. 
(iv) Preparation of S, Mix 
The S5 mix fraction was prepared fresh every time for use 
in the culture. It contained 0.04 ml of S^  fraction, 8 nM Mg Clj, 
33 i^M KCl, 5 \iU glucose-6-phosphate (G-6-P), 4 \iU NADR 
100 ^M Na^ HPO, and NaH^PO^ buffer with 7.4 pH. 0.8 ml of S^  
mix. was added every time along with the test chemicals in the 
culture. 
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EVALUATION OF CHROMOSOMAL ABERRATION 
IN VITRO AND IN VIVO 
Culture media from TC-199 medium (GIBCO BRL, Life 
Technologies) with L-glutamine and Hepes buffer without NaHCOj 
was always prepared in advance and stored at 4°C but the storage 
never lasted longer than a week. 10.4 gm of medium was dissolved 
in 100 ml of sterilized distilled water by gentle shaking. Antibiotics 
- Antimycotic [lOOx lyophilized (10,000 units/ml penicillin G 
sodium, 10,000 ng/ml streptomycin sulfate, 25 |xg/ml amphotericin 
B) GIBCO BRL, Life Technologies] was also added and the pH 
was adjusted between 6.8 to 7.2 with N/10 NaHCOj and HCl. 
The media was then filter sterilized in the negative pressure 
millipore filtration assembly by using 0.22 i^M millipore filters. 
This lOX filtered stock medium was then stored in sterilized and 
tightly capped glass bottles at 4°C in dark. 
PREPARATION OF WORKING MEDIA 
The stock medium prepared by the above mentioned method 
was used for preparation of working media. Around 10 ml of this 
stock medium was dissolved in 90 ml of sterilized triple distilled 
water, 20 ml of fetal calf serum (GIBCO BRL, Life Technologies) 
was also added, and 2 ml of phytohemagglutinin-M (PHA-M; 
93 
GIBCO BRL, Life Technologies) and 1 ml of Heparin (500 lU/ 
ml; Micro Lab) were added to the total volume of working media 
respectively as a mitogen and anticoagulant respectively. 
Preparation of culture media and working media was done under 
sterile conditions in the laminar flow cabinet. 
BLOOD SAMPLES 
For each culture peripheral blood sample by venipuncture 
was taken from different male and female healthy donors. It was 
confirmed in advance that the donors are occupationally not 
exposed to any sort of mutagen. The blood was taken fresh every 
time using needles (21 gauge) and disposable syringes (steriware). 
Heparin (500 lU/ml; Micro Lab) was used as anticoagulant. The 
blood was collected in glass vials which were tightly capped, 
gently mixed and stored at 4°C for half an hour to separate red 
blood cells (RBCs) from plasma. 
SETTING OF THE CULTURE 
Human blood lymphocyte cultures were carried out by 
adding 0.8 ml of blood containing white blood cells (WBCs) into 
6 ml of working culture medium. The culture vials were then tightly 
capped to avoid. COj loss. This was don under laminar flow 
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cabinet and spirit lamp flame was kept close to avoid further 
contamination. The culture vials were gently shaken to mix their 
contents, and were incubated at 37°C in dark for 72 hours. 
Colchicine (0,2 |ig/ml; Micro Lab) was added to the culture Vh 
hours prior to harvesting to arrest the cells at metaphase stage. 
SELECTION OF DOSES 
In general, the maximum concentration of the test compound 
that is used will be related to its cytotoxicity. Cytotoxicity can be 
estimated from several end-points, with reductions in mitotic index 
(MI) or proliferation index (PI) being the most frequently used 
index. The reduction in MI and PI will indicate a combination of 
cytotoxicity and cell cycle delay, but can be considered as an 
indication that a particular test agent is producing an effect at the 
level of the cell. An example of an acceptable protocol is to use 
that dose as a maximum concentration which reduces MI or PI by 
about 50%. The choice of additional concentrations varies widely 
but is generally based on the maximum concentration itself, such 
that, for the minimum, there must be a total of 3 doses, with the 
lowest being about one-fourth of the highest and the third being 
mid-way between the high and low. Thus minimum 3-dose battery 
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guards against any occasional chemical that expresses clastogenic 
activity only at less than the maximum dose, and allows an 
evaluation of dose-response relationships. 
The dose selection scheme has to be selected with and 
without S5 and different concentrations have to be selected for 
these two conditions if significantly different cytotoxicity level is 
encountered as a result of S^  itself. Preliminary screening of the 
steroids under investigation with various concentrations was 
undertaken for determining their influence on the MI. Only those 
doses, which did not drastically reduce the MI but yielded sufficient 
number of scorable metaphases, were considered for the final 
experimental protocol. On the bases of these, the lower and the 
medium doses were selected and the highest dose selected was 
normally the maximum tolerated dose (MTD) beyond which the 
MI showed a steep decline. Following these norms the various 
doses selected for the various steroids were 10, 25 and 50 i^g/ml 
for all three progesterones and betamethasone. The doses taken 
for triamcinolone were 10, 50 and 100 jxg/ml and 20, 40 and 75 
|ng/ml for prednisolone. 
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STUDIES ON THE STEROIDS WITHOUT S, MIX 
In the experiments where no exogenous metabolic activation 
was incorporated, the cultures were exposed to three different 
concentrations of each steroid for 24, 48 and 72 hours. For this 
purpose the steroids were added to the cultures at 0,24 and 48 
hours after the initiation of cultures for 72, 48 and 24 hours of 
exposures respectively. Negative (Dimethyl Sulphoxide or DMSO, 
5 |il/ml) and positive (Cyclophosphamide or CP, 1x10'' M) control 
cultures were also simultaneously set for all treatment durations. 
STUDIES ON THE STEROIDS WITH S, MIX 
To study the effects of steroids in the presence of exogenous 
metabolic activation system, 30 h old cultures were given six hours 
treatment with different concentrations of each steroid in the 
presence of S^  mix. 
After centrifugation, the cell plates were collected and 
washed twice in the pre-warmed medium to remove the chemical 
and the S^ . Parallel cultures receiving the same dose of the steroids 
for similar treatment duration but without S, mix were also 
simultaneously set for comparison. DMSO (5 nl/ml; SRL, Mumbai) 
and CP (1x10-'' M; Khandelwal Labs, Mumbai) were used as 
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negative and positive controls respectively in these metabolic 
activation experiments. 
HARVESTING THE CULTURES 
The time at which there can be sufficient metaphases 
following the first division after the treatment varies to some extent 
with culture conditions. After 72 hours since cultures were put, 
the culture vials were taken out from the incubator. These were 
gently shaken to mix their contents and then transferred to different 
centrifuge tubes. The cells were spun down by centrifugation (10 
minute, 1200 rpm) and the supernatant discarded. Pre-warmed 
hypotonic solution (0.075 M KCl) was added to the centrifuge 
tubes, while shaking continuously with the help of a cyclomixer. 
Hypotonic treatment was carried out for 10-12 minutes at 
37*'C and the cells were recollected by centrifugation. The cell 
pellets were suspended in 7 ml freshly prepared chilled fixative 
(3:1:: Methanol : Acetic Acid) which was added drop by drop 
with a pasteur pipette while continuously shaking the pellet on the 
cyclomixer so as to avoid formation of clots. In order to ensure 
proper fixation, the cells were kept suspended in the fixative for a 
maximum period of one hour but preferably overnight. The cells 
were washed thrice with fresh fixative before preparing the slides. 
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PREPARATION OF SLIDES AND STAINING 
After the final washing of the cells in the fixative, the cells 
were resuspended in 0.2 ml of fresh fixative. Two to three drops 
of this cell suspension were dropped on clean, grease free 
prechilled and wet micro-slides which were quickly airdried. One 
day old slides were stained in 5% Giemsa (Loba Chem, India) for 
3 minutes. After that slides were rinsed in triple distilled water 
and then air dried. The slides were dipped in xylene for 5 minutes 
before mounting in DPX (BDH). 
ANALYSIS OF CELLS 
Metaphase preparations are analysed for all types of 
chromosomal aberrations, and the observations recorded on a 
score sheet. In order to avoid bias in scoring of the chromosomal 
anomalies, all slides were coded prior to scoring. A total of 300 
well spread metaphases were analysed for each concentration of 
the steroid and for each time duration to analyse various 
chromosome and chromatid type aberrations. Whilst statistical 
analyses are generally performed on combinations of aberration 
types, it is important to record the complete information for each 
observed aberration, because different types can provide additional 
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information on the potential mode of action of a particular agent. 
There is a set of criteria that is used to establish the suitability of 
a particular cell for analysis. The slide is scanned at low 
magnification, and a cell that appears analyzable at low 
magnification is scored under oil immersion. 
There are many published classification schemes for 
chromosomal aberrations, and good examples can be found in 
Savage (1975, 1979) and Bloom (1981) and the IAEA Technical 
Report Series No. 260 (1986). Here in the present study the same 
classification scheme has been followed. 
A. CHROMOSOME TYPE ABERRATIONS 
Analysis of chromosomal aberrations included the following 
parameters : 
1. Terminal and interstitial deletions 
2. Asymmetrical interchanges (usually dicentrics) 
3. Asymmetrical interchange (centric ring) 
4. Symmetrical interchanges (reciprocal translocations) 
5. Symmetrical interchanges (peri-and paracentric inversions) 
B. CHROMATID TYPE ABERRATIONS 
Chromatid-type aberrations are generally classified in the same 
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way as chromosome-type aberrations. The apparent unit of 
involvement in a chromatid-type aberration is, in most cases, the 
single chromatid, and not the whole chromosome as seen for 
chromosome type aberrations. The examination of the chromatid 
type aberrations considered the following parameters: 
1. Terminal deletions: 
2. Interstitial deletions 
3. Achromatic lesions ("gaps") 
4. Isochromatid deletions 
5. Asymmetrical interchanges (interarm interchanges, 
asymmetrical chromatid exchanges) 
6. Symmetrical interchanges (symmetrical chromatid exchanges 
7. Asymmetrical and symmetrical intrachanges (interarm 
intrachanges) 
8. Triradials 
C. MULTIPLE ANOMALIES 
1. Polyploidy : An increase in the chromosome number in excess 
of diploid set in multiple of the haploid (N) number. 
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2. Endoreduplications: The chromosome reduplication occurring 
in the absence of sister chromatid separation. 
3. Cells with multiple anomalies: The cells with 10 or >10 
aberrations. 
4. Pulverization: The extreme fragmentation of the chromatin 
material. 
SISTER CHROMATID EXCHANGE (SCE) ANALYSIS 
Mechanism of the sister chromatid exchange (SCE) 
detection : Sister chromatid exchange is a sensitive, rapid and 
objective method of observing reciprocal exchanges between sister 
chromatids. This method depends upon the phenomenon of 5-
bromo-2-deoxyuridine (BrdU), an analogue of thymidine, 
incorporation into DNA in place of thymidine. After two rounds 
of cell division the chromatids are labelled with BrdU and 
consequently get differentially stained with Hoechst stain. The 
BrdU incorporation quenches the fluorescence of the fluorochrome 
33258 Hoechst. Therefore, the light energy is absorbed but not 
emitted by such dyes which results in the reduced staining of 
chromatid with Giemsa (Latt and Wolleb, 1975; Latt, 1976). 
Labelling of chromosomes with BrdU: Sister chromatid 
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exchange analysis was carried out following the standard 
procedure of Latt et al. (1981) with suitable modifications. The 
cells in the cultures were exposed to nucleoside, BrdU (Sigma) 
after 24 hours of initiation of cultures, at the final concentration 
of 2 |ig/ml. The culture vials were tightly capped and covered 
with tin foil to avoid light exposure and incubated at 37°C for 
another 48 hours in the dark. 
Studies on the steroids without S, mix: After 48 hours of the 
initiation of cultures, three different log doses of each of six 
steroids were added into these cultures which did not contain any 
85 mix. The culturing was further continued for 24 hours. Positive 
(CP, IxlO-^M), negative (DMSO, 5 nl/ml) and untreated (normal) 
controls were also simultaneously studied. The detailed 
information regarding donors, doses, durations etc. has already 
been described. 
Studies on the steroids with S, mix : The steroids along with S^  
mix was added into the cultures after 48 hours of its initiation and 
were reincubated at 37**C. After 90 minutes of pulse treatment, 
the cells were spun down and supernatant discarded. The cells 
were then washed with pre-warmed medium twice so as to remove 
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the traces of the steroids and liver metabolites. Finally, the cell 
pellets were resuspended in fresh and warm working media 
supplemented with fetal calf serum, PHA-P, antibiotics-
antimycotic and BrdU, and cultured for another 24 hours in the 
dark at 37°C. In order to compare the effects of the steroids with 
and without metabolic activation, parallel cultures with same 
concentrations of the steroids and same exposure durations but 
without Sg mix were also simultaneously set. Positive (CP, 1x10' 
'M), negative (DMSO, S i^l/ml) and untreated (normal) controls in 
the presence of S^  mix were also simultaneously studied. 
Slide preparation and staining: After 2^ 2 hours of colchicine 
treatment, the cultures were harvested and processed following 
the same procedure as described for the chromosomal aberration 
analysis. 
The methods of Perry and Wolff (1974) and Latt et a/. (1981) 
with slight modifications were followed for the differential staining 
of SCEs. One day old slides were dipped in 0.5 ng/ml of 33258 
Hoechst stain (Sigma) dissolved in double distilled water in 
horizontal couplin jar. The slides were rinsed twice in distilled 
water. The air-dried slides were then put in flat glass dish with the 
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layer of cells facing upwards. These were covered by thick layer 
(2-3 cm) of phosphate buffer (pH 6.8) and exposed to UV lamp 
(15W, 254 nm; Philips) from a distance of 10-15 cm for 30-45 
minutes. The slides were taken out from the buffer, washed twice 
in double distilled water and air dried. These were then incubated 
in 2XSSC (0.3M sodium chloride, 0.3M sodium citrate, pH 7.0) 
at 65°C in water bath for 90 minutes using vertical couplin jars. 
The slides were taken out and rinsed in distilled water. The air 
dried slides were then stained in giemsa for 3 minutes and again 
rinsed in distilled water. The dried slides were dipped in xylene 
for 5 minutes and mounted in DPX. 
Analysis of the cells: All slides were coded prior to scanning so 
as to avoid any confusion. 50 second-division metaphases with 
differentially stained chromatids were scored for each steroid 
treatment in the absence as well as in the presence of S^  mix. The 
interstitial exchanges between two sister chromatids were scored 
as two exchanges and the terminal exchanges were scored as a 
single exchange. Students 't' test was applied for calculating the 
significance of difference between the treated and the controls. 
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CELL CYCLE KINETICS 
The cells undergoing first (M,), second (Mj) and third (M3) 
division were detected by studying the BrdU labelled differentially 
stained chromosomes following the methodology of Tice et al 
(1976) and Crossen and Morgan (1977). The cells with both the 
chromatids being darkly stained were scored as M, cells while 
those with one dark and one lightly stained chromatids as Mj cells, 
and those having mixture of both the differentially stained and 
uniformally stained chromatids were scored as M3 metaphases. 
iOOwell spread metaphases were scored for each concentration 
and each treatment duration from each donor in the absence as 
well as in the presence of S^  mix. The replication index (RI) was 
calculated according to the formula of Tice et al (1976) as given 
below. The deviation from the controls was determined by using 
Chi-Square test. 
RI = (M,X 1) (MjX 2) (M3X 3) / 100 
STATISTICAL ANALYSIS 
Standard deviation (SD) and standard error (SE) were 
calculated using the following formula -
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Mean X = X/n 
Variance 5^  = X^-IxVn- l 
5 = VX2 - Ix-Vn-l 
SE = SD/Vn 
wherex = variable 
n = number of observations 
Sx^ = sum of square of individual variables 
X = Mean of variables 
2x3 Chi-Square test (x )^ for homogeneity test of variance 
was used to analyse the cell growth kinetics with the normal 
control. The level of significance was tested from standard 
statistical tables of Fisher and Yates (1963). 
The endoreduplication, ploidies, pulverizations and cells with 
multiple anomalies were not included in the statistical analysis. 
Student's two tailed 't' test was used for calculating the 
statistical significance in SCE and chromosomal aberrations by 
comparing the effects induced by different steroids with the 
respective controls. Following formula was used for this purpose. 
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X, (control) - Xj (treated) 
t= —'~~~ZZZ~ZI~~~~~ 
V(SE of control)MSE of treated)^ 
The statistical significance was calculated from Fisher and Yates table 
at (n,+n2-2) degree of freedom (df) at 0.05% level of significance (P). 
CLINICAL STUDIES 
For clinical study patients were selected from Jawaharlal 
Nehru Medical College and Hospital of AMU. Patients who were 
on therapeutic doses of test steroidal drugs for at least 1 to 3 
months were examined. Two types of controls were taken : (i) 
normal healthy individuals from the general population and (ii) 
patients before taking any medicine. 
The following patients were not included in the study : 
Previous exposure to steroidal therapy 
Children below 12 years of age and pregnant women 
Associated marked nutritional deficiencies 
Having any endocrinal or hormonal disorder 
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RESULTS 
The following steroids were evaluated for their genotoxic 
potentials on human lymphocyte chromosomes. They were 
evaluated at different concentrations and different time durations. 
Three parameters were taken for the present work. The student's 
t-test paired was applied for chromosomal aberrations and sister 
chromatid exchanges. The 2x3 chi-square test was used for cell 
growth kinetics studies. The level of significance was compared 
at P < 0.05 for all parameters. 
I. PROGESTINS : 
1. Medroxyprogesterone acetate 
(a) Chromosomal aberrations : 
Table 2 depicts the results observed for chromosomal 
aberrations at different concentrations and different time durations. 
At 10 ng/ml of concentration the value of chromosomal aberrations 
were 2.33%, 4.00% and 5.67% at 24, 48 and 72 hours of 
incubations respectively. At 25 |Ag/ml the values for the above 
said hours of durations were 19.50%, 21.00% and 27.67% which 
were highly significant at P < 0,05 compared to the normal control 
value. A high frequency of chromosome aberrations and aberrant 
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metaphases were observed for all exposure times at 50 ng/ml of 
concentration (Fig. A-B in Appendix). These values were 21.00%, 
21.67% and 32.33% at 24, 48 and 72 hours of incubations. Which 
were highly significant at P < 0.05. The results of the positive 
control drug cyclophosphamide (CP) were also very much 
significant at P < 0.05 which were 30.00%, 68.00% and 66.00% 
at 24, 48 and 72 hours of incubations respectively. The drug was 
effective at all treatments (10, 25 and 50 M-g/ml) and an increased 
frequency of aberrant metaphases as well as chromosomal 
aberrations were observed when the drug was treated with S^  mix 
(Table 3). These value were 10.00%, 22.50% and 33.50% at 10, 
25 and 50 ng/ml of concentrations respectively. These data were 
highly significant at P < 0.05 when compared to the normal control 
(4.50%). The percentage of chromosomal aberrations was 61.00% 
for CP which was highly significant. 
(b) Sister Chromatid Exchange (SC£) 
Data on the mean frequency of SCE for cell after the 
treatment of Medroxyprogesterone acetate is presented in Table 
4. The maximum frequency of SCE per cell was found to be 
4.50± 1.24 at 50 jug/ml of concentration (Fig.C in Appendix). This 
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value was highly significant when compared with the mean SCE 
value of normal control 1.72±0.14. The same increased SCE 
frequency was observed at 25 |ig/ml but with less magnitude i.e. 
3.58±0.51. The mean SCE frequency at 10 ng/ml was not 
significant i.e. 1.84±0.15. The mean SCE frequency for CP was 
observed to be 6.80±1.29 which was highly significant. 
When the mean SCE frequency was observed in lymphocyte 
after the treatment of Medroxy progesterone acetate in the presence 
of Sj mix (Table 5), both the doses (25 and 50 i^g/ml) enhanced 
the mean SCE frequency significantly. These values were 4.22±0.39 
and 6.20±1.32 at 25 and 50 ng/ml concentrations respectively 
both these values were significantly higher than the mean SCE 
value of 1.56±0,12 observed in normal controls (p < 0.05). The 
mean SCE value for CP was found to be 7.60±1.34 which was 
very significant when compared to the control value. 
(c) Cell Growth Kinetics 
The data for cell growth kinetics of the drug Medroxy 
progesterone acetate are presented in Table 6. The replication index 
(RI) at 25 i^g/ml was found to be 1.53 and it was 1.56 at 50 ng/ml 
of concentration. Both these values were statistically significant 
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at P < 0.05 when compared to the nonnal control (RI = 1.73). 
The RI at 10 |ig/ml did not produce any significant value (1.69). 
The frequency of the M, cells were higher and the M^ cells were 
lower at 25 ^g/ml and 50 |ig/ml of doses than those of the normal 
control. 
Medroxyprogesterone acetate in the presence of S, mix 
(Table 7) also inhibit cell growth kinetics. A slightly decreased 
frequency was observed at 25 and 50 ng/ml of doses. At 25 i^g/ 
ml the value was 1.53 and at 50 |ng/ml the value was 1.52. Both 
these values were significant at p < 0.05 when compared to the 
normal control (RI = 1.65). The value obtained at 10 ng/ml of 
dose was not significant. However, the CP showed a highly 
significant value i.e. 1.45. 
2. Hydroxyprogesterone caproate : 
(a) Chromosomal aberrations 
The results of chromosomal aberration analysis are presented 
in Table 8. At 10 |ig/ml of concentration, the value for 
chromosomal aberrations were 3.00%, 4.67% and 5.33% at 24, 
48 and 72 hours of incubations respectively. At 25 ng/ml the values 
for the said hours of duration were 3.67%, 4.67% and 5.33%, 
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while at 50 ng/ml of concentration the same were 4.00%, 4.67% 
and 5.33%. These values were not found significantly different 
from the normal control values. Aberrant metaphases were not 
observed to be increased at all doses of treatment, although the 
effect of positive control i.e. CP was found significant in all 
exposure times. 
When the drug was treated with metabolic activation (Table 
9), no significant results were observed at any of the doses of 
treatment as compared to the normal control. At 10, 25 and 50 
Hg/ml of concentrations the values were 4.50%, 4.50% and 5.00% 
respectively. The CP was found significant at P < 0.05 level after 
metabolic activation (61.00). 
(b) Sister Chromatid Exchange : 
The results of the sister chromatid exchange (SCE) analysis 
are given in Table 10. The drug with 10 ng/ml of concentration 
had a mean SCE frequency of 1.70±0.14 which was not significant 
when compared to the mean SCE value of 1.72±0.14 observed in 
normal control. The results observed at 25 |ig/ml and 50 ng/ml 
of concentration were also non-significant. The SCE mean values 
of these doses were 1.58±0.12 and 1.60±0.13. The CP gave a 
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highly increased SCE frequency (6.80±1.29) which was significant 
at P < 0.05. 
SCE observed in human lymphocytes after Hydroxy 
progesterone caproate exposure in the presence of S, mix is 
presented in Table 11. Here again the steroid did not affect the 
lymphocytes to enhance the mean SCE i.e. at 10, 25 and 50 ng/ml 
of concentrations. The mean SCE frequency were 1.58±0.13, 
1.60±0.13 and 1.52±0.12 which were not found significant 
compared to the normal control value (1.56±0.12). The mean SCE 
for CP was 7.60±1.34, significant at P < 0.05. 
(c) Cell Growth Kinetics : 
The analysis of cell growth kinetics of Hydroxyprogesterone 
caproate is presented in Table 12. Hydroxyprogesterone caproate 
did not affect the proliferation of lymphocytes at any given 
concentration. At 10, 25 and 50 i^g/ml of concentrations, the 
replication index (RI) were 1.80, 1.78 and 1.76, which again were 
not significant compared to the normal control (1.73). The RI 
value of CP was 1.43, significant at P < 0.05. 
The results of the replication index of the drug in the presence 
of S, mix are summarised in Table 13. The drug did not affect the 
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cell growth kinetics at any treatment, while the positive control, 
CP had affected the proliferation index of lymphocytes. At 10, 25 
and 50 ng/ml of doses the RI values were 1.77, 1.76 and 1.70. 
The RI of CP was 1.45, which was significant at P < 0.05. 
(3) Megestrol acetate 
(a) Chromosomal aberrations : 
The effects of Megestrol acetate on the frequency of 
chromosomal aberrations in human lymphocytes is described in 
Table 14. At the lower dose of concentration (10 ng/ml) no 
significant difference was observed. In all exposure times i.e. 24, 
48 and 72 h, there was no increase in the frequency of abnormal 
metaphases nor in the chromosomal abnormalities counted (3.67%, 
4.33% and 5.00%) respectively. There was sharp increase in the 
frequency of abnormal metaphases and aberrations were noted at 
25 |ig/ml of concentrations at all exposure times(Fig D-E in 
Appendix). These values were 21.33%, 24.67% and 26.33% for 
24, 48 and 72 h of treatment respectively, which were highly 
significant at P < 0.05 when compared to the values of normal 
control (2.33%). However, peculiar results from observations were 
obtained at the highest concentration (50 ^ig/ml). The frequency 
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of aberrant metaphases and chromosomal aberrations were 
decreased (as compared to the 25 ng/ml dose) and no significant 
difference was noted at all exposure times. The decrease in the 
chromosomal aberrations may be attributed to the toxic effect of 
the drug at this concentration on the mitotic index. The CP gave a 
significant increase in the frequency of aberrant metaphases and 
chromosomal aberrations (30.00%, 68.00% and 66.fl»%) at all 
exposure times i.e. 24, 48 and 72 hours of incubation. 
The results of the frequency of chromosomal aberration of 
Megestrol acetate treated with S^  mix are presented in Table 15 . 
Again at lower concentration, the drug did not enhance the 
frequency of chromosomal aberrations as well as aberrant 
metaphases. At 25 jig/ml of concentration the drug showed 
maximum aberrations i.e. 29.50%. At the highest concentration 
(50 ng/ml) the frequency was not much increased but it was 
significant statistically when compared to the normal control 
(4.50%). The value of the CP for the chromosomal aberrations 
was 61.00% which was highly significant. 
(b) Sister Chromatid Exchange 
Data on the mean frequency of sister chromatid exchange 
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(SCE) per cell in human lymphocytes after Megestrol acetate 
exposure is presented in Table 16. The drug with 25 (ig/ml of 
concentration had a mean SCE frequency 5.66±0.29 which was 
significantly higher than the mean SCE value of 1.72±0.14 
observed in normal control. The mean SCE frequencies of the 
doses 10 lig/ml and 50 ng/ml were 1.86±0.19 and 2.14+0.18 
respectively which were not significant. The drug was only 
effective in enhancing the SCE frequency at 25 ^ig/ml of 
concentration. The mean SCE frequency of the CP was 6.80±1.29 
which was significant compared to the normal control value. 
Table 17 documents the mean SCE/cell in human 
lymphocytes after megestrol acetate treatment with metabolic 
activation (S^ mix). At 25 ^ig/ml of concentration there was 
significant increase in SCE frequency i.e. 5.42±0.28 as compared 
to the value of normal control (1.50±0.12). At the highest 
concentration (50 |Lig/ml), the drug enhanced the frequency of SCE 
but with lesser magnitude (2.26±0.21). At lowest dose the drug 
did not enhance the SCE frequency significantly. 
(c) Cell Growth Kinetics 
Table 18 summarises the effect of megestrol acetate on the 
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cell growth kinetics. The replication index at 25 ^ig/ml was 
significant (1.51) when compared to the normal control value 
(1.73). The values observed at 10 |ig/ml and 50 |ag/ml of 
concentration were not significant. The RI at 10 and 50 |ig/ml 
concentrations were 1.73 and 1.73 respectively. The CP was found 
to be effective and also significant at P < 0.05 (1.43). 
Table 19 shows the effect of megestrol on cell growth 
kinetics in the presence of S^  mix. The replication index at 25 |ig/ 
ml concentration was 1.51 and significant at p < 0.05 compared 
to the value of normal control (1.65). The frequency of Mj cells 
were higher than the M^ cells. Fewer M^ cells were found. At 
lower and higher concentrations (10 i^g/ml and 50 fxg/ml) the drug 
did not affect the cell growth significantly. 
II. CORTICOSTEROIDS 
1. Triamcinolone 
(a) Chromosomal aberrations : 
Table 20 documents the effects of Triamcinolone on the 
frequency of chromosomal aberrations. A wide range of 
concentrations were used (10 ^lg/ml, 50 ^ig/ml and 100 ^ig/ml) to 
see the genotoxic effects of the drug. It did not show any 
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significant increase in the frequency of chromosomal aberrations 
at any of the concentrations nor were they effective at any exposure 
time. The data for CP obtained were 30.00%, 68.00% and 66.00% 
at 24, 48 and 72 hours of incubations. This value was significantly 
higher to that of the normal control (2.33) at P < 0.05. 
In the presence of metabolic activation, the drug was unable 
to induce clastogenic effect on the human lymphocytes at 10 )ig/ 
ml of concentration (6.00%) (Table 21). The values were 13.00% 
and 18.50% at 50 and 100 ^ig/ml of concentration. Which were 
significant compared to normal control (4.50%) at P < 0.05 (Fig. 
F-G in Appendix). 
(b) Sister Chromatid Exchanges : 
The result of SCE in human lymphocytes after triamcinolone 
exposure is presented in Table 22. The mean SCE frequency of 
the drug at 10, 50 and 100 |LAg/ml were 1.96±0.18, 2.02±0.20 and 
2.42±0.29. These values were not significant statistically compared 
to normal control (1.74±0.14). The mean SCE frequency was 
enhanced by the positive control drug (CP) and the effect was 
observed to be significant (6.80±1.29) at P < 0.05. 
Triamcinolone is effective in enhancing the SCE frequency 
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in the presence of S^  mix (Table 23) at all of the concentrations. 
The mean frequency values were 2.80±0.11, 3.96±0.19 and 
4.40±0.21 at 10, 50 and 100 x^g/ml concentrations respectively. 
(c) Cell Growth Kinetics : 
Table 24 shows the analysis of cell growth kinetics after 
triamcinolone exposure in human lymphocytes. The 2x3 chi-square 
contingency test indicated no significant deviation from the control 
cultures. The RIs were 1.92, 1.86 and 1.84 at 10, 50 and 100 i^g/ 
ml concentrations respectively, whereas normal control value of 
RI was 1.73. CP showed significant RI value i.e. 1.43. 
When the drug was treated with S^  mix (Table 25) the result 
showed decreasing RI with increasing dose of the drug. RI were 
1.73, 1.69 and 1.56 at 10, 50 and 100 ng/ml of concentration. RI 
at 100 )ig/ml concentration was significant when compared with 
the normal (1.65). 
2. Prednisolone 
(a) Chromosomal aberrations : 
Table 26 summarises the results of chromosomal aberration 
in lymphocytes after prednisolone treatment. The drug did not 
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induce any significant chromosomal aberration at any 
concentration. A wide range of concentration was used (20, 40 
and 75 ng/ml) and the drug was not found to be clastogenic to 
the human lymphocytes. 
Even in the presence of S^  mix no significant results were 
obtained at any of the concentration (Table 27) 
(b) Sister Chromatid Exchange : 
Result of mean SCE frequency is presented in Table 28. 
The mean SCE value obtained at 20, 40 and 75 ng/ml of doses 
were not significant when compared to the normal control value. 
The same pattern was observed in the mean SCE frequency 
when the drug was treated in the presence of S^  mix (Table 29). 
The drug did not give any significant result as compared to the 
normal control. 
(c) Cell Growth Kinetics : 
Table 30 shows the analysis of cell growth kinetics after 
prednisolone exposure in human lymphocytes. The 2x3 chi-square 
contingency test indicated no significant deviation from the control 
cultures. 
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No significant value was observed even in the presence of 
S9 mix (Table 31). Thus prednisolone was not genotoxic at any 
concentration. 
3. Betamethasone 
(a) Chromosomal aberrations : 
The data on the influence of betamethasone on chromosomal 
aberrations are presented in Table 32. At 10 |ig/ml of dose 
significant increase in the percentage of chromosomal aberrations 
was found when the drug was continued for 72 hours of incubation 
(7.67%). This value is higher than the value of normal control 
(2.33%). At 24 and 48 hours of incubations, this dose did not 
affect the chromosomal aberrations (3.33%, 3.00%). At 25 ng/ml 
of concentration the drug induced chromosomal aberration at all 
exposure times (Fig. H-J in Appendix). The values were 18.00%, 
20.00% and 26.00% at 24, 48 and 72 hours of incubations 
respectively. Increased frequency at this dose showed the 
significant result compared to the normal control (2.33%) at P < 
0.05. However, at 50 jig/ml of concentration some interesting 
observations were made. At 24 hours of incubation, the drug 
influenced the rate of chromosomal aberration significantly (29.33) 
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while at 48 and 72 hours of incubations the drug did not give any 
significant increase in the chromosomal aberration i.e. 5.67% in 
both the cases. 
The effect of betamethasone on human lymphocyte in the 
presence of Sg mix has been summarised in Table 33. The mean 
percentage value at 10 |ig/ml was 11.00 in the presence of Sg mix 
which was significantly higher than the mean percent of 
chromosomal aberration value of 4.50 observed in normal control 
(P < 0.05). At 25 fig/ml of concentration, the drug enhanced the 
rate of aberrations (22.50%), which gave a statistically significant 
value at p < 0.05. There was no significant increase in the mean 
aberration frequency at 50 ng/ml of concentration (4.00). 
(b) Sister Chromatid Exchange 
Table 34 shows the effect of betamethasone in the frequency 
of SCE in human lymphocytes. The mean SCE frequency at 10 
Hg/ml did not enhance it significantly (2.52±0.18) when this is 
compared with normal control value (1.72±0.14). The result with 
25 ^g/ml of drug concentration had a mean SCE frequency of 
3.78±0.21 which was significantly higher than the mean SCE value 
of normal control (P < 0.05). No significant value was observed 
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at higher concentration i.e. 50 ng/ml . The mean SCE value was 
2.58±0.17, which was not found significant at P < 0.05. The data 
of the mean SCE frequency value of the positive control drug 
(CP) was 6.80±1.29. The value was highly significant compared 
to normal control. 
The data of SCE in human lymphocyte after betamethasone 
exposure in the presence of S^  mix has been described in Table 
35. There was not any significant increase in SCE value observed 
at 10 ng/ml (1.84±0.15). Both the doses at 25 and 50 ng/ml of 
concentration in the presence of S^  mix, enhanced the frequency 
of SCE. At 25 ng/ml , the mean SCE frequency was 4.02±0.19 
which was significant at p < 0.05 when compared to the normal 
control (1.56±0.12). A slightly increased SCE frequency was 
observed and found significant (2.94±0.17) with 50 ng/ml 
compared to normal control. 
(c) Cell Growth Kinetics 
Analysis of cell growth kinetics of betamethasone is 
presented in Table 36. No significant effect of the drug was found 
at the lowest (10 |ng/ml) concentration and 25 ng/ml 
concentrations. The replication index (RI) were 1.67 and 1.66 for 
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10 and 25 ng/ml concentration of the drug respectively. At 50 
)ig/ml concentration lower replication index was observed, the 
value was significant (1.53) as compared to that of the normal 
control (1.73) at P < 0.05. The frequency of the M, cells were 
higher than M^ cells when compared to the normal control. CP 
also showed a decreased frequency of RI which was significant 
at P < 0.05. 
Table 37 represents the effect of betamethazone on the 
frequency of cell growth kinetics in the presence of S, mix. The 
RI values were 1.68 and 1,61 at 10 |ig/ml and 25 ng/ml of 
concentrations respectively which were not significant statistically 
compared to the normal control (1.65). At 50 ng/ml the frequency 
of RI was 1.56 and the value was significantly higher than the 
frequency of normal control (p < 0.05) RI was depleted when 
treated with CP (1.45), which again was highly significant as 
compared to the normal control value. 
IN VIVO STUDY 
Results obtained in the in vivo study of the effect of 
Medroxyprogesterone acetate are summarised in Table 38. The 
difference between the values of general control and patient control 
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in regard to chromosomal aberrations (3.67 and 3.00) was not 
significant. This indicates that the disorder per se does not exert 
any influence on the chromosomal aberration frequency. The 
frequency of chromosomal aberrations was significantly increased 
(14.33) in patients under medroxyprogesterone acetate therapy as 
compared to the two types of controls (P<0.05) (Fig. K-L in 
Appendix). The frequency of SCE analysis in human lymphocytes 
after medroxyprogesterone acetate exposure in vivo is described 
in Table 39 The difference between the mean SCE of the general 
control and patient control was statistically not significant. The 
mean SCE frequency of the patient exposed to the drug on the 
other hand was found to be highly significant (3.96±0.20). It was 
also observed that the drug is affecting the cell growth kinetics in 
human lymphocytes of the patients exposed to 
medroxyprogesterone acetate (Table 40). Result shows that the 
replication index is highly significant (1.47) when compared with 
the general and patient controls (1.78 and 1.75). 
Chromosomal aberrations in human lymphocytes in vivo of 
the patients exposed to hydroxyprogesterone caproate were found 
insignificant (5.67) when compared with normal and patient 
controls (3.67 and 4.00) (Table 41). The frequency of SCE in 
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human lymphocytes of the patients exposed to 
hydroxyprogesterone caproate was 1.64±0.12 which is not 
significant when compared with normal and patient controls 
(1.50±0.12 and 1.56±0.12) (Table 42). The result of cell growth 
kinetics shows that the drug is ineffective in causing cell cycle 
delay. The replication index was found insignificant (1.75) when 
compared with normal (1.78) and patient controls (1.81) 
(Table 43). 
The in vivo study of the chromosomal aberrations of the 
patients exposed to another progestin, megestrol acetate again 
gives significant results. The frequency of CAs in general control 
is 3.67 and in patient control it is 5.00, while in the patients exposed 
to the drug it is highly significant (17.33) (Table 44). Similar results 
have been observed in SCE analysis and in the analysis of cell 
growth kinetics. SCE frequency in the patients exposed to the 
drug was found to be highly significant (0.06±0.19) while it was 
1.50±0.12 and 1.76±0.12 in general and patients controls 
respectively (Table 45). Cell growth kinetics was also significantly 
affected and RI was 1.49 in the case of exposed patient while it 
was 1.78 and 1.82 in case of general controls and patient controls 
respectively (Table 46). 
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The corticosteroidal drug triamcinolone significantly 
increased the frequency of chromosomal aberrations in vivo. The 
results of the present investigation showed that triamcinolone did 
not induce chromosomal aberration in vitro but significantly 
increased the aberration frequency in vivo (14.67) (Table 47). The 
SCE frequency was also higher (3.36±0.20) and in cell growth 
kinetics study RI was 1.51 which is significant in compaiison to 
general control (1.78) and patient control (1.82) (Table 48 & 49). 
The differences in the in vivo and /« vitro studies can be explained 
on the basis of the fact that some chemicals and drugs are not 
mutagenic and clastogenic by themselves but require metabolic 
activation. The possibility that the increase in the aberrations in 
the cells of patients on triamcinolone therapy could be due to 
their disorder is ruled out by the fact that there was no significant 
difference in the chromosomal aberration frequency between the 
untreated patients and the normal healthy individuals from the 
general population. A predominance of chromatid gaps and breaks 
was observed suggesting, that the drug acts mostly in the late S 
or Gj phase of the cell-cycle. 
Prednisolone did not induce chromosomal aberrations 
significantly (8.00) when compared with general control (3.67) 
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and patient control (7.33) (Table 50). SCE frequency was also 
insignificant (1.96±0.15) in human lymphocytes of the patients 
exposed to prednisolone. It was 1.50±0.12 in general control and 
1.66±0.13 in patient control (Table 51). Analysis of cell growth 
kinetics in human lymphocytes of the patients exposed to 
prednisolone shows that the drug did not produce significant result 
i.e. replication index was 1.80. The replication index was 1.78 for 
general control and 1.74 for patient control (Table 52). 
The frequency of chromosomal aberrations (Fig. M-N in 
Appendix) in vivo when the patients were exposed to 
betamethasone was found to be highly significant (18.67) in 
comparison to general control (3.67) and patient control (7.33) 
(Table 53). Similar observations were made in case of SCE 
(3.38±0.17) (Fig 0 in Appendix) and cell growth kinetics (RI -
1.51) (Table 54 & 55). In the case of betamethasone both in vivo 
and in vitro studies show similarity in the results. 
Adverse/side effects of the steroidal drugs 
Very small sample study has been done for observing some 
adverse/side effects among the patients exposed to test steroidal 
drugs continuously for atleast 1 to 3 months. It was found that 
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some adverse effects were very common and severe eg. vomiting, 
headache, hypersensitivity, sweating etc. in the case of medroxy 
progesterone acetate. Most of the drug users experienced mild 
adverse effects, but edema, headache, fatigue, rash, drowsiness 
etc. were very common. Very few patients experienced pruritus 
vulvae, urticaria, dyspnea and spotting. Observations among the 
patients exposed to hydroxyprogesterone caproate showed that 
severe fatigue and sweating were experienced by the patients while 
mild rash & drowsiness are more common. No patient was found 
with pruritus vulvae and dyspnea. Patients exposed to megestrol 
acetate experienced severe and mild drowsiness, headache, fatigue, 
rash and sweating in most of the cases. Urticaria was not observed 
in any patient (Table 56 to 58). 
Corticosteroidal drug betamethasone was found producing 
severe and mild dizziness, depression, acne & delayed wound 
healing in most of the cases while very few experienced psychosis, 
euphoria, hoarseness, cataract and insomnia. Very few patients 
experienced severe and mild adverse effects when exposed to 
prednisolone. Most of the patients had no effects. Triamcinolone 
was found capable of producing several adverse effects among 
the patients exposed to this drug. Severe and mild coughing. 
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delayed wound healing, indigestion, hypertension etc. were 
common among the patients. Very few patients experienced weight 
gain, vertigo, anorexia, dizziness, depression, acne, moon face, 
itching, edema, hoarseness, cataract and thinning of scalp hair 
(Table 59 to 61). 
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Table 4 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Medroxyprogesterone acetate exposure in vitro. 
Treatment 
(Hg/ml) 
Medroxy 
progesterone 
acetate 
10 
25 
50 
Control 
Normal 
DMS0(5nl/mr 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Duration 
(hr) 
48 
48 
48 
48 
) 48 
48 
No. of 
Methaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
92 
179 
225 
87 
96 
340 
Range 
0-6 
1-9 
2-10 
0-5 
0-6 
2-11 
SCEs/Cell±SE 
1.84±0.15 
3.58±0.51* 
4.50±1.24* 
1.72±0.14 
1.92±0.12 
6.80±1.29* 
Table 5 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Medroxyprogesterone acetate exposure with metabolic activation (S, 
mix). 
Treatment 
(Hg/ml) 
Duration No. of Total 
(hr) Methaphases SCE 
Range SCEs/Cell ±SE 
Medroxy 
progesterone 
acetate 
10 
25 
50 
Control 
Normal 
DMSO (5nl/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
48 
48 
48 
48 
48 
48 
CP : Cyclophosphamide; 
SE : Standard error; 
50 
50 
50 
50 
50 
50 
DMSO : 
* 
92 
211 
310 
78 
89 
380 
0-5 
1-10 
2-12 
0-5 
0-6 
4-12 
Dimethyl sulphoxide 
Significant at P<0.05 
1.84±0.48 
4.22±0.39* 
6.20±1.32* 
1.56±0.12 
1.78±0.11 
7.60±1.34* 
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Table 6 : Analysis of cell growth kinetics after Medroxyprogesterone acetate 
exposure in vitro. 
Treatment 
(Mg/ml) 
Medroxy 
prgoesterone 
acetate 
10 
25 
50 
Control 
Normal 
DMS0(5|iil/ml) 
(-ve control) 
CP(lxlO-''M) 
(+ve control) 
Cell 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells i 
M, 
39 
56 
49 
37 
38 
60 
M, 
53 
35 
46 
53 
46 
37 
in 
M3 
08 
09 
05 
10 
16 
03 
Replication 
Index 
1.69 
1.53* 
1.56* 
1.73 
1.78 
1.43* 
2x3 Chi-square 
test 
Significant 
Significant 
Table 7 : Analysis of cell growth kinetics after Medroxyprogesterone acetate 
exposure with metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Medroxy 
progesterone 
acetate 
10 
25 
50 
Control 
Normal 
DMS0(5^1/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Cell 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
M, 
39 
53 
56 
41 
40 
60 
CP : Cyclophosphamide; 
SE : Standard error; 
M, 
51 
41 
36 
53 
50 
35 
DMSO : 
* 
in 
M3 
10 
06 
08 
06 
10 
05 
Replication 
Index 
1.71 
1.53* 
1.52* 
1.65 
1.70 
1.45* 
Dimethyl sulphoxide 
Significant at P<0.05 
2x3 Chi-square 
test 
Significant 
Significant 
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Table 10 : Sister Chromatid Exchange (SC£) in humna lymphocytes after 
Hydroxyprogesterone caproate exposure in vitro. 
Treatment 
(Hg/ml) 
Hydroxy 
progesterone 
caproate 
10 
25 
50 
Control 
Nonnal 
Duration 
(hr) 
48 
48 
48 
48 
DMS0(5nl/ml) 48 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
48 
No. of 
Methaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
85 
79 
80 
87 
96 
340 
Range 
0-4 
0-5 
0-3 
0-5 
0-6 
2-11 
SCEs/Cell±SE 
1.70±0.14 
1.58±0.12 
1.60±0.13 
1.72±0.14 
1.92±0.12 
6.80±1.29* 
Table 11 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Hydroxyprogesterone caproate exposure with metabolic activation (S, 
mix). 
Treatment 
(Mg/ml) 
Hydroxy 
progesterone 
caproate 
10 
25 
50 
Control 
Normal 
DMSO (5^1/ml) 
(-ve control) 
CP(lxl0-''M) 
(+ve control) 
Duration 
(hr) 
48 
48 
48 
48 
48 
48 
No. of 
Methaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
79 
80 
76 
78 
89 
380 
Range 
0-5 
0-6 
0-5 
0-5 
0-6 
4-12 
SCEs/Cell±SE 
1.58±0.13 
1.60±0.13 
1.52±0.12 
1.56±0.12 
1.78±0.11 
7.60±1.34* 
CP : Cyclophosphamide; 
SE : Standard error; 
DMSO : Dimethyl sulphoxide 
* : Significant at P<0.05 
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Table 12 : Analysis of cell growth kinetics after Hydroxy progesterone caproate 
exposure in vitro. 
Treatment 
(Mg/ml) 
Hydroxy 
progesterone 
caproate 
10 
25 
50 
Control 
Normal 
DMS0(5^1/ml) 
(-ve control) 
CP(lxlO-''M) 
(+ve control) 
Cell 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
M, 
39 
40 
41 
37 
38 
60 
M, 
42 
42 
42 
53 
46 
37 
in 
M3 
19 
18 
17 
10 
16 
03 
Replication 
Index 
1.80 
1.78 
1.76 
1.73 
1.78 
1.43* 
2x3 Chi-square 
test 
Significant 
Table 13 : Analysis of cell growth kinetics after Hydroxyprogesterone caproate 
exposure with metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Hydroxy 
progesterone 
caproate 
10 
25 
50 
Control 
Normal 
DMS0(5nl/ml) 
(-ve control) 
CP(lxIO-^M) 
(+ve control) 
Cell 
Scored 
200 
200 
200 
200 
200 
200 
CP : Cyclophosphamide 
SE : Standard error; 
Percent cells 
M, 
46 
41 
45 
41 
40 
60 
M, 
40 
42 
40 
53 
50 
35 
DMSO : 
* 
in 
M3 
17 
17 
15 
06 
10 
05 
Replication 
Index 
1.77 
1.76 
1.70 
1.65 
1.70 
1.45* 
Dimethyl sulphoxide 
Significant at P<0.05 
2x3 Chi-square 
test 
Significant 
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Table 16 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Megestrol acetate exposure in vitro. 
Treatment 
(Mg/ml) 
Megestrol 
acetate 
10 
25 
50 
Control 
Normal 
Duration 
(hr) 
48 
48 
48 
48 
DMS0(5^1/ml) 48 
(-ve control) 
CP(lxlO-'M) 
(+ve control) 
48 
No. of 
Methaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
93 
283 
107 
87 
96 
340 
Range 
0-5 
2-10 
0-6 
0-5 
0-6 
2-11 
SCEs/Cell ±SE 
1.86±0.19 
5.66±0.29* 
2.14±0.18 
1.72±0.14 
1.92±0.12 
6.80±1.29* 
Table 17 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Megestrol acetate exposure with metabolic activation (S, mix). 
Treatment 
(Hg/ml) 
Megestrol 
acetate 
10 
25 
50 
Control 
Normal 
DMSO (5^1/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Duration 
(hr) 
48 
48 
48 
48 
48 
48 
CP : Cyclophosphamide; 
SE : Standard error; 
No. of Total 
Methaphases SCE 
50 
50 
50 
50 
50 
50 
DMSO : 
* 
95 
271 
113 
78 
89 
380 
Range 
1-5 
2-10 
2-5 
0-5 
0-6 
4-12 
Dimethyl sulphoxide 
Significant at P<0.05 
SCEs/Cell ±SE 
1.90±0.21 
5.42±0.28 
2.26±0.21 
1.56±0.12 
1.78±0.11 
7.60±1.34* 
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Table 18 : Analysis of cell growth kinetics after Megestrol acetate exposure 
in vitro. 
Treatment 
(Mg/ml) 
Megestrol 
acetate 
10 
25 
50 
Control 
Normal 
DMS0(5til/ml) 
(-ve control) 
CP(lxlO-'M) 
(+ve control) 
Cell 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
M, 
36 
53 
38 
37 
38 
60 
M, 
55 
37 
51 
53 
46 
37 
in 
M3 
09 
08 
11 
10 
16 
03 
Replication 
Index 
1.73 
1.51* 
1.73 
1.73 
1.78 
1.43* 
2x3 Chi-square 
test 
Significant 
Significant 
Table 19 : Analysis of cell growth kinetics after Megestrol acetate exposure 
with metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Megestrol 
acetate 
10 
25 
50 
Control 
Normal 
DMS0(5nl/ml) 
(-ve control) 
CP(lxl0-''M) 
(+ve control) 
Cell 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
M, 
51 
53 
51 
41 
40 
60 
M, 
39 
43 
38 
53 
50 
35 
in 
M3 
10 
04 
11 
06 
10 
05 
Replication 
Index 
1.59 
1.51* 
1.60 
1.65 
1.70 
1.45* 
2x3 Chi-square 
test 
Significant 
Significant 
CP : Cyclophosphamide; DMSO : Dimethyl sulphoxide 
SE : Standard error; * : Significant at P<0.05 
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Table 22 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Triamcinolone exposure in vitro. 
Treatment 
(Hg/ml) 
Triamcinolone 
10 
50 
100 
Control 
Normal 
DMSO (5^1/ml] 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Duration 
(hr) 
48 
48 
48 
48 
( 48 
48 
No. of 
Methaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
98 
101 
121 
87 
96 
340 
Range 
0-5 
0-5 
0-6 
0-5 
0-6 
2-11 
SCEs/Cell ±SE 
1.96±0.18 
2.02±0.20 
2.42±0.29 
1.74±0.14 
1.92±0.12 
6.80±1.29* 
Table 23 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Triamcinolone exposure with metabolic activation (S, mix). 
Treatment 
(Hg/ml) 
Triamcinolone 
10 
50 
100 
Control 
Normal 
DMSO (5^1/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Duration 
(hr) 
48 
48 
48 
48 
48 
48 
No. of 
Methaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
140 
198 
220 
78 
89 
380 
Range 
0-5 
1-7 
2-9 
0-5 
0-6 
4-12 
SCEs/Cell ±SE 
2.80±0.11 
3.96±0.19 
4.40±0.21 
1.56±0.12 
1.78±0.11 
7.60±1.34* 
CP : Cyclophosphamide; DMSO : Dimethyl sulphoxide 
SE : Standard error; * : Significant at P<0.05 
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Table 24 : Analysis of cell growth kinetics after Triamcinolone exposure 
in vitro. 
Treatment 
(^ lg/ml) 
Triamcinolone 
10 
50 
100 
Control 
Normal 
DMS0(5^1/ml) 
(-ve control) 
CP(lxl0-''M) 
(+ve control) 
Cell 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
M, 
36 
39 
38 
37 
38 
60 
M, 
36 
36 
40 
53 
46 
37 
in 
M3 
28 
25 
22 
10 
16 
03 
Replication 
Index 
1.92 
1.86 
1.84 
1.73 
1.78 
1.43* 
2x3 Chi-square 
test 
Significant 
Table 25 : Analysis of cell growth kinetics after Triamcinolone exposure with 
metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Triamcinolone 
10 
50 
100 
Control 
Normal 
DMS0(5nl/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Cell 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
Ml 
38 
39 
54 
41 
40 
60 
M, 
51 
53 
36 
53 
50 
35 
in 
M3 
11 
08 
10 
06 
10 
05 
Replicatii 
Index 
1.73 
1.69 
1.56* 
1.65 
1.70 
1.45* 
test 
Significant 
Significant 
CP : Cyclophosphamide; DMSO : Dimethyl sulphoxide 
SE : Standard error; * : Significant at P<0.05 
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Table 28 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Prednisolone exposure in vitro. 
Treatment 
(Mg/ml) 
Prednisolone 
20 
40 
75 
Control 
Normal 
Duration 
(hr) 
48 
48 
48 
48 
DMS0(5nl/ml) 48 
(-ve control) 
CP(lxlO-'M) 
(+ve control) 
48 
No. of 
Methaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
70 
98 
102 
87 
96 
340 
Range 
0-4 
0-5 
0-6 
0-5 
0-6 
2-11 
SCEs/CeIl±SE 
1.40±0.11 
1.96±0.13 
2.04±0.16 
1.72±0.14 
1.92±0.12 
6.80±1.29* 
Table 29 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Prednisolone exposure with metabolic activation (S, mix). 
Treatment 
(Hg/ml) 
Prednisolone 
20 
40 
75 
Control 
Normal 
DMSO (5nl/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Duration 
(hr) 
48 
48 
48 
48 
48 
48 
No. of 
Methaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
85 
95 
101 
78 
89 
380 
Range 
0-4 
0-4 
0-6 
0-5 
0-6 
4-12 
SCEs/Cell ±SE 
1.70±0.12 
1.90±0.13 
2.02±0.16 
1.56±0.12 
1.78±0.11 
7.60±1.34* 
CP : Cyclophosphamide; DMSO : Dimethyl sulphoxide 
SE : Standard error; * : Significant at P<0.05 
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Table 30 : Analysis of cell growth kinetics after Prednisolone exposure in vitro. 
Treatment 
(Mg/ml) 
Cell Percent ceils in 
Scored M, M, M, 
Replication 2x3 Chi-square 
Index test 
Prednisolone 
20 200 29 39 32 2.03 
40 200 28 41 31 2.13 
75 200 29 41 30 2.01 
Control 
Normal 
DMS0(5)il/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
200 
200 
200 
37 53 
38 46 
60 37 
10 
16 
03 
1.73 
1.78 
1.43^ Significant 
Table 31 : Analysis of cell growth kinetics after Prednisolone exposure with 
metabolic activation (S, mix). 
Treatment 
()ig/ml) 
Prednisolone 
20 
40 
75 
Control 
Normal 
DMS0(5^1/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Cell 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
M, 
27 
30 
32 
41 
40 
60 
M, 
39 
37 
35 
53 
50 
35 
in 
M3 
34 
33 
33 
06 
10 
05 
Replication 
Index 
2.07 
2.03 
2.01 
1.65 
1.70 
1.45* 
2x3 Chi-square 
test 
Significant 
CP : Cyclophosphamide; DMSO : Dimethyl sulphoxide 
SE : Standard error; * ; Significant at P<0.05 
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Table 34 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Betamethasone exposure in vitro. 
Treatment Duration 
(Hg/ml) (hr) 
Betamethasone 
10 
25 
50 
Control 
Normal 
DMSO (5^1/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
48 
48 
48 
48 
48 
48 
No. of 
Methaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
126 
189 
129 
87 
96 
340 
Range 
0-6 
1-9 
0-7 
0-5 
0-6 
2-11 
SCEs/CelUSE 
2.52±0.18 
3.78±0.21* 
2.58±0.17 
1.72±0.14 
1.92±0.12 
6.80±1.29* 
Table 35 : Sister Chromatid Exchange (SCE) in humna lymphocytes after 
Betamethasone exposure with metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Betamethasone 
10 
25 
50 
Control 
Normal 
DMSO (5^il/ml) 
(-ve control) 
CP(lxlO-''M) 
(+ve control) 
Duration 
(hr) 
48 
48 
48 
48 
48 
48 
CP : Cyclophosphamide; 
SE : Standard error; 
No. of Total 
Methaphases SCE 
50 
50 
50 
50 
50 
50 
DMSO : 
* 
92 
201 
147 
78 
89 
380 
Range 
0-4 
0-9 
0-6 
0-5 
0-6 
4-12 
Dimethyl sulphoxide 
Significant at P<0.05 
SCEs/Cell±SE 
1.84±0.15 
4.02±0.19 
2.94±0.17 
1.56±0.12 
1.78±0.11 
7.60±1.34* 
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Table 36 : Analysis of cell growth kinetics after Betamethasone exposure 
in vitro. 
Treatment 
(Mg/ml) 
Cell 
Scored 
Percent cells in 
M, M, M, 
Replication 2x3 Chi-square 
Index test 
Betamethasone 
10 200 49 35 16 
25 200 47 40 13 
50 200 57 33 10 
1.67 
1.66 
1.53* Significant 
Control 
Normal 200 
DMS0(5^yml) 200 
(-ve control) 
CP(lxlO-''M) 200 
(+ve control) 
37 53 
38 46 
60 37 
10 
16 
03 
1.73 
1.78 
1.43* Significant 
Table 37 : Analysis of cell growth kinetics after Betamethasone exposure with 
metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Cell 
Scored 
Percent cells in 
M. M, M, 
Replication 2x3 Chi-square 
Index test 
Betamethasone 
10 200 
25 200 
50 200 
Control 
Normal 200 
45 
51 
54 
41 
42 
37 
36 
53 
13 
12 
10 
06 
DMS0(5Ml/ml) 200 40 50 10 
(-ve control) 
1.68 
1.61 
1.56* 
1.65 
1.70 
Significant 
CP(lxlO-^M) 200 
(+ve control) 
60 35 05 
CP : Cyclophosphamide; 
SE : Standard error; 
1.45^ 
DMSO : Dimethyl sulphoxide 
* : Significant at P<0.05 
Significant 
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Table-38 Chromosomal aberrations in human lymphocytes of the patients exposed to 
Medroxyprogesterone acetate. 
General Control 
Patient Control 
Patient exposed to 
Medroxyprogeste-
rone acetate 
No. of 
. Metaphases 
300 
300 
300 
Percent aberration 
Metaphase 
Including 
gap 
3.33 
4.00 
13.33 
Excluding 
gap 
3.00 
2.67 
10.67 
Types of aberration% 
Chro-
matid 
2.33 
2.00 
8.33 
Chrom-
osome 
1.33 
1.00 
6.00 
Total 
3.67 
3.00 
14.33* 
Aberration/ 
Cell + SE 
0.04±0.01 
0.03±0.01 
0.14±0.03 
Table-39 Sister chromatid exchange in human lymphocytes of the patients exposed to 
Medroxyprogesterone acetate. 
General control 
Patient control 
Patient exposed to 
Medroxyprogesterone 
acetate 
No.of 
Metaphases 
50 
50 
50 
Total SCE 
75 
87 
198 
Range 
0-4 
0-5 
1-9 
SCE/Cell ± SE 
1.5010.12 
1.7410.13 
3.9610.20* 
Table-40 Analysis of cell growth kinetics in human lymphocytes of the patients exposed to 
Medroxyprogesterone acetate. 
General control 
Patient control 
Patient exposed to 
Medroxyprogesteone 
acetate 
Cells 
Scored 
200 
200 
200 
Percent cells in 
Ml 
34 
36 
56 
M? 
54 
53 
41 
Ms 
12 
11 
03 
Replication 
Index 
1.78 
1.75 
1.47* 
2x3 Chi-square 
test 
Significant 
SE = Standard Error Significant at P<0.05 
156 
Table-41 Chromosomal aberrations in human lymphocytes of the patients exposed to 
Hydroxyprogesterone caproate. 
General Control 
Patient Control 
Patient exposed to 
Hydroxyprogest-
erone caproate 
No. of 
Metaphases 
300 
300 
300 
Percent aberration 
Metaphase 
Including 
gap 
3.33 
3.67 
11.00 
Excluding 
gap 
3.00 
2.67 
7.67 
Types of aberration% 
Chro-
matid 
2.33 
3.67 
3.67 
Chrom-
osome 
1.33 
0.33 
2.00 
Total 
3.67 
4.00 
5.67 
Aberration/ 
Cell ± SE 
0.04±0.01 
0.04±0.01 
0.06±0.02 
Table-42 Sister chromatid exchange in human lymphocytes of the patients exposed to 
Hydroxyprogesterone caproate. 
General control 
Patient control 
Patient exposed to 
Hydroxyprogesterone 
caproate 
No.of 
Metaphases 
50 
50 
50 
Total SCE 
75 
78 
82 
Range 
0-4 
0-5 
0-6 
SCE/Cell±SE 
1.5010.12 
1.56±0.12 
1.64±0.12 
Table-43 Analysis of cell growth kinetics in human lymphocytes of the patients exposed to 
Hydroxyprogesterone caproate. 
General control 
Patient control 
Patient exposed to 
Hydroxyprogesterone 
caproate 
Cells 
Scored 
200 
200 
200 
Percent cells in 
M, 
34 
32 
33 
Mj 
54 
55 
53 
M3 
12 
13 
14 
Replication 
Index 
1.78 
1.81 
1.81 
2x3 Chi-square 
test 
SE = Standard Error * Significant at P<0.05 
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Table-44 Chromosomal aberrations in human lymphocytes of patients exposed to Megestrol acetate. 
General Control 
Patient Control 
Patient exposed to 
Megestrol acetate 
No. of 
Metaphases 
300 
300 
300 
Percent aberration 
Metaphase 
Including 
gap 
3.33 
4.33 
13.67 
Excludin 
ggap 
3.00 
3.33 
12.33 
Types of aberration % 
Chro-
matid 
2.33 
2.67 
10.33 
Chrom-
osome 
1.33 
2.33 
7.00 
Total 
3.67 
5.00 
17.33* 
Aberration/ 
CeU ± SE 
0.04±0.01 
0.05±0.01 
0.17±0.03 
Table-45 Sister chromatid exchange in human lymphocytes of the patients exposed to Megestrol 
acetate. 
General control 
Patient control 
Patient exposed to 
Megestrol acetate 
No.of 
Metaphases 
50 
50 
50 
Total SCE 
75 
88 
153 
Range 
0-4 
0-6 
1-7 
SCE/Cell ± SE 
1.50+0.12 
1.76±0.12 
3.06±0.19* 
Table-46 Analysis of cell growth kinetics in human lymphocytes of the patients exposed to Megestrol 
acetate. 
General control 
Patient control 
Patient exposed to 
Megestrol acetate 
Cells 
Scored 
200 
200 
200 
Percent cells in 
Ml 
34 
34 
59 
Mi 
54 
50 
33 
M j 
12 
16 
08 
Replication 
Index 
1.78 
1.82 
1.49* 
2x3 Chi-square 
test 
Significant 
SE = Standard Error * Significant at P<0.05 
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TabIe-47 Chromosomal aberrations in human lymphocytes of the patients exposed to Triamcinolone. 
General Control 
Patient Control 
Patient exposed 
to Triamcinolone 
No. of 
Metaphases 
300 
300 
300 
Percent ab 
Metap 
Including 
gap 
3.33 
4.33 
10.33 
erration 
lase 
Excludin 
ggap 
3.00 
3.67 
8.67 
Types 
Chro-
matid 
2.33 
3.67 
8.67 
of aberration % 
Chrom-
osome 
1.33 
2.67 
6.00 
Total 
3.67 
6.33 
14.67* 
Aberration/ 
Cell ± SE 
0.04±0.01 
0.06±0.02 
0.15±0.06 
Table 48 Sister Chromatid exchange in human lymphocytes of the patients exposed to Triamcinolone. 
General control 
Patient control 
Patient exposed to 
Triamcinolone 
No.of 
Metaphases 
50 
50 
50 
Total SCE 
75 
87 
168 
Range 
0-4 
0-5 
1-8 
SCE/Cell ± SE 
1.50±0.12 
1.74±0.14 
3.36±0.20* 
Table-49 Analysis of cell growth kinetics in human lymphocytes of the patients exposed to 
Triamcinolone. 
General control 
Patient control 
Patient exposed to 
Triamcinolone 
Cells 
Scored 
200 
200 
200 
Percent cells in 
M, 
34 
35 
54 
M, 
54 
53 
41 
Ms 
12 
14 
05 
Replication 
Index 
1.78 
1.82 
1.51* 
2x3 Chi-square 
test 
Significant 
SE = Standard Error Significant at P<0.05 
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Table-50 Chromosomal aberrations in human lymphocytes of the patients exposed to Prednisolone. 
General Control 
Patient Control 
Patient exposed to 
Prednisolone 
No. of 
Metaphases 
300 
300 
300 
Percent ab 
Metap 
Including 
gap 
3.33 
3.67 
6.00 
erration 
lase 
Excludin 
ggap 
3.00 
3.33 
5.33 
Types of aberration % 
Chro-
matid 
2.33 
4.00 
4.67 
Chrom-
osome 
1.33 
3.33 
3.33 
Total 
3.67 
7.33 
8.00 
Aberration/ 
CeU ± SE 
0.04±0.01 
0.07±0.03 
0.08±0.03 
Table-51 Sister chromatid exchange in human lymphocytes of the patients exposed to Prednisolone. 
General control 
Patient control 
Patient exposed to 
Prednisolone 
No.of 
Metaphases 
50 
50 
50 
Total SCE 
75 
83 
98 
Range 
0-4 
0-5 
0-6 
SCE/Cell ± SE 
1.50±0.12 
1.66±0.13 
1.96±0.15 
TabIe-52 Analysis of cell growth kinetics in human lymphocytes of the patients exposed to 
Prednisolone. 
General control 
Patient control 
Patient exposed to 
Prednisolone 
Cells 
Scored 
200 
200 
200 
Percent cells in 
M, 
34 
37 
34 
Mj 
54 
52 
52 
M j 
12 
11 
14 
Replication 
Index 
1.78 
1.74 
1.80 
2x3 Chi-square 
test 
SE = Standard Error • Significant at P<0.05 
160 
Table-S3 Chromosomal aberrations in human lymphocytes of the patients exposed to Betamethasone. 
General Control 
Patient Control 
Patient exposed 
to 
Betamethasone 
No. of 
Metaphases 
300 
300 
300 
Percent aberration 
Metaphase 
Including 
gap 
3.33 
4.67 
18.33 
Excluding 
gap 
3.00 
3.00 
15.33 
Types of aberration % 
Chro-
matid 
2.33 
4.00 
10.00 
Chrom-
osome 
1.33 
2.33 
8.67 
Total 
3.67 
7.33 
18.67* 
Aberration/ 
Cell ± SE 
0.04±0.01 
0.07±0.03 
0.1010.05 
Table-54 Sister chromatid exchange in human lymphocytes of the patients exposed to Betamethasone. 
General control 
Patient control 
Patient exposed to 
Betamethasone 
No.of 
Metaphases 
50 
50 
50 
Total SCE 
75 
78 
169 
Range 
0-4 
0-5 
0-9 
SCE/Cell ± SE 
1.5010.12 
1.5610.12 
3.3810.17* 
TabIe-55 Analysis of cell growth kinetics in human lymphocytes of the patients exposed to 
Betamethasone. 
General control 
Patient control 
Patient exposed to 
Betamethasone 
CeUs 
Scored 
200 
200 
200 
Percent cells in 
Ml 
34 
32 
53 
Uj 
54 
55 
37 
Ms 
12 
13 
08 
Replication 
Index 
1.78 
1.81 
1.51* 
2x3 Chi-square 
test 
Significant 
SE = Standard Error Significant at P<0.05 
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Table 56: Adverse/side effects observed in the patients exposed to 
Medroxyprogesterone acetate for 1 to 3 months (n=7) 
ADVERSE / SIDE EFFECTS 
Nausea 
Vomiting 
Diarrhea 
Edema 
Hirsutism 
Weight gain 
Headache 
Pruritus Vulvae 
Fatigue 
Urticaria 
Hypersensitivity 
Doyspnea 
Breast discomfort 
Swollen ankles 
Irregular menstruation 
Rash/Itching/Acne 
Raised bp 
Drowsiness 
Spotting 
Decreased libido 
Sweating 
Leg cramps 
SEVERE 
(in no. of patients) 
2 
3 
1 
2 
1 
0 
3 
1 
2 
1 
3 
0 
2 
1 
1 
2 
1 
2 
1 
1 
3 
1 
MILD 
(in no. of patients) 
2 
2 
1 
3 
2 
2 
3 
1 
4 
1 
2 
1 
2 
2 
1 
3 
2 
3 
0 
2 
2 
1 
No EFFECT 
(in no. of patients) 
3 
2 
5 
2 
4 
5 
1 
5 
1 
5 
2 
6 
3 
4 
5 
2 
4 
2 
6 
4 
2 
5 
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Table 57: Adverse/side effects observed 
Hydroxyprogesterone caproate for 
in the patients 
1 to 3 months (n=8) 
exposed to 
ADVERSE / SIDE EFFECT 
Nausea 
Vomiting 
Diarrhea 
Edema 
Hirsutism 
Weight gain 
Headache 
Pruritus Vulvae 
Fatigue 
Urticaria 
Hypersensitivity 
Doyspnea 
Breast discomfort 
Swollen ankles 
Irregular menstruation 
Rash/Itching/Acne 
Raised bp 
Drowsiness 
Spotting 
Decreased libido 
Sweating 
Leg cramps 
SEVERE 
(in no. of patients) 
1 
0 
0 
1 
0 
2 
2 
0 
3 
0 
1 
0 
1 
1 
1 
2 
1 
2 
1 
1 
3 
0 
MILD 
(in no. of patients) 
1 
1 
2 
2 
1 
1 
2 
0 
2 
1 
1 
0 
1 
1 
2 
3 
1 
3 
1 
1 
2 
1 
No EFFECT 
(in no. of patients) 
6 
7 
6 
5 
7 
5 
4 
8 
3 
7 
6 
8 
6 
6 
• 5 
3 
6 
3 
6 
6 
3 
7 
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Table 58: Adverse/side effects observed in the patients exposed to Megestrol 
acetate for 1 to 3 months (n=8). 
ADVERSE / SIDE EFFECTS 
Nausea 
Vomiting 
Diarrhea 
Edema 
Hirsutism 
Weight gain 
Headache 
Pruritus Vulvae 
Fatigue 
Urticaria 
Hypersensitivity 
Doyspnea 
Breast discomfort 
Swollen ankles 
Irregular menstruation 
Rash/Itching/Acne 
Raised bp 
Drowsiness 
Spotting 
Decreased libido 
Sweating 
Leg cramps 
SEVERE 
(in no. of patients) 
1 
1 
0 
1 
1 
1 
2 
0 
2 
0 
1 
0 
1 
1 
1 
2 
2 
3 
0 
0 
2 
2 
MILD 
(in no. of patients) 
2 
1 
2 
1 
2 
2 
3 
2 
3 
0 
3 
1 
3 
3 
2 
3 
2 
3 
3 
2 
4 
2 
No EFFECT 
(in no. of patients) 
5 
6 
6 
6 
5 
5 
3 
6 
3 
8 
4 
7 
4 
4 
5 
3 
4 
2 
5 
6 
2 
4 
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Table 59 : Adverse/side effects observed in the patients exposed to Betamethasone 
for 1 to 3 months (n=8). 
ADVERSE / SIDE EFFECTS 
Anorexia 
Weight gain 
Vertigo 
Headache 
Muscle Weakness 
Dizziness 
Depression 
Psychoses 
Hypertension 
Acne 
Moon face 
Itching 
Edema 
Euphoria 
Indigestion 
Breathing problem 
Throat irritation 
Coughing 
Hoarseness 
Delayed wound healing 
Cataract 
Insomnia 
Suppression of response 
to infection 
Thinning of scalp hair 
SEVERE 
(in no. of patients) 
1 
1 
0 
1 
0 
2 
3 
1 
1 
2 
0 
1 
1 
1 
1 
1 
1 
1 
1 
2 
0 
1 
2 
1 
MILD 
(in no. of patients) 
2 
3 
2 
3 
2 
3 
3 
1 
2 
3 
2 
2 
3 
1 
3 
2 
3 
2 
1 
3 
1 
1 
2 
3 
No EFFECT 
(in no. of patients) 
5 
4 
6 
4 
6 
3 
2 
6 
5 
3 
6 
5 
4 
6 
4 
5 
4 
5 
6 
3 
7 
6 
4 
4 
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Table 60: Adverse/side effects observed in the patients exposed to Prednisolone 
for 1 to 3 months (n=7). 
ADVERSE / SIDE EFFECTS 
Anorexia 
Weight gain 
Vertigo 
Headache 
Muscle Weakness 
Dizziness 
Depression 
Psychoses 
Hypertension 
Acne 
Moon face 
Itching 
Edema 
Euphoria 
Indigestion 
Breathing problem 
Throat irritation 
Coughing 
Hoarseness 
Delayed wound healing 
Cataract 
Insomnia 
Suppression of response 
to infection 
Thinning of scalp hair 
SEVERE 
(in no. of patients) 
0 
1 
0 
2 
0 
1 
1 
0 
0 
1 
0 
0 
1 
0 
1 
0 
1 
1 
1 
1 
0 
0 
1 
1 
MELD 
(in no. of patients) 
1 
2 
1 
2 
1 
1 
2 
2 
1 
1 
1 
2 
1 
1 
2 
1 
1 
2 
1 
2 
1 
1 
2 
2 
N o EFFECT 
(in no. of patients) 
6 
4 
6 
3 
6 
5 
4 
5 
6 
5 
6 
5 
5 
6 
4 
6 
5 
4 
5 
4 
6 
6 
4 
4 
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Table 6 1 : Adverse/side effects observed in the patients exposed to Triamcinolone 
for 1 to 3 months (n=7). 
ADVERSE / SIDE EFFECTS 
Anorexia 
Weight gain 
Vertigo 
Headache 
Muscle Weakness 
Dizziness 
Depression 
Psychoses 
Hypertension 
Acne 
Moon face 
Itching 
Edema 
Euphoria 
Indigestion 
Breathing problem 
Throat irritation 
Coughing 
Hoarseness 
Delayed wound healing 
Cataract 
Insomnia 
Suppression of response 
to infection 
Thinning of scalp hair 
SEVERE 
(in no. of patients) 
0 
0 
0 
1 
1 
0 
0 
1 
1 
0 
0 
0 
0 
0 
2 
1 
1 
2 
0 
1 
0 
1 
1 
0 
MILD 
(in no. of patients) 
2 
1 
2 
2 
2 
1 
3 
1 
1 
1 
1 
N o EFFECT 
(in no. of patients) 
6 
6 
6 
5 
5 
6 
6 
5 
4 
6 
6 
6 
6 
5 
4 
4 
4 
3 
6 
3 
6 
5 
5 
6 
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DISCUSSION 
J n the present work the cytogenetic study of the effects 
of some steroidal drugs have been done both in vitro and in vivo. 
Some clinical observations have also been undertaken to correlate 
the adverse genotoxic effects with the adverse physiological or 
clinical symptoms. The advantages, disadvantages, objectives and 
limitations of the test systems used, the parameters assayed and 
cytogenetic and clinical effects of the steroids evaluated on these 
parameters are discussed below. 
(A) GENERAL CONSIDERATIONS 
Human health safeguard is the main aim of the steroid 
genotoxicity/mutagenicity evaluation studies. That is why it is ideal 
to evaluate them directly on humans who are exposed to these 
steroidal drugs or test them for genotoxicity on a system that has 
the same sensitivity of response as the human genome. The human 
peripheral blood lymphocyte has enormous potentials and 
properties to be the best test system for such evaluations. The 
human peripheral blood lymphocyte culture system is a single 
system that provides us with a large number of dividing cells. 
These can be easily cultured to yield large number of mitotic 
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figures from chromosome analysis. It can be very easily collected 
and a little quantity is enough for obtaining a large and desired 
number of metaphases. The lymphocytes also contain some 
metabolising enzyme systems that can be able, to some extent, to 
activate certain promutagens into a mutagenically active state 
(Buckton and Evans, 1982; Preston, 1999). 
IN VITRO AND IN VIVO EVALUATION 
Mutations are detected among organisms by their phenotypic 
expression. Depending upon the complexity of the organization 
of the genetic material, the primary change leading to a mutation 
can vary. In prokaryotic systems, such as Salmonella and E. coli, 
single base pair changes or additions or deletions of single bases 
in the DNA can lead to mutations. However, large deletions and 
duplications cannot be tolerated by these organisms, as unrepaired 
or misrepaired breaks in DNA lead to lethality. In eukaryotic 
systems on the contrary, in which the genetic material is organised 
in the form of separate chromosomes which contain a complex of 
DNA with proteins, in addition to mutations resulting from single 
base pair changes similar to bacteria, those due to small and large 
chromosomal rearrangements can be detected. This basic 
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difference between prokaryotes and eukaryotes obviously makes 
a unified definition of mutations impossible and makes direct 
comparisons and extrapolations difficult. 
While most of the directly acting mutagens can readily be 
detected in both in vitro and in vivo test systems, it is difficult to 
detect mutagens which require metabolic activation. This, for 
instance, can be achieved by employing a mammalian liver 
activation system in in vitro studies. (Natarajan et al., 1976). This 
test, however, cannot always fully replace an in vivo situation, 
and thus limits detection of certain classes of chemicals in vitro. 
In such cases in vivo tests would be appropriate. 
Bacterial tests can be of predictive value for the ability of a 
compound to induce point mutations but a chemical which 
predominantly induces DNA strand breaks and thus chromosomal 
aberrations will not be detected in this test easily. Since 
chromosomal aberrations per se contribute to a significant 
proportion of detectable genetic damage in human it is important 
that the test system (battery) employed should include the ability 
to detect chromosomal aberrations. Information is also needed 
with respect to tissue-specific responses of mutagens in germinal 
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vs somatic cells. In several instances a potent mutagen may turnout 
to be negative in a mammal in an assay measuring damage in germ 
cells simply because the active metabolite does not reach the germ 
cells due to the existence of the blood-testis barrier. Though such 
a chemical may not pose a hazard for future generations it might 
induce changes in the somatic cells of the exposed individual, 
leading to somatic mutations (cancer). Accumulating evidence 
points towards an involvement of specific chromosomal 
rearrangements in the etiology of different types of cancers in 
humans, such as lymphomas, leukemias, Wilm's tumour etc. 
(Rowley, 1983). 
Since most mutagens are also known to induce chromosomal 
aberrations, the ability of a compound to induce chromosomal 
aberrations has been used as an index of mutagenic potential of 
an agent (Natarajan and Obe, 1982). Chromosomal aberrations 
can be detected in different types of proliferating cells of plants 
and animal origin. Howevr, for routine screening, mammalian cells 
are employed, such as established Chinese hamster cells or 
stimulated human peripheral blood lymphocytes. The types of and 
the frequencies of aberrations induced depend on the cell cycle 
stage treated and the mutagen in question. Agents which directly 
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induce DNA double-strand breaks, such as X-rays and Bleomycin 
induce chromosome type of aberrations in Gj, chromatid type in 
Gj and both types in the S phase of the cell cycle. These agents 
are considered as S-independent agents. On the other hand 
mutagens such as alkylating agents and UV light induce chromatid 
type of aberrations irrespective of the cell cycle stage treated and 
the cells have to go through an S phase before the aberrations can 
be visualised. These agents are classified as S-dependent agents. 
Chromosomal aberrations induced among animals can be 
evaluated in all of the proliferating cells e.g., bone marrow cells 
as well as spermatogonial cells are usually studied. When induced 
breaks are not induced in the daughter nucleus the fragments usually 
form a small nucleus, termed as micronucleus appearing in the 
cytoplasm separated from the main nucleus. In the bone marrow, 
micronuclei formed in the erythroblasts are retained during 
maturation in contrast to the main nuclei which are extruded from 
the cells. Thus, in polychromatic erythrocytes, micronuclei can 
be recognized and scored. Because of the ease with which it can 
be performed, this test is widely used. All the cytogenetic tests 
involving bone marrow and germ cells can be done in one animal 
if an appropriate protocol is used (Tales and Natarajan, 1976). 
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SCEs can be detected in proliferative bone marrow and 
spermatogonia! cells. In vivo SCEs are scored from cells which 
have gone through the first cycle in the presence of BrdU, due to 
the fast depletion of BrdU from the animal when BrdU tablets are 
implanted in the animal. SCEs can also be detected in lymphocytes 
from spleen or from peripheral blood which are stimulated in vitro 
the presence of BrdU (Perry, 1981; Abe and Sasaki, 1982). 
It is known that about 6 out of 1000 newborns have a 
chromosomal abnormality though there is no estimate of point 
mutations in the newborns. Population exposed to mutagens 
respond with increased frequencies of chromosomal aberrations 
and cancer rather than detectable point mutations. This 
demonstrates the importance of screening chemicals for their ability 
to induce chromosome aberrations in vitro or in vivo as an indicator 
of potentiality for mutagenicity and carcinogenicity in man. This 
brings us to the question of the choice of a test battery to detect 
mutagenicity of chemicals. While in general, all potent mutagens 
induce chromosomal aberrations, potent chromosome breaking 
agents do not always induce point mutations efficiently eg., X-
rays & bleomycin. In a routine test for mutagenicity it is important 
to employ an in vitro cytogenetic assay because such an assay 
173 
would detect chemicals which are not efficient inducers of point 
mutations but are of potential hazard to man by inducing 
chromosomal aberrations. Similar conclusions were arrived at by 
the analysis of the results of a study designed to compare short-
term tests for mutagens and carcinogens (Ashby et al., 1985). 
In mutagenicity testing, in vitro and in vivo assays serve 
different purposes. For preliminary screening, in view of the 
increased sensitivity, the possibility to use higher concentrations 
of test chemical and the short term involved, in vitro tests are 
ideal. These assays detect the genotoxic potential of the test 
chemical. However, to study the ability of a chemical the genotoxic 
potential in vivo, animal test system should be used (Ashby et 
al., 1996). A decision tree approach to detect possible human 
carcinogens has been proposed by Ashby (1983) in which it is 
clear that in vivo tests have a very important position, not at the 
detection stage, but at validation stage. It is clear that when a 
chemical is being considered to be released for large-scale public 
use, an in vivo mammalian assay should be mandatory. It is ideal 
to study the effect of chemicals directly on persons exposed to 
the test chemicals or drugs (Gebhart, 1982; 1984). But ethical 
reasons preclude the experimental approach on evaluation of 
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genotoxicity among humans. The in vivo study is possible only in 
specific cases when individuals have been exposed to the agents 
either as a chemotherapeutic necessity (e.g. exposure to styrene, 
aniline, polyvinyl chloride etc.), accidental reasons (e.g. exposure 
to radiation, atom bomb explosions etc.), or even occupational 
exposure. 
The study of genotoxicity of a test chemical among patients 
on therapy is difficult. Patients may be on multiple therapy and 
the effects observed may either be additive, synergistic or 
antagonistic to each other. In vivo studies in humans have been 
found to be of high significance in the observation of the effect 
of mutagens on chromosomal aberrations (Pinto, 1986) and SCE 
(Krishnamurthy and Prema, 1985; Azfer and Afzal, 1996). 
The genotoxicity evaluation in vivo also has its short comings 
too. The cytogenetic abnormalities found in exposed persons 
represent the most drastic and obvious expression of genetic 
damage while the frequent and subtle genetic changes like 
mutations are not detected. Another limitation is that the peripheral 
lymphocytes which are cultured are not in the dividing cell cycle 
at the time when the chemicals exert their influence in vitro. Drugs 
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which can cause primary genetic lesions in the G, phase only can 
manifest their detrimental effects while agents that cause genetic 
damage in the S-phase may not exhibit cytogenetic damage in 
lymphocyte cultures of persons exposed to these agents (Gebhart 
1982). 
These shortcomings of the in vivo evaluations can be 
overcome by in vitro treatment of peripheral blood lymphocytes 
in cultures. The experimental approach can be used and the effect 
of drug/chemical can be evaluated at a range of concentrations 
(including subtoxic and toxic level) on lymphocyte cultures of 
healthy individuals. This also permits the evaluation of effects of 
different time exposure to the drug and fate of lesion after 
consecutive cell division as well as the effect of drug during the 
Gj as well as S-phase of the cell cycle. In vitro test, however has 
its own shortcomings because it has no metabolising system of 
the drugs and chemicals in it. But lymphocytes have been known 
to metabolise atleast some compounds eg activation of polycyclic 
hydrocarbon benzo(a) pyrene (Whitlock et. al, 1972; Okano et. 
al., 1979). The presence of erythrocytes in cultures is also known 
to aid in metabolising compounds like aniline, HCl (Wilmer et. 
al, 1984), sodium selenite (Ray and Allenburg, 1978) and styrene 
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and its analogues (Norppa et. ai, 1983; Norppa and Tursi 1984). 
In the present study three progestins, Medroxyprogesterone 
acetate, Hydroxyprogesterone caproate, and Megestrol acetate and 
three corticosteroidal hormones, Triamcinolone, Prednisolone and 
Betamethasone,were tested for their adverse/side effects and 
cytogenetic effects on human lymphocyte chromosomes in 
peripheral blood cultures in vitro and in vivo. All the drugs were 
tested in vitro in the presence of metabolic activation (S^ mix) 
also. 
(B) ADVERSE/SroE EFFECTS OF THE STEROmAL DRUGS 
Adverse effects with standard-dose regimens of progestins 
are rare and are usually minimal; fluid retention, and pain at the 
site of injection may occur (Bordy et al., 1998). Hypercalcemia 
develops occasionally if there are osseous metastasis (Munson, 
1995). In women treated with standard-dose regimens of megestrol 
acetate for breast cancer, the most common side effects were 
nonfluid weight gain (in 23% of patients) and vaginal bleeding (in 
2% of patients). The frequency of all other adverse events was 
1% or less (Schacter et al., 1990). The amount of weight gained 
and the incidence of edema were greater in those given high-dose 
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regimens (Laurence et al., 1997). 
Weight gain also occurs in most patients taking 
medroxyprogesterone acetate. Other adverse reactions to standard 
doses of this progestin in patients include edema, fatigue, sweating, 
vaginal discharge, and amenorrhea. Gluteal abscesses, tremors, 
leg cramps and moon shaped facies were observed in those 
receiving-large doses of medroxyprogesterone acetate 
intramuscularly in combination regimens (Foyl et.al., 1995). 
The occasional and less serious side effects of high dose 
progestin therapy, as it is used to treat advanced endometrial 
cancer or in progestin-only contraceptives, include breakthrough 
bleeding, spotting, changes in menstrual flow, amenorrhea, edema, 
weight changes, nausea, bloating, headache, allergic rash, mood 
changes and changes in lipoprotein concentration (HDL, decreased; 
LDL, increased). Glucose tolerance test results are abnormal in 
4% to 16% of women receiving high-dose progestin therapy. The 
most common side effects of IM medroxyprogesterone acetate 
and Nonplant used for contraception are menstrual abnormalities, 
characterised by irregular bleeding early in the treatment, followed 
by amenorrhea in 50% to 70% of patients after 2 years of treatment 
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(Hardman and Limbird, 1996). 
Long term therapy can cause cushingoid features with 
accumulation of fat on the trunk and face. Metabolic effects include 
sodium retention, potassium loss, which may produce muscle 
weakness; and decreased glucose tolerance, which may result in 
glycosuria and overt Diabetes mellitus. Loss of skin collagen can 
result in paper thin skin and cutaneous striae. Proximal myopathy, 
osteoporosis, osteonecrosis, and vertebral compression fractures 
can develop. Peptic ulcerations may occur. Pituitary-adrenal 
suppression and retardation or interruption of growth have been 
observed in children. Euphoria is common and some patients may 
develop psychoses. The acute tumour lysis syndrome 
(hyperkalemia, hypermicemia, hyperphosphatemia, hypocalcemia, 
lactic acidosis, and acute renal insufficiency) can occur although 
it is rare in patients treated with glucocorticoids alone (Laurence 
and Bennett, 1992). 
Caution should be exercised in patients receiving long term 
steroid therapy, since they are more susceptible to severe 
infections, and sudden withdrawal of medication or development 
of stress may result in acute adrenocortical insufficiency (Brody 
etal., 1998). 
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In patients exposed to corticosteroidal drugs gastrointestinal 
disturbances (anorexia, nausea, vomiting, and diarrhoea) occur in 
80% of patients and are usually dose limiting. About 40% of 
patients experience central nervous system side effects (Lethargy 
and Somnolence 25%, dizziness or vertigo 15%). About 15% of 
patients develop dermatitis. Less frequent adverse effects are visual 
disturbances (eg. blurred vision, diplopia, lens opacities, 
retinopathy), albuminuria, hemorrhagic cystitis, flushing, 
hyperpyrexia, orthostatic hypotension, and hypertension (Laurence 
etal., 1997). 
Adverse effects virtually do not occur with 1 or 2 doses 
though some occur with a few days' use, eg. spread of infection. 
They follow prolonged administration and are sufficiently frequent 
and dangerous to warrant serious consideration by the physician 
whether the disease which he is attempting to suppress is more 
dangerous to the patient than the cushing's syndrome which he 
might induce (Liddle GW. Clin Pharmacol Ther 1961). The 
undesired effects recounted should never be experienced in 
replacement therapy, but are sometimes unavoidable when the 
steroid is used as pharmacotherapy. Naturally, the nature of 
unwanted effects depends on the choice of steroid. 
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Fludrocortisone in ordinary doses does not cause osteoporosis 
and prednisolone does not normally cause oedema. In general, 
serious unwanted effects are unlikely if the daily dose is below 
the equivalent of hydrocortisone 50 mg or prednisolone 10 mg 
(Rang and Dale, 1994). 
Cushing's syndrome symptoms include moon face, 
characteristic deposition of fat on the body, oedema, hypertension, 
striae, bruising, acne, hirsutism, muscle wasting and osteoporosis 
of the spine (with fractures of vertebrae, ribs, femora and feet). 
Avascular necrosis of bone is another serious complication (at 
higher doses); it appears to be due to restriction of blood flow 
through bone capillaries. Pain and restriction of movement may 
occur months in advance of radiographic charge (Munson, 1995). 
Diabetes mellitus may occur, sometimes with suicide, especially 
in those with a history of mental disorder; insomnia is common. 
Patients taking continuous corticosteroids probably have an 
excess incidence of peptic ulcer and haemorrhage of about 1-2% 
(Brody et al., 1998). It is plainly unreasonable to seek to protect 
all such patients by routinely giving prophylactic antiulcer therapy. 
Other adverse effects include posterior subcapsular lens cataract 
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(risk if dose exceeds 10 mg) glaucoma (with prolonged use of 
eyedrops), blood hypercoagulability, menstrual disorders and 
fever. The incidence of infection is increased with high dose 
therapy, and any infection can be more severe when it occurs. 
The incidence of unwanted effects of one kind or another depends 
on drug used, dosage and duration of therapy but can be as high 
as 50% of cases (Hardman and Limbird, 1996). 
CHROMOSOMAL ABERRATIONS 
At the chromosomal level, genetic damage is observed as 
an alteration either in chromosome number or chromosome 
structure. Although numerical changes represent a significant 
proportion of human heritable genetic diseases, their consequence 
in somatic cells are less well characterized. Moreover, estimates 
of numerical changes in somatic cells are heavily influenced by 
technical artifacts. Alterations in chromosome structure are more 
accurately assessed in somatic cells and are observed cytologically 
as chromosomal aberrations or sister chromatid exchanges (SCEs). 
These are currently the most readily available and widely used 
end-points for evaluating somatic mutations in human beings. 
Chromosome aberration assessment serves as a good indicator 
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of the clastogenic effects of test chemicals/drugs (Gebhart, 1970; 
Buckton and Evans, 1982; Hsu 1982; Ashby et al., 1996; Preston, 
1999). 
The chromosomal aberrations can be classified into 
chromatid type aberrations which are caused in the latest S^  or G^ 
phase of cell cycle and the chromosome type aberration which 
are caused by damage to the chromosome materials in the Gj or 
early S-phase. The chromatid type aberrations include chromatid 
and isochromatid gap, chromatid break, chromatid minutes, 
chromatid acentric rings, centric rings, inversions, isochromatid 
aberrations, symmetrical interchanges and asymmetrical 
interchanges. Chromosome type aberrations include terminal 
deletions, minutes acentric rings, centric rings, inversions, 
reciprocal translocations and dicentric or polycentric aberrations 
(Evans and O'Riordan, 1974; Hsu, 1982). 
Inclusion of gaps in the quantitation of chromosome damage 
following exposure to drugs and chemicals is controversial. Many 
workers ignore gaps in their analysis (Buckton and Pike, 1964, 
Goetz et al., 1975). However others suggest that since an incraese 
in the frequency of gaps is related to mutagen exposure, they 
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should be included in the analysis (Gebhart, 1977; Anderson and 
Richardson, 1981; Hsu, 1982; Brogger, 1982). The distinction 
between chromatid gap and break is very arbitrary. A gap is 
cytogenetically distinguished from a break depending on the length 
of the non-staining region in the chromosome. If the attenuated 
region is shorter than the width of the chromatid, it is classified 
as a gap and if longer than the width it is a break. But the problem 
in this classification is that chromosome at prometaphase are 
elongated with a small width of chromatid while at late metaphase 
they are condensed with larger width. This results in classification 
of more breaks in early metaphase and more gaps in late metaphase 
(Preston, 1999). 
To look into the nature of gaps and breaks, various studies 
have been done. A combination of studies with light microscopy, 
transmission electron microscopy and scanning electron 
microscopy of X-ray induced aberrations in Vicia showed that 
gaps and breaks are different manifestations of the same event 
and that gaps may be completed breaks. Breaks, for example, are 
thought to have chromatin bridges. But electron microscopic 
studies (Brecher, 1977) demonstrated that few breaks had and 
chromatin material bridging the space while some gaps had no 
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such chromatin bridges. Thus the distinction between the two is 
arbitrary at the light microscopy level and both are apparently 
different manifestations of the same phenomenon. 
Comings (1974) offered a hypothesis regarding the nature 
of gap. According to him gaps and breaks represents the same 
basic lesions but differ in the time at which the lesions are induced. 
If a break in chromatin fibre occurs when the chromatin is fully 
extended (e.g. G,, S and early G^ phase), subsequent condensation 
of chromosome results in a chromatid break. But if the 
chromosome is already partially condensed (e.g. Gj phase) and a 
break occurs, a few fibres still hold the chromosome together, 
resulting in a gappy appearance. Silver staining technique of the 
chromatid has shown that the chromatid core is not continuous 
in chromatid gaps (Satya Prakash et. al., 1981). Some authors 
suggest that gaps are produced due to loss of despirilization of 
both DNA as well as chromosomal proteins (Stoain and Raicu, 
1973). An increase in constriction and gaps in human chromosomes 
following mercapto-ethanol exposure suggests that gaps may occur 
from damage to the protein moiety of the chromatid causing 
deficient folding of the chromatin fibre in metaphase chromatid 
(Brogger, 1975). 
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However, the frequencies of both gaps and breaks increases 
under the influence of mutagen. It has been suggested by many 
authors that gaps are indicative of toxic phenomena from genetic 
point of view and the aberrations could be useful sensitive 
indicators of chemically induced genetic damage ( Goetz et. al, 
1975; Dipaolo and Popescu, 1976; Hansteen et. al, 1984; Hsu, 
1982;Anderson and Richardson, 1981; Gebhart, 1977; 1982; 1984; 
Haggfari et. al., 1994). It has been claimed that gaps could be 
artefacts of staining and processing and are most subjective 
parameters of analysis. But this claim does not appear to be correct 
because if they are really artefacts, a similar incidence would be 
expected in the control and treated groups (Preston, 1999). 
Any damage altering the normal morphology of a 
chromosome (be it because of damage to DNA and chromatin or 
to the packing proteins of chromosomes) could interfere with 
normal functioning of the chromosome causing genotoxicity. 
Therefore, gaps were included in the present study. 
SISTER CHROMATID EXCHANGES (SCEs) 
Sister Chromatid Exchanges (SCEs) were first reported by 
Taylor (1958), who found that if chromosomes were allowed to 
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replicate once in the presence of tritiated thymidine, and then again 
in the absence of the isotope, autoradiographs showed that only 
one chromatid of each chromosome was labelled as a result of 
the semi-conservative replication of DNA. SCEs represent the 
interchange of DNA strands between sister chromatids at 
apparently homologus loci. The dilution of SCEs became simple 
and more precise with the incorporation of 5-Bromodeoxyuridine 
(BrdU) into the DNA by culturing cells for two cell cycles to give 
one unifilary substituted and one bifilary substituted chromatid in 
a chromosome (Latt, 1973). Subsequent differential staining of 
these chromatids was obtained by fluorescent dyes (Latt, 1981) 
or fluorescent plus giemsa strain (Perry and Wolf, 1974; Afzal and 
Azfer, 1994; Preston, 1999). 
The frequency of SCEs has been found to be greatly 
increased on exposure to mutagenic agents. Therefore, SCEs are 
considered to be sensitive indicators of DNA damage (Latt, 1974; 
Perry and Evans, 1975; Carrano et. al. 1978; Gebhart, 1981; 1982; 
1984; Azfer and Afzal, 1995a). A positive correlation between the 
frequencies of chromosome aberrations and SCEs has been found 
with most of the mutagenic chemicals (Latt, 1974; Preston, 1999). 
But, some mutagenic agents cause an increase only in aberration 
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frequency and not in SCEs, e.g. X-rays (Perry and Evans, 1975), 
certain antitubercular drugs in combination in vivo (Madhuri et 
al, 1983) and some antibiotics in vitro (Manjula et al, 1984). On 
the other hand there are other mutagenic chemicals that induce 
only SCEs but do not cause chromosome aberrations e.g. aniline 
(Abe and Sasaki, 1977; Ishidate and Odashima, 1977). There is 
also a fourth category with a small number of mutagenic chemicals 
that neither cause chromosome aberrations nor induce SCEs e.g. 
sodium azide (Arenaz and Nilan, 1981). 
Thus SCEs and chromosome aberrations are two different 
endpoints depicting cytogenetic damage due to mutagenic action. 
The mechanism of these end points is probably different. One 
system cannot replace the other. Therefore both the endpoints 
should be scored to assess the genetic damage caused by drugs 
and chemicals. 
CELL GROWTH KINETICS 
Cell cycle kinetics analysis is based on the differential 
staining technique of sister chromatids. Scoring of cells prepared 
at M,, Mj and Mj (metaphase in P*, 2°'*and y^ replication cycle) is 
a sensitive method for detecting delay or stimulation in human 
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lymphocyte cultures (Tice et. al, 1976; Crossen and Morgan, 
1977; Morimoto and Wolff, 1980). 
The rate at which mitosis occurs is measured by the mitotic 
index. The index gives an idea about the stimulation of lymphocytes 
to divide and the mitotic activity in culture (Melarango and Smith, 
1984; Sinha et. al, 1984). Any change in mitotic index following 
drug exposure compared to concurrent control, provides 
information on mitostimulative or mitodepressive activity of the 
drug. 
Treatments resulting in SCE formation have been found to 
induce cell cycle delay (Morimoto, 1983; Craig-Holmes and Shaw, 
1976). However, the relationship between the proliferation rate as 
measured by cell growth kinetics and the induction of SCEs is 
controversial. Santessen et. al, (1979) found that SCE levels in 
B-lymphocytes (early proliferating cells) were significantly lower 
than those in T-lymphocytes from the same individual. Snope and 
Rary (1979) and Block et. al, (1982) also found a lower SCE 
frequency in the more rapidly dividing cell populations. Lindblad 
and Lambert (1981) found that though the percentage of B and T 
lymphocytes did not correlate with SCE frequency, a significantly 
higher SCE rate was presented in slowly proliferating cultures. 
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Becher et. ai, (1981) however found low SCE and longer cell 
cycle in leukemic cells while Heidemann et. ai, (1983) found 
increased SCE rate and shortened cell cycle time in trisomic cells 
of a Downs Syndrome mosaic. Many other workers however failed 
to find any relationship between SCE rate and cell cycle kinetics. 
For example, in second generation metaphases collected from 
different culture times (Beck and Obe, 1979). Morimoto and Wolff 
(1980) and Morgan and Crossen (1981) found no significant 
differences in SCE frequency. Guilotto et al. (1980) also 
concluded that the incidence of SCE appeared to be independent 
of the proliferation properties of cultured lymphocytes, such as 
length of cell cycle, fast or delayed response to PHA and number 
of divisions performed in vitro. Lambert et. al, (1983) set up 
repeated cultures in three different tissue culture media and formed 
a great variability in proliferation kinetics between tissue culture 
media and between donors. Speit et. al., (1986) studied the SCEs 
frequency and proliferation of cultures in repeated human 
lymphocytes cultures. They also found no systematic relationship 
between the proliferation of culture and basal SCE values. Also, 
a great variation in the two parameters was observed in repeated 
cultures. 
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(C) CYTOGENETIC EFFECTS OF STEROIDAL DRUGS 
IN VITRO AND IN VIVO 
I. Progestins 
There are contradictory reports regarding in vitro and in 
vivo mutagenic activity of sex steroids Carr (1967) found that 
there is no evidence of an increase in congenital anomalies and 
multiple births in pregnancies which result after discontinuing sex 
steroids in the form of oral contraceptives, although he found, in 
another investigation (Carr, 1970), chromosome abnormalities in 
6 out of 8 spontaneous abortions from women who had become 
pregnant after taking the steroids in the form of oral contraceptive. 
According to him a striking increase in triploidy took place which 
was considered highly significant statistically. Dhillon and Dhillon 
(1996) reported the clastogenic potential of a commonly used 
progestogen, norethisterone acetate. They found increased 
frequency of chromosomal aberrations and SCEs induced both 
with and without S^  mix in cultured human lymphocytes and also 
observed increased frequency of micronuclei formation and SCEs 
in mice. Shyama and Rahiman (1993) assessed Primolut-N tablets 
containing norethisterone for their in vivo genotoxic effect on the 
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bone marow cells of Swiss albino mice and found statistically 
significant increase in chromosomal aberrations. Rohborn and 
Hansmann (1974) found a slight but not significant increase of 
non-disjunction due to 1 mg of norethisterone acetate immediately 
after treatment or after an interval without the drug application. 
Rice- Wray et al. (1970) found no congenital defects and the 
studies of karyotypes and sex-chromatin revealed no abnormalities 
in any of the children born from women who had taken the sex 
steroids before pregnancy. The same results were reported by 
Bishun and Mills (1971) and Van Leuven et al. (1974). Mills et al. 
(1975) found no significant difference in the frequencies of 
aberrations between the test and control mothers, although minor 
differences were found among the babies. 
The three widely used progestins i.e. Medroxyprogesterone 
acetate, Hydroxyprogesterone caproate and Megestrol acetate, 
were evaluated for their genotoxic potential in vitro and in vivo. 
The results reveal the fact that Hydroxyprogesterone caproate was 
not potent enough to cause genotoxic damage in human 
lymphocytes in vitro as well as in vivo. Whereas 
Medroxyprogesterone acetate was effective in inducing 
chromosomal aberrations at higher doses. In the similar fashion 
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Megestrol acetate was also found effective in inducing damage 
but at highest concentration the result was found negative, which 
reveals its high toxicity and cell killing effects at high doses. 
Hydroxyprogesterone caproate is several times more potent 
than progesterone, and its duration of action is longer, but its 
onset of action is also slower. It is not converted to progesterone 
or hydroxyprogesterone in the body. It is generally used in 
combination with an estrogen when used to regulate an irregular 
estrous cycle. It is used to treat uterine carcinoma, amenorrhea 
and to induce a secretary endometrium and desquamation (Brody 
etai,199%). 
Medroxyprogesterone acetate has been found very effective 
as a contraceptive and its oral efficacy is an advantage over 
progesterone. But this drug is teratogenic during the first four 
months of pregnancy. It has been found to be beneficial in some 
cases of sleep apnea. It is also used in endometrial 
carcinoma(Gennaro, 1995).. 
Megestrol acetate is considered to be one of the potent 
progestins. It has been found to be very potent in inhibiting 
ovulation and is employed as an oral contraceptive. But for 
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contraceptive purpose it is supplemented with an estrogen 
generally ethinyl estradiol. It is also used for the treatment of 
inoperable advanced carcinoma of the breast or endometrium,as 
an adjunct to other therapy. Many other progestins are also used 
for contraceptive purpose either alone or in combination with 
estrogens. The progestational drugs are also used for the treatment 
of many diseases e.g. infertility, secondary amenorrhea, 
dysfunctional uterine bleeding, premenstrual tension, sexual 
infantalism, mastogonia, preeclampsia, toxemia, endometrial 
carcinoma etc. (Munson, 1995). 
The genotoxic effects of various progestins have been 
evaluated (Goh, 1967; Carr, 1967). They found chromosomal 
abnormalities in the peripheral blood lymphocytes of women taking 
oral contraceptives. Goh (1967) suggested that oral contraceptives 
may cause chromosome breaks and pointed out that the breakage 
was not observed in peripheral venous sampling after 
discontinuation of the pills and suggested that the individuals are 
capable of removing "mutant cells". Although it might be possible 
to remove the somatic mutant cells by discontinuation of the 
steroidal contraceptive, the germ cells may not be removed so 
easily. The chances of pregnancy incorporating the mutant cells 
194 
are possible if these cells are affectd (McQuarrie et al., 1970). 
Therefore, the greatest danger of oral contraceptives lies in the 
potential damage to the gametes. Since contraceptive hormones 
are in circulation, they presumably have free access to germ cells. 
The existence of chromosome damage in these cells can lead to a 
hazardous situation. 
Badr et al. (1972) have also reported about the cytogenetic 
aberration causing potential of progestrogens in lymphocytes from 
women taking oral contraceptives. Littlefield et al. (1975) have 
observed chromosome damage in lymphocytes from women 
exposed to progestins. They concluded that the effect of synthetic 
hormones on chromatin is not directly related to the concentration 
of circulating hormone molecules or length of time of exposure. 
Northindrone acetate, a synthetic derivative of northindrone, was 
also studied by different groups of scientists and the result found 
was again contradictory (Stenchever et al., 1969; Shyama et al., 
1991). 
Goh (1967) and Carr (1970) suggested that the imbalance in 
steroidal hormones in the blood was the causative factor of 
chromosomal breaks. A somewhat lower frequency of 
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chromosomal breaks was found in cross cultures after the women 
had stopped taking the pills. However, Stenchever and his 
associates (1969) did not find obvious chromosomal effects in 
vitro of various gestagens in lymphocyte cultures with varied 
concentrations and with controls. Goh (1967) suggested that the 
steroidal oral contraceptives may cause chromosome breaks as 
do some other drugs and pointed out that the breakage was not 
observed in peripheral venous sampling after discontinuation of 
"the pills". In another study by McQuarrie et al (1970), cytogenetic 
changes of increased chromosome breakage and satellite 
association were observed in 23 patients using steroidal oral 
contraceptives. Cytogenetic aberrations in lymphocytes from 
women taking oral contraceptives have also been observed by 
Badr et al. (1971). In contrast, another group of scientists 
demonstrated that oral contraceptive pills do not have potential 
to induce chromosome breakage in pill users (Shapiro et al, 1972). 
It was found that synthetic steroidal hormones may induce 
cytogenetic abnormalities in germ cells of rats, dogs and hamsters. 
Littlefield et al. (1974) suggested after comparing the results of 
cytogenetic studies of lymphocytes culture from normal women, 
pregnant women and women taking oral contraceptives, that the 
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increase in breakages in cultures from the oral contraceptive users 
was not related with length of time on pill or statge of the pill-
cycle, and thus the synthetic hormones do not directly damage 
lymphocyte chromosomes. Timson (1969) dealt with the in vitro 
and in vivo cytogenetic effects of lyndiol (an oral contraceptive). 
He observed no chromosome abnormalities in either conditions. 
The same steroid was again studied by Bishun et al. (1975), who 
also did not find any significant effect on chromosomal aberration 
incidence. Another study involving chromosomal examinations of 
babies whose mothers had taken oral-contraceptives was 
undertaken by Rice-Wray et al. (1970). They did not find 
significant level of structural or chromosomal abnormalities in the 
cells examined from the babies. Fitzgerald et al. (1973) compared 
the results of chromosomal aberrations in lymphocytes of women 
taking oral contraceptives for over 4.5 years, from control women. 
He also reported no increase in chromosomal aberrations in their 
cells. DeGutierrez and Lisker (1973) studied 35 patients on 
mestranol and ethynodiol acetate, and failed to confirm any 
chromosomal abnormality in the women after culturing their blood 
for 65 hours. These results were also confirmed by Mills et al. 
(1975) and Matton-Van-Leuven et al. (1974). On the other hand 
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Littlefield and Mailhes (1975) observed a statistically significant 
increase in average breakages in a series of cultures from the group 
of oral contraceptive users. Shyama and Rahiman (1996) studied 
genotoxicity of Lynoral (ethinyl estradiol, an estrogen) in mouse 
bone marrow cells in vivo and found that lynoral failed to induce 
significant genetic damage in the bone marrow erythrocytes of 
mice, regarding chromosomal aberrations and micronuclei. 
Rohborn and Hansmann (1974) found a slight but not significant 
increase of non-disjunction due to norethisterone acetate treatment. 
Estradiol, the most potent naturally occurring estrogen was found 
to induce very low frequencies of hyperploidies in human synovial 
cells in vitro (Lycette et al., 1970), and various numerical 
aberrations in pig oocytes in vitro (McGaughey, 1977). In human 
embryonal fibroblasts and kidney epithelial cells, estradiol was 
reported to induce structural chromosomal aberrations (Serova 
and Kerkis, 1974). In contrast, Banduhn and Obe (1985) observed 
no structural chromosomal aberration in human lymphocytes in 
vitro after estradiol treatment. In another study the use of hormonal 
contraceptives was found to be associated with a highly significant 
increase of chromosome aberrations (Pinto, 1986; Bernstein et 
al., 1992; Mishell, 1994). 
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Ovral 50, an oral contraceptive, was found to be genotoxic 
in mice (Devi and Reddy, 1986) whereas, the same drug was unable 
to induce genotoxic effects in human lymphocyte cultures in vitro 
. Anovlar 21, another oral contraceptive containing estrogen, 
ethinyl estradiol, and progestin, norethisterone acetate, causes a 
statistically significant increase in chromosomal aberration in 
cultured mouse bone marrow (Shyama et al., 1991). Dhillon et al. 
(1994) found that mestranol was capable of causing chromosomal 
aberrations in mouse bone-marrow cells in vitro. Hundal et al. 
(1997) evaluated the genotoxicity potential of three commoinly 
used estrogens - ethinyl estradiol, cyclotriol and cyclodiol using 
short-term in vitro and in vivo assays and found that the genotoxic 
potential of these drugs became evident from the increased number 
of chromosomal aberrations and SCEs in human lymphocyte 
cultures both in the presence and absence of S^  mix. They also 
found increased frequencies of micronuclei and SCEs in mice 
which confirmed their clastogenic potential. Ethinyl estradiol, a 
potent estrogen, was found to induce chromosomal aberrations 
in male Syrian hamster kidney cells in vivo, and in mouse bone 
marrow cells in vivo (Shyama and Rahiman, 1996). Estradiol-1713, 
another potent estrogen was found to induce various structural 
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chromosomal aberrations in human lymphocyte chromosomes in 
vitro (Ahmad et aL, 2000a). 
Sex steroids and related compounds may produce teratogenic 
effects on genital tissues. Large doses of diethylstibestrol (and 
possibly other estrogens) cause defects in the reproductive tracts 
of both female and male offspring. Masculinization of female 
fetuses has occurred when some progestins were taken during 
early pregnancy (eg. for threatened abortion). 
Among women who discontinue use of OCs, the risk of 
spontaneous abortion; congenital abnormalities, including any of 
the so-called VACTERL anomalies (vertebral, anal, cardiac, 
tracheal, esophageal, renal, or limb); or Down's syndrome in 
liveborn infants is not increased. In a prospective study of women 
who were questioned during pregnancy about prior contraceptive 
use, there was no increased risk of malformation associated with 
OC use discontinued up to one month before conception (Harlap 
et al, 1985). The FDA-approved package insert for OCs has been 
revised to indicate that there is no increased risk of birth defects 
in women who have higher risk of congenital malformations among 
infants exposed to sex steroid, including in advertent continuation 
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of OCs during susceptible periods in embryogenesis. 
Cardiovascular and other defect in the VACTERL group have been 
described (Nora et al, 1978; Heinonen et al, 1977; Janerich et al, 
1980), mostly in male infants. 
In general, the increased risk of nongenital congenital 
malformations associated with OC use is small, and the likelihood 
of a causal association has been questioned (Wilson and Bemt 
1981) and refuted (Nora et al, 1982). A case-control study of 
1,091 infants with at least 1 of 11 major malformations or Down's 
syndrome found that the risk of esophageal atresia associated with 
use of hormonal pregnancy tests was increased but the risk with 
use of OCs unchanged (Lamer and Cordero, 1986). It has been 
suggested that the non-random association of VACTERL 
anomalies (regardless of cause) may be explained on the basis of 
defective mesodermal development during embryogenesis (Khoury 
et al, 1983. Because OCs may cause such abnormalities, therapy 
should be discontinued as soon as pregnancy is confirmed. 
Women with fibrocystic breast disease who have 
proliferative lesions on biopsy (especially those with atypia) have 
an increased risk of breast cancer (Dupont and Page, 1985). Several 
studies have shown that the risk of benign breast disease in women 
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who use combination OCs is not increased (Franceschi et al, 1984) 
or is decreased (Hislop and Threlfall, 1984). The fact that OCs 
often are not prescribed for women with a history of benign breast 
disease may account for the higher incidence among control 
subjects. 
In an early report (Paffenbarger et al, 1977), OC use for 
more than six years was associated with increased breast cancer 
among women with a prior history of benign breast diseases; 
however, when more data were collected,the association largely 
disappeared (Paffenbarger et al, 1980). Other studies show no 
increased risk for OC users with prior benign breast disease 
(Cancer and Steriod Hormone Study, 1983 A; Rosenberg et al. 
1985). 
Numerous retrospective and prospective studies of a 
possible association with or causal role of OCs in the development 
of breast cancer have been conducted and others are ongoing. 
Most investigators agree that there is no overall increase in the 
incidence of breast cancer with OC use. Studies to date have 
been reviewed critically (Thomas, 1991), and it has been noted 
that most suffer from potential bias and possible confounding 
factors and that results are inconsistent (Harlap, 1991). Some 
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studies have suggested that the risk of premenopausal breast 
cancer is higher in women who used OCs for longer durations 
before their mid-twenties or prior to first full-term pregnancy, and 
a meta-analysis of completed studies supported this observation 
{RomiQU etai, 1990). 
Since estrogen can stimulate growth of preexisting cancerous 
breast lesions, OCs are contraindicated in women with known or 
suspected breast carcinoma, and caution must be exercised if they 
are prescribed for patients at high risk of breast cancer. 
Epidemiologic studies continue to monitor this issue, particularly 
since some carcinogens have very long latencies before they are 
expressed. 
The risk of endometrial carcinoma among women who have 
used combined OCs appears to be about one-half that of nonusers 
overall; the protective effect increases with duration of use and 
persists for at least 10 to 15 years after discontinuation of OCs. 
There was no difference in risk associated with use of specific 
combination OC preparations (Weiss and Sayvetz, 1980; Kaufman 
et al, 1980 B; Hulka et al, 1982; Cancer and Steriod Hormone 
Study, 1983 B, 1987 A). However, since estrogen may stimulate 
the growth of existing endometrial cancer, OCs should not be 
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prescribed for women with undiagnosed abnormal genital bleeding. 
The incidence of cervical dysplasia, carcinoma in situ, and 
invasive cervical cancer has been reported to increase with OC 
use. However, differences between OC users and nonusers with 
respect to age at commencement of regular intercourse, total 
number of sexual partners, and use of barrier contraceptives by 
control subjects, appear to explain at least some of this increase. 
In one study, the incidence of cervical dysplasia and neoplasia 
and neoplasia increased in OC compared to lUD users, and there 
was a trend toward increased risk with increasing duration of OC 
use. Lack of data on venereal factors precluded consideration of 
this confounding variable (Vessey et al, 1983). Later studies 
support the association of cervical cancer with OC use, however. 
OC use for seven or more years and first use at 24 years of age or 
younger were independent risk factors associated with increased 
relative risks for invasive cervical cancer of 1.8 and 3.0 respectively 
(Ebeling et al, 1987). A prospective study of 47,000 women 
followed for almost 20 years showed an increased risk of cervical 
cancer with OC use, the incidence quadrupled when the duration 
of use exceeded 10 years (Beral et al, 1988). 
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Women taking OCs appear to have a reduced risk of ovarian 
cancer, which further decreases with duration of use (Casagrande 
et al, 1979; Rosenberg et al, 1982). It has been estimated that 
1,700 cases of ovarian cancer are avoided each year because of 
past or current OC use in the United States (Cancer and Steriod 
Hormone Study, 1983 C). The sensitive risk of epithelial ovarian 
cancer is 0.6 in OC users. The protective effect occurs within 
several cycles of treatment and lasts 15 years after cessation of 
OCs. No difference among preparations was found. No 
assessment of risk for nonepithelial ovarian cancer was possible 
because of insufficient data (Cancer and Steriod Hormone Study, 
1987 B). 
Firm conclusions about the carcinogenicity of OCs are not 
yet possible because of the potentially long latent period (up to 
15 years) between the administration of a carcinogen and the 
development of cancer. A comprehensive review of the status of 
OCs related to various types of neoplasia is available . 
Chromatid and, chromosome fragments and breaks were 
more frequent among the various chromosomal aberrations 
induced by medroxyprogesterone acetate and megestrol acetate 
in the present study. In certain cases, at higher doses, multiple 
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anomalies were also observed. Similar observations have been 
made earlier by McQuarrie et al. (1970) in human lymphocytes, 
and in anovlar treated plant chromosomes by Kabarity and 
Mazrooei (1984). Breaks and structural aberrations observed in 
the present study were not restricted to any particular chromosome 
or segment and were random. Few metaphases were also observed 
with 45 chromosomes and few others with 47 chromosomes. A 
few metaphases were observed with endoreduplication in drug 
treated cultures at highest dose and time duration. This effect might 
have resulted due to the inhibition of microtubule formation during 
cell division. 
In most of the metaphases, more than one chromosomes 
were found affected. Because the breaks were random, no any 
particular fragile site was observed for any particular chromosome. 
It has been observed in earlier studies that the common effects of 
steroid hormones on chromosomes are stickiness in diakinesis 
and metaphase and bridges and sometimes lagging chromosomes 
in anaphase (Hakeem and Amer, 1965). Anovlar has been found 
to cause chain of bivalents in addition to stickiness, which may 
be due to the stickiness of the ends of the different bivalents with 
each other (Kabarity and Mazrooei, 1984; Ahmad et al., 2000a). 
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In the in vitro lymphocyte cultures different chromosomal 
abnormalities were observed when treated with 
medroxyprogesterone acetate and megestrol acetate. It was further 
observed that chromatid breaks were more frequent than 
chromosome breaks. This indicates that the drug introduces 
replication errors or breaks replicated chromatids (Ahmad et al, 
2000). Shyama et al. (1991) suggested that frequent chromatid 
breaks were due to the effects of the drug on the DNA strand at 
its late S-phase or after the DNA has replicated or duplicated. 
The peripheral lymphocytes are cells which remain in G -^stage of 
their cell cycle and do not divide inside the body. But the majority 
of chemical mutagens affect the chromosomes only when the cell 
is dividing and passing through the S-phase. When the DNA is 
uncoiled during S-phase, for replication of the DNA molecule, 
the mutagens act on it. Therefore, it is necessary for the cells to 
go through S-phase at least once in between treatment with the 
chemical mutagen and observations. So, the mitogen (PHA) 
stimulates the lymphocytes to enter cell cycle in vitro. It can be 
said that the frequency of chromatid type aberrations are 
observed, following exposure of G^  cells in G^ or S-phase. 
The chromatid type aberrations may be due to errors in DNA 
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regions that have already replicated at the time of exposure or by 
errors in DNA replication on a damaged DNA template. Aberration 
is a rare occurrence in comparison to the amount of induced DNA 
damage, most of which is efficiently repaired. The kinetics of 
repair of different types of DNA damage affects the types of 
structural alterations produced. Most clastogenic chemicals 
produce aberration on an adducted template. The probability of 
obtaining such coincident repair is greatly enhanced by using a 
DNA repair inhibitor, such as cytosine arabinoside (Ashby et al, 
1996; Preston, 1999). 
Chromosome-type aberrations are formed in cells in G,, 
treated with chemicals that are commonly described as S-phase 
dependent (Preston and Gooch, 1981). Thus, it is essential in any 
cytogenetic assay for so-called S-phase dependent chemicals to 
ensure that the cells observed at metaphase have passed through 
the S-phase between treatment and sampling. If the induced 
frequency of all aberration classes is required, cells should be 
sampled for metaphase analysis at their first mitosis after a single 
treatment. Since several types of aberration produce cell lethality 
and/or loss of an acentric fragment at division, observation at the 
second or subsequent mitosis after treatment leads to a lower 
208 
aberration frequency than that induced (Ashby et al., 1996; 
Preston, 1999). 
The frequency of chromatid aberrations produced by DNA 
replication errors is influenced most strongly by the dose to the 
cell, the phase of the cell cycle, DNA repair kinetics, DNA 
replication fidelity and maintenance of cell cycle checkpoints. 
Thus, different cell types can have different sensitivity to 
chromosomal aberration induction as a consequence of differences 
in these factors. 
A limited set of chemicals has been demonstrated to cause 
aneuploidy through interaction with components of chromosome 
movements. These include benomyl, griseofulvin, nocodazole, 
colchicine, colcemid, vinblastine and taxol. These chemicals affect 
tubulin polymerization or spindle micro-tubule stability. Till date, 
other mechanisms of aneuploidy induction have not been clearly 
identified. 
In the present study three different doses i.e. 10,25 and 50 
Hg/ml concentrations and three different time durations i.e. 24, 
48 and 72 h were taken. It was observed that at 10 ng/ml 
concentration medroxyprogesterone acetate, hydroxyprogesterone 
caproate and megestrol acetate i.e. all three progestins are unable 
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to induce significant level of chromosomal aberration at any 
duration of time. At 25 i^g/ml concentration. Medroxyprogesterone 
acetate and megestrol acetate both induce significant increase and 
the highest effects are at 72 h of treatment. Whereas, at the highest 
concentration (50 jig/ml) megestrol acetate did not induce 
significant increase in chromosomal aberration while 
medroxyprogesterone acetate showed significant increase. 
Hydroxyprogesterone caproate did not induce significant increase 
in chromosomal aberration while medroxyprogesterone acetate 
showed significant increase. Hydroxyprogesterone caproate did 
not induce significant chromosomal aberrations at any 
concentration and treatment duration. More or less similar results 
have been observed in in vivo study also. Medroxyprogesterone 
acetate and megestrol acetate induced CAs increased SCE 
frequency and affected cell growth kinetics while 
hydroxyprogesterone caproate was found unable to give any 
significant results. The variation in the pattern of results for 
different drugs at different concentration and treatment durations 
may be due to some or all of the following reasons, namely (i) 
repair of damaged genetic material; (ii) elimination of drug and its 
metabolites; (iii) elimination of cells/chromosomes with damaged 
genetic material; (iv) inactivation of the drug and its metabolites; 
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(v) and due to cell cycle delay or cell killing effect (Dhillon and 
Dhillon, 1996; Hundal et al., 1997; Preston, 1999; Ahmad et al, 
2000). 
In the present work all the three progestins were also 
evaluated for their cytogenetic effects in the presence of metabolic 
activation. All the drugs were found to be ineffective at 10 ng/ml 
dose concentration whereas, highly effective dose was 25 l^g/ml 
for megestrol acetate while medroxyprogesterone acetate was 
effective at 25 ng/ml and 50 ng/ml both. Megestrol acetate was 
found effective at 50 i^g/ml of concentration in contrast to the 
results obtained in the absence of S^  mix. This increase in the 
chromosomal abnormalities may be due to the action of the 
metabolites of the drug. In the microsomal activation system drugs 
are metabolised into different metabolites which may or may not 
be a harmful compound. In this case the metabolites of the drug 
might have been more potent cytogenetically than the drug 
themselves and consequently have caused more chromosomal 
abnormalities. But these metabolites were less potent than the drug 
in terms of their abilities to induce probable cell killing effect. 
In the present investigation it was observed that both the 
progestins medroxyprogesterone acetate and megestrol acetate 
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affected the SCE frequency in a similar fashion that had been 
observed in the case of chromosomal aberration. Maximum value 
of SCE was observed at 48 h of treatment durations for all dose 
concentrations. But statistically significant value of SCE was 
observed only for 25 and 50 i^g/ml dose concentration in the case 
of medroxyprogesterone acetate and for 25 ng/ml dose 
concentration in the case of megestrol acetate both in the presence 
as well as absence of S^  mix. But in case of medroxyprogesterone 
acetate the frequency of SCE was maximum at 50 iig/ml 
concentration. The decrease in the frequency of SCE at the highest 
concentration in case of megestrol acetate might have been due to 
the cell killing effect of the drug. 
Similar observations have been made earlier also by different 
groups of scientists. Murthy and Prema (1979) reported an 
increased set frequency in peripheral lymphocytes of oral 
contraceptive users. It was also observed that estrogen 
progestogen combination contraceptive exhibited an increased 
frequency of SCE (Murthy and Prema, 1983). Similar results for 
estradiol were observed by Banduhn and Obe (1985). Dose 
response effect was observed by Kochhar (1988) for four different 
estrogens in cultured Chinese hamster ovary cells. The drug 
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mestranol was found to induce SCE in mouse bone-marrow cells 
(Dhillon et ai, 1994). Another estrogen estradiol-17p was found 
to be effective in contrast to few other reports in inducing SCE in 
human lymphocytes in vitro in the presence as well as in the 
absence of S^  mix (Ahmad et al 2000a). 
The study of the cell growth kinetics in the present 
investigation show that medroxyprogesterone acetate and 
megestrol acetate inhibit in vitro proliferation of lymphocytes in 
the presence as well as in the absence of metabolic activation. It 
has been reported earlier that the estrogen, estradiol, strongly 
inhibits proliferation of human lymphocytes, but another estrogen, 
estriol, was weak inhibitor (Hill and Wolff, 1983). Estradiol also 
inhibits which may result in the inhibition of cell proliferation 
whereas the estriol did not inhibit DNA and protein synthesis 
(Kuchler and Grauer, 1962). Both in the presence and absence of 
metabolic activation estradiol was found to inhibit cell proliferation 
(Ahmad et al, 2000a). The present finding is supported by earlier 
studies on most of the sex steroids and specially estrogens. 
Proliferation of lymphocytes in culture is dependent on the time 
of phytohaemagglutinin (PHA) mediated transformation of small 
resting (G )^ lymphocytes into blast cells and the length of the cell 
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cycle after proliferation has taken place (Morimoto and Wolff, 
1980). 
It has also been observed that T-lymphocytes respond to 
PHA first (Greaves et al., 1974). As activated T-cells are necessary 
to produce a later B-cell response, so it is possible that these 
estrogens slow down the T-cell proliferation, thus B-cell 
transformation is delayed in treated cultures.On the other hand it 
has also been reported that the estrogens accelerate the mitotic 
activity immediately after administration of the first dose (Gopala 
Krishna and Inamdar, 1971). However, accelerated level never 
exceeds normal level that is established in the target tissues in due 
course. Cell growth is inhibited after estrogen exposure due to an 
extended G^ phase. The average length of time for G^ in actively 
dividing lymphocytes is 3.5 h (Hill and Wolff, 1983). The cells 
may be arrested in Gj or may stop division due to damage to 
DNA and cell division may be blocked. Such G^ blocks are well 
known after cells are X-rayed. Chinese hamster ovary cells have 
been reported to be blocked in G^ phase when treated with 
nitrosourea. In the same study by using the premature chromosome 
condensation technique, it was observed that a linear relationship 
exists between the number of extensively damaged G^  
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chromosomes and the accumulation of G^ cells in treated cultures, 
and it was suggested that chromosome damage is a contributing 
factor to the G^ arrest (Rao and Rao, 1976). 
Adverse effects with standard-dose regimens of progestins 
are rare and are usually minimal; fluid retention, and pain at the 
site of injection may occur (Bordy et al., 1998). Hypercalcemia 
develops occasionally if there are osseous metastasis (Munson, 
1995). In women treated with standard-dose regimens of megestrol 
acetate for breast cancer, the most common side effects were 
nonfluid weight gain (in 23% of patients) and vaginal bleeding (in 
2% of patients). The frequency of all other adverse events was 
1% or less (Schacter et al., 1990). The amount of weight gained 
and the incidence of edema were greater in those given high-dose 
regimens (Laurence et al., 1997). 
Weight gain also occurs in most patients taking 
medroxyprogesterone acetate. Other adverse reactions to standard 
doses of this progestin in patients include edema, fatigue, sweating, 
vaginal discharge, and amenorrhea. Gluteal abscesses, tremors, 
leg cramps and moon shaped facies were observed in those 
receiving-large doses of medroxyprogesterone acetate 
intramuscularly in combination regimens (Foyl et al., 1995). 
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The occasional and less serious side effects of high dose 
progestin therapy, as it is used to treat advanced endometrial 
cancer or in progestin-only contraceptives, include breakthrough 
bleeding, spotting, changes in menstrual flow, amenorrhea, edema, 
weight changes, nausea, bloating, headache, allergic rash, mood 
changes and changes in lipoprotein concentration (HDL, decreased; 
LDL, increased). Glucose tolerance test results are abnormal in 
4% to 16% of women receiving high-dose progestin therapy. The 
most common side effects of IM medroxyprogesterone acetate 
and Norplant used for contraception are menstrual abnormalities, 
characterised by irregular bleeding early in the treatment, followed 
by amenorrhea in 50% to 70% of patients after 2 years of treatment 
(Hardman and Limbird, 1996). 
II. Corticosteroids 
Adrenal steroids are teratogenic in animals. Although a 
relationship between steroid pharmaco therapy and cleft palate 
and other fetal abnormalities has been suspected in man, there is 
no doubt that many women taking a steroid throughout have both 
conceived and borne normal babies. Dosage during pregnancy 
should be kept as low as practicable and fluorinated steroids are 
best avoided as they are more teratogenic in animals (dexa- and 
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betamethasone, triamcinolone and various topical steroids, e.g. 
fluocinolone) (Munson, 1995; Laurence, 1997; Brody etal., 1998). 
The result of the corticosteroids namely triamcinolone, 
prednisolone and betamethasone on the frequency of the 
chromosomal aberrations showed that, only Betamethasone affect 
the lymphocytes in vitro as well as in vivo. Triamcinolone enhanced 
the frequency of chromosomal aberration only in the presence of 
metabolic activation and in vivo. The present study is in line with 
the study conducted by Bali et al. (1990). Prednisolone did not 
prove to be genotoxic in the present in vitro and in vivo studies. 
Similar results were observed by Dhillon (1990) in the Salmonella 
test, that no evidence of any mutagenicity of some corticosteroidal 
drugs either in the presence and absence of metabolic activation 
was seen. No significant increase was observed in the frequency 
of His^ revertants. In another study by Singh et al. (1994) on the 
genotoxicity evaluation of a widely used glucocorticoid medicine, 
dexamethasone, using in vitro and in vivo assay it was found that 
the drug is capable of attacking the genetic material. The drug 
increased the frequency of CAs and SCEs in human lymphocytes 
and micronuclei and SCEs in mouse bone marrow cells. 
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It has been shown that the administration of even low doses 
of glucocorticoid hormone to rapidly growing rats results in a 
prompt and virtually complete inhibition of DNA synthesis in the 
liver (Henderson et al, 1971, Kimberge etal., 1971). It has been 
found that glucocorticoid hormones are capable of exerting a 
profound suppressing effect in thymidine incorporation by a variety 
of cell lines of liver origin in vitro. They show, moreover, that the 
observed inhibition of precursor incorporation represents a true 
suppression of DNA synthesis, and that this inhibition of thymidine 
incorporation is accompanied by a corresponding inhibition of 
•cell proliferation and of net DNA synthesis. In sharp contrast to 
the effects of glucocorticoids on a number of cells of lymphoid 
origin, the inhibition of DNA synthesis which are observed in these 
hepatoma cells is not attended by a comparable inhibition of RNA 
synthesis (Makman etal., 1966; Harris, 1970), and even prolonged 
exposure to hormone, resulting in sustained suppression of DNA 
synthesis, is reversible and unaccompanied by DNA degradation 
or cell lysis (Harris, 1970). 
The genotoxic effect of Betamethasone on human 
chromosome is evident. The drug caused maximum number of 
aberrations at 25 ng/ml concentration. The higher dose of this 
218 
drug (50 |ag/ml) could exhibit clastogenic effect but at 24 h of 
treatment duration only. The reduction could be attributed to cell 
cycle delay and cell killing effect caused by the drug at highest 
concentration. The continuous presence of the DNA synthesis 
inhibiting drugs in the medium may greatly reduce the mitotic index 
without increasing the frequency of chromosomal aberrations, as 
the severely damaged cells remain in interphase (Au and Hsu 1982). 
The same findings are further corroborated by the reports of 
Navoma (1977) and Rubin (1982), indicating the suppression of 
DNA synthesis, prevention of protein binding of the drugs at its 
higher doses and reduction in mitotic cell population. 
The mechanism by which the glucocorticoid hormones inhibit 
DNA synthesis may differ from one cell type to another. Thus, 
while the glucocorticoid induced suppression of DNA synthesis 
observed in certain lymphoid cells is attended by an overall 
suppression of both RNA (Makman et al. 1966 and Harris, 1970) 
and protein (Makman et al. 1966). Synthesis and is promptly 
followed by cell death (Harris 1970) and tissue involution. The 
inhibition of DNA synthesis noted both in the hepatoma system 
and in intact liver is readily reversible and is unaccompanied by 
cell lysis. All the observations in the hepatoma system have their 
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counterparts in previously observed effects of glucocorticoid 
hormone administration on DNA synthesis and hyperplasia 
associated with normal liver growth in the intact animal (Henderson 
et al., 1973, Loeb et al., 1970), and suggest that the familiar 
inhibitory effects on liver growth in vivo may well be attributable, 
at least in part to a direct effect of these compounds on 
hepatocytes. 
The effect of hydrocortisone on the appearance of aneuploid 
cells in bone marrow cells of mice has been observed by 
Longinova etal. (1970; Bali et al., 1990). The increased frequency 
of aneuploid cells with increasing concentration of the test 
compound has been observed. The phenomenon of aneuploidy 
gets increased at the expense of both hypoploid and hyperploid 
cells. Some disturbances of the hormonal equilibrium is associated 
with aneuploidy during early embryogenesis or gametogenesis. The 
deleterious effect of hydrocortisone on the frequency of 
chromosome aberration was also studied by Illinskikh (1979) and 
Bali e/a/. (1990). 
The frequency of sister chromatid exchange (SCE) also 
increased with higher dose, but with lesser magnitude at the highest 
concentration of betamethasone. The effect was same even in the 
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presence of metabolic activation. Prednisolone did not enhance 
the SCE frequency, either with or without metabolic activation. 
But triamcinolone was found effective with metabolic activation. 
SCE arise from DNA breaks and the reunion of broken exchanged 
fragments at almost homologous loci (Latt et al., 1981). The 
observed rise in the frequency of SCE could be attributed to the 
betamethasone's influence in increasing the number of DNA 
lesions. The present study is in line with Loeb et al. (1973), 
Navoma (1977), and Illinskikh (1979) who observed DNA 
suppression, cell proliferation inhibition, and bone marrow 
deterioration effects of the hydrocortisone. The hydrocortisone 
was found to be non-mutagenic both with and without S^  mix in 
the AmQs/Salmonella test system (Bali et al., 1990). 
In earlier studies on the genotoxicity evaluation, 
hydrocortisone was found to inhibit the proliferation of human 
lymphocytes (Bali et al., 1990; Shadab et al., 1999). It was 
concluded that hydrocortisone is genotoxic and potent steroidal 
drug-capable of directly attacking the genetic material. In the 
present study betamethasone was also found showing similar 
results. 
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Long term therapy can cause cushingoid features with 
accumulation of fat on the trunk and face. Metabolic effects include 
sodium retention, potassium loss, which may produce muscle 
weakness; and decreased glucose tolerance, which may result in 
glycosuria and overt Diabetes mellitus. Loss of skin collagen can 
result in paper thin skin and cutaneous striae. Proximal myopathy, 
osteoporosis, osteonecrosis, and vertebral compression fractures 
can develop. Peptic ulcerations may occur. Pituitary-adrenal 
suppression and retardation or interruption of growth have been 
observed in children. Euphoria is common and some patients may 
develop psychoses. The acute tumour lysis syndrome 
(hyperkalemia, hypermicemia, hyperphosphatemia, hypocalcemia, 
lactic acidosis, and acute renal insufficiency) can occur although 
it is rare in patients treated with glucocorticoids alone (Laurence 
and Bennett, 1992). 
Caution should be exercised in patients receiving long term 
steroid therapy, since they are more susceptible to severe 
infections, and sudden withdrawal of medication or development 
of stress may result in acute adrenocortical insufficiency (Brody 
etal, 1998). 
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In patients exposed to corticosteroidal drugs gastrointestinal 
disturbances (anorexia, nausea, vomiting, and diarrhoea) occur in 
80% of patients and are usually dose limiting. About 40% of 
patients experience central nervous system side effects (Lethargy 
and Somnolence 25%, dizziness or vertigo 15%). About 15% of 
patients develop dermatitis. Less frequent adverse effects are visual 
disturbances (eg. blurred vision, diplopia, lens opacities, 
retinopathy), albuminuria, hemorrhagic cystitis, flushing, 
hyperpyrexia, orthostatic hypotension, and hypertension (Laurence 
etal, 1997). 
Adverse effects virtually do not occur with 1 or 2 doses 
though some occur with a few days' use, eg. spread of infection. 
They follow prolonged administration and are sufficiently frequent 
and dangerous to warrant serious consideration by the physician 
whether the disease which he is attempting to suppress is more 
dangerous to the patient than the cushing's syndrome which he 
might induce (Liddle GW. Clin Pharmacol Ther 1961). The 
undesired effects recounted should never be experienced in 
replacement therapy, but are sometimes unavoidable when the 
steroid is used as pharmacotherapy. Naturally, the nature of 
unwanted effects depends on the choice of steroid. 
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Fludrocortisone in ordinary doses does not cause osteoporosis 
and prednisolone does not normally cause oedema. In general, 
serious unwanted effects are unlikely if the daily dose is below 
the equivalent of hydrocortisone 50 mg or prednisolone 10 mg 
(Rang and Dale 1994). 
Cushing's syndrome symptoms include moon face, 
characteristic deposition of fat on the body, oedema, hypertension, 
striae, bruising, acne, hirsutism, muscle wasting and osteoporosis 
of the spine (with fractures of vertebrae, ribs, femora and feet). 
Avascular necrosis of bone is another serious complication (at 
higher doses); it appears to be due to restriction of blood flow 
through bone capillaries. Pain and restriction of movement may 
occur months in advance of radiographic charge (Munson, 1995). 
Diabetes mellitus may occur, sometimes with suicide, especially 
in those with a history of mental disorder; insomnia is common. 
Patients taking continuous corticosteroids probably have an 
excess incidence of peptic ulcer and haemorrhage of about 1-2% 
(Brody et al., 1998). It is plainly unreasonable to seek to protect 
all such patients by routinely giving prophylactic antiulcer therapy. 
Other adverse effects include posterior subcapsular lens cataract 
(risk if dose exceeds 10 mg) glaucoma (with prolonged use of 
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eyedrops), blood hypercoagulability, menstrual disorders and 
fever. The incidence of infection is increased with high dose 
therapy, and any infection can be more severe when it occurs. 
The incidence of unwanted effects of one kind or another depends 
on drug used, dosage and duration of therapy but can be as high 
as 50% of cases (Hardman and Limbird, 1996). 
Because of the apparent relationship between chromosome 
abnormalities,mutagenesis and carcinogenesis (Sandberg, 1980; 
Zeiger and Tennant, 1986), in vivo and in vitro screening for 
chromosome aberrations is an established tool in the evaluation 
of potential hazards to the genetic material due to environmental 
agent. However, the great limitations of this morphological 
approach is that only gross genetic damage is visible and negative 
findings do not exclude other types of genetic damage such as 
those resulting in point mutations. Although point mutations are 
visible in the case of SCEs, but when the value of SCE in 
insignificant, the point mutations are not considered hazardous, 
although a single base pair change sometimes lead to death of the 
cell. Therefore, there must be a system to detect single gene 
mutations also. The present observation also suggest that for a 
complete and confirmatory evaluation of mutagenic effects, a 
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battery of test systems should be used, since no single test can 
be expected to detect all mutagens and mutations (Ashby et al, 
1996; Van Zeeland and Vrieling, 1999). 
The phenotypic expression of genetic damage, either as 
visible chromosome aberrations or single point mutations, is 
dependent on the developmental time when the damage occurs, 
namely pre-or post-natal life and the type of cell, somatic or 
germinal, in which the damage occurs (German, 1979). If such 
damage occurs in somatic cells of the developing embryo it can 
lead to malformation and abortions in extreme cases. The 
malformations could be result of (i) chromosome breakage with 
consequent extensive cell death; (ii) unbalanced stable 
chromosome abnormalities; (iii) single gene mutations. The 
teratogenic effects of synthetic and steroidal drug might have been 
the result of genetic damage as reported in several studies (Nova 
and Nova, 1973, 1975; Royal College of General Practitioners, 
1976; Janerich and Piper,1978; Bracken et al, 1978; Rohman and 
Louik, 1978;Harlape^a/., 1979; Kasan and Andrews, 1980; Janerich 
etal., 1974, 1980; Joshie/a/., 1983; Ashby ef a/., 1996; Preston, 
1999; Ahmad et.al, 2000a). The reasons could be explained by 
one or more of the above mentioned mechanisms. An exces of 
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chromosomally abnormal spontaneous abortions have been 
reported in mothers who use synthetic steroids when compared 
with normal non users. (Albermane/. al, 1976; Wingfield, 1991). 
Any mutational effect on adult somatic cells could lead to 
cancer and although data are accumulating on the possible 
association between the use of these drugs and different types of 
cancers, yet these are not conclusive and still more study need to 
be done. The theoretical possibility of genetic damage during post 
natal life will apply directly to the health of the drug user (Weiss 
etMl, 1976; Nissen et.al., 1978; Royal College of General 
Practitioners, 1981; Swan and Petitti, 1982; Zeiger and Tennant, 
1986; Ashby and Tennants, 1991; Ashby et. a/.,1996; Van Zeeland 
andVrieling, 1999). 
Any genetic damage occurring in germ cells of a person 
taking these drugs would only be manifested in his or her offspring 
either in the form of single gene mutations or chromosome 
abnormalities leading to teratogenesis or carcinogenesis. Even if 
a recessive mutation or balanced chromosome abnormality is not 
expressed in the first generation, it could possibly manifest several 
generations later, due to fetal germ or somatic cell mutations. 
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It is, therefore, advisable to be careful of the potential 
hazards of these drugs to which we are continuously exposed to 
day in and out in modern life. This demands the lowest possible 
use of effective and acceptable doses of these drugs so as to 
minimise any potential risk. Otherwise they may become capable 
of attaching the genetic material directly in their unmetabolised as 
well as metabolised state. 
Studies conducted in vivo assume greater importance as they 
present real evidence per se of the hazardous effects undergoing 
by the cells. Their long term effect may further exacerbate the 
genotoxic effect in the life span of the organism itself and may 
assume serious damage to life itself 
Therefore, extreme care should be taken of the potential 
hazards of possible genotoxic steroidal drugs, especially if they 
are used for longer periods of time. 
c 
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AFPIMDIX 
Aberrations induced by Medroxyprogesterone Acetate 
Fig. A. Cell with chromatid gap and chromatid break. 
Fig. B. Cell showing diploidy. 
Fig. C. Cell showing sister chromatid excnahges. 
J1^ 
Aberrations induced by Megestrol Acetate 
Fig. D. Cell showing extreme chromosome shortening. 
Fig. £. Cell with chromatid break and chromatid gap. 

Aberrations when treated with Triamcinolone 
Fig. F. Cell showing chromatid break, chromatid gap and termial deletions. 
Fig. G. Cell with breaks in chromatid. 

Some of the anomalies when treated with Betamethasone 
Fig. H. Cell with diploidy. 
Fig. I. Cell showing gaps and breaks in chromatids. 
Fig. J. Cell with terminal deletion, chromatid breaks, gaps and 
chromosome break. 


Aberrations induced by Medroxyprogesterone Acetate in vivo 
Fig. K. Cell showing endoreduplication. 
Fig. L. Cell showing chromatid gaps, deletions and chromatid separation. 
Aberrations when treated with Betamethasone in vivo 
Fig. M. Cell showing chromatid separation and abnormal chromosomes. 
Fig. N. Cell showing chromatid gap. 
Fig. O. Cell with sister chromatid excnahges. 
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Abstract 
The cytogenetic effect of a hormonal steroid, estradiol-17(3, was assessed in peripheral blood human lymphocyte culture. 
Sister chromatid exchanges (SCE) and chromosome aberrations (CA) were scored as genetic end points. Significant 
induction of CA was observed at 25 n.g/inl and 50 yxg/ml concentrations of estradiol-lT^ in the absence of microsomal 
activation. The drug was effective in all treatments in the presence of rat liver S9 microsomal fraction (S9 mix) and 
exhibited increased frequency of chromosomal aberrations. The drug was effective in increasing the SCE frequency which 
was found to be maximum at the dose of 50 M-g/ml concentration (i.e., 4.34+ 1.22) both with and without metabolic 
activation. It was found that estradiol-17p itself and possibly its metabolites are potent mutagens beyond a particular dose in 
human lymphocytes. ©2000 Elsevier Science B.V. All rights reserved. 
Keywords: Estradiol-17^; Chromosomal aberration; Sister chromatid exchange; Lymphocyte 
1. Introduction 
Sex hormonal steroids are used as medicine for 
human for a large variety of conditions, apart from 
their uses as oral contraceptive agents, viz., in the 
treatment of dysmenorrhea, endometriosis, dysfunc-
tional uterine bleeding, climacterics and in the 
prevention of postmenopausal osteoporosis. They 
diffuse through the cell membrane and after conju-
gating with specific receptor proteins in the cyto-
plasm, pass through the nuclear pore to form 
steroid-DNA complexes. This complex alters the 
Corresponding author. Fax: -1-91-571-409081; e-mail: 
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gene expression of many cellular processes including 
enzyme synthesis [1]. Estradiol also binds to isolated 
DNA [2,3] and induces fragmentation [4]. Several 
sex steroids have been studied for their teratogeriic 
[5], carcinogenic [6], mutagenic and clastogenic [7] 
potentialities. Estrogens have been identified as mi-
totic inhibitors. It was suggested that the structural 
specificity is required for mitotic inhibition [8]. Es-
trogens are mitotic poisons, which at high concentra-
tion, cause metaphase arrest, abnormal cell division 
and CA [7]. Estrogens also induce the formation of 
endogenous DNA adducts both in human and ani-
mals and can ultimately lead to cancer development 
[9,10]. Contraceptive steroids induce DNA repair 
synthesis in rat hepatocytes cultures, indicating DNA 
damage [11]. These drugs can also have a tumor 
inducing potential in rat liver in addition to its tumor 
1383-5718/00/$ - see front matter © 2000 Elsevier Science B.V. All rights reserved. 
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promoting activity [12], Estradiol is carcinogenic in 
experimental animals. Administration of estrogens 
leads to an increase in endometrial cancer in women, 
and estradiol can be expected to have a similar effect 
[13]. Esrtradiol-17p is one of the sex hormones, and 
occurs in two forms alpha and beta. Beta estradiol 
has the greatest physiological activity of naturally 
occurring estrogens. The alpha form is relatively 
inactive. Estradiol was found to induce very low 
frequencies of hyperploidies in human synovial cells 
in vitro [14] and various numerical aberrations in pig 
oocytes in vitro [15]. In human embryonic fibroblasts 
and kidney epithelial cells, estradiol was reported to 
induce structural chromosomal aberration [16]. Si-
multaneous addition of estradiol, progesterone and 
human chorionic gonadotrophin (HCG) increased the 
SCE frequency in human lymphocyte culture, but 
their separate administration did not induce SCEs 
[17]. The hormone is negative in the Ames test [6] 
and does not induce point mutations in mammalian 
cells in vitro [18]. In the present study, we investi-
gated the genotoxic effect of estradiol-17p on human 
chromosomes in lymphocytes cultures in vitro. 
2. Materials and methods 
2.1. Chromosomal aberration analysis 
Metaphase chromosome analysis for the detection 
of CAs was performed according to conventional 
technique [19]. Lymphocyte cultures were set up by 
adding 0.5 ml of heparinized whole blood, from two 
adult and healthy male donors (who were not occu-
pationally exposed to mutagens) to 4.5 ml of TC-199 
medium (Flow Laboratories) supplemented with 15% 
fetal calf serum (Gibco), antibiotics (Penicillin and 
Streptomycin 100 lU/ml each; Hoechst) and 
L-glutamine (1 mM; Gibco). Lymphocytes were 
stimulated to divide by adding 0.1 ml of phyto-
haemagglutinin-M (PHA-M; Microlab). The cultures 
were incubated at 37°C and 5% COj for 72 h in the 
dark. Estrtadiol-17p (Wyeth Lab, India), at a final 
concentration of 10, 25 and 50 jAg/ml was added for 
24, 48 and 72 h of duration by adding the steroid 
after 0, 24 and 48 h in reverse order after the 
initiation of cultures. Dimethylsulphoxide (DMSO 5 
jjLg/ml; SRL Bombay, India) was added to the 
simultaneously kept cultures for 72 h of incubation 
as negative control. And for positive control, cyclo-
phosphamide (CP 1 X 10"'' M) was added for 24, 48 
and 72 h of incubation. 
In the metabolic activation experiments, 6 to 30 h 
old cultures were given treatment with 10, 25 and 50 
|jLg/ml concentrations of the drug in the presence of 
rat liver S9 microsomal fraction. Liver S9 fraction 
was prepared from healthy albino rats induced with 
phenobarbital and it was stored in liquid nitrogen 
until use. Sg mix was freshly prepared for use. The 
cells were collected after centrifugation and the pel-
lets were washed twice in the pre-warmed medium 
to remove the chemical and the S9 mix. The parallel 
cultures receiving the same doses of the drug for 
similar treatment duration but without S, mix were 
also simultaneously set for comparison. Colchicine 
(0.20 (xg/ml; Microlab) was added to the cultures 
prior to harvesting. The cells were collected by 
centrifugation (10 min; 1200 rpm), hypotonic treat-
ment (0.075 M KCl) was given for 10-12 min at 
37°C and the cells recollected by centrifugation were 
fixed in methanol: acetic acid (3:1). Preparation of 
slides, staining and scanning was done under code. A 
total of 300 well-spread metaphases were analyzed 
per treatment per duration for all types of chromatid 
and chromosome type of aberrations. In case of 
cultures with metabolic activation, only 200 well-
spread metaphases were analyzed. 
2.2. Sister chromatid exchange analysis 
Analysis of SCEs was carried out following the 
fluorescent plus Giemsa techniques [20,21]. The cells 
in the cultures were exposed to 5-bromo-2-de-
oxyuridine (BrdU 2 |JLg/ml; Sigma) after 24 h of the 
initiation of cultures. The test compounds were added 
together with the BrdU. To minimize photolysis of 
BrdU another 48 h of cultures were maintained in 
the dark. 
For SCE analysis in the presence of metabolic 
activation system, the drug along with S9 mix was 
added into the culture after 48 h of its initiation and 
re-incubated at 37°C. After 90 min of this pulse 
treatment the cells were spun down and the super-
natant discarded. The cells were washed twice to 
remove the traces of the steroid and the liver metabo-
lites. Finally, the cells pellets were re-suspended in 
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fresh medium supplemented with fetal calf serum, 
PHA-M and BrdU, and put to culture for another 24 
h in the dark at 37°C. For comparison, parallel 
cultures without S^ mix were also set simultane-
ously. Hoechst 33258 stain (0.5 |i.g/ml; Sigma) was 
used along with 10% Giemsa stain for differential 
staining of the sister chromatids. The slides were 
coded prior to scoring, and 50 well-spread metaphase 
cells were scanned per concentration and the number 
of exchanges scored. 
3. Results 
3.1. Chromosomal aberrations 
The chromosomal aberration frequencies in hu-
man lymphocytes induced by 10 to 50 fJLg/ml estra-
diol-17p are presented in Table 1. At 10 [xg/ml of 
dose, the drug was not effective at any exposure 
time. At 25 ng/ml and 50 jxg/ml of concentration, 
the drug affects both the aberrant metaphases as well 
as chromosomal aberration frequency. At 25 |jLg/ml, 
the values for 24, 48 and 72 h of incubations were 
18.20%, 18.80% and 48.60%, respectively, while at 
50 |xg/ml the values were 19.33%, 21.00% and 
54.34% at 24, 48 and 72 h of incubations, respec-
tively, which were highly significant at p < 0.05 
compared to the normal control value. 
The drug was effective in all treatments and an 
increased frequency of aberrant metaphases as well 
as chromosomal aberrations were observed when 
treated with Sy mix (Table 2). These values were 
9.60%, 20.00% and 18.00% at 10, 25 and 50 jj-g/ml 
of concentrations, respectively. These data were 
highly significant at p < 0.05 when compared to 
normal control (3.5%). The percentage of chromoso-
mal aberration was 61.00% for CP, which was highly 
significant. 
3.2. Sister chromatid exchanges 
Data on the mean frequency of SCEs for cells 
after the treatment of estradiol-17P are presented in 
Table 3. The enhanced SCE rate was observed and at 
Table 1 
Chromosomal aberrations in human lymphocytes after estradiol-17p treatment 
Treatment 
(|jLg/ml) 
Estradiol-up 
10 
25 
50 
Control 
Normal 
DMSO 
(5 ^Lg/ml) 
( —ve control) 
CP 
(1 X 10" ' M) 
( + ve control 
Duration 
(h) 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
24 
48 
72 
Metaphase 
scanned 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
Percent aberration 
metaphase 
Including 
gap 
7.33 
5.00 
8.30 
11.34* 
26.67* 
39.70* 
16.00* 
23.00* 
39.67* 
2.30 
3.30 
23.00* 
39.00* 
40.00* 
Excluding 
gap 
3.70 
2.70 
3.70 
11.34* 
20.00* 
39.00* 
15.00* 
20.00* 
38.33* 
1.60 
1.00 
20.00* 
35.00* 
34.00* 
Types of aberration (%) 
Chromatid 
3.70 
2.70 
3.00 
12.50 
11.50 
21.30 
13.33 
12.67 
23.67 
1.30 
2.00 
24.00 
44.00 
45.00 
Chromosome 
0.00 
0.00 
1.50 
5.70 
7.30 
27.30 
6.00 
8.33 
30.67 
1.00 
1.00 
6.00 
24.00 
21.00 
Total 
3.70 
2.70 
4.50 
18.20* 
18.80* 
48.60* 
19.33* 
21.00* 
54.34* 
2.30 
3.00 
30.00* 
68.00* 
66.00* 
Aberration/ 
cell + SE 
0.04 ± 0.01 
0.03 ± 0.00 
0.05 + 0.01 
0.18 ±0.02 
0.19 ±0.02 
0.49 + 0.04 
0.19 ±0.03 
0.21 ±0.03 
0.54 ± 0.05 
0.02 ± 0.01 
0.03 ± 0.01 
0.30 ± 0.03 
0.68 ± 0.09 
0.66 ± 0.09 
CP: Cyclophosphamide; DMSO: dimethyl sulphoxide; SE: standard error. 
'Significant at p < 0.05. 
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Table 2 
Chromosomal aberrations in 1 
Treatment 
((jLg/ml) 
Estradiol-17p 
10 
25 
50 
Control 
Normal 
DMSO 
(5 M-g/ml) 
( - ve control) 
CP 
(1 X I 0 - ' M) 
(+ ve control) 
Metabolic 
activation 
- S , 
+ 8, 
-s , 
+ S, 
-s , 
+s. 
- s , 
+ S,, 
-s , 
+s, 
- S 9 
+s, 
human lymphocyti 
Metaphase 
scanned 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
es after estradiol-17^ treatment with and without metabolic 
Percent aberration 
metaphase 
Including 
gap 
8.70* 
10.50* 
11.30* 
16.00* 
10.00* 
14.00* 
2.30 
4.50 
3.30 
4.50 
6.30* 
40.50* 
Excluding 
gap 
7.90* 
9.00* 
11.30* 
15.00* 
9.30* 
13.00* 
1.70 
3.00 
1.70 
3.50 
4.67* 
39.50* 
Types of aberration (%) 
Chromatid 
6.60 
8.60 
12.50 
15.00 
8.30 
13.50 
1.30 
3.50 
2.00 
3.50 
10.00 
37.50 
Chromosome 
0.60 
1.00 
5.60 
5.00 
4.00 
4.50 
0.30 
0.00 
0.00 
0.00 
8.67 
23.50 
activation 
Total 
7.20* 
9.60* 
18.10* 
20.00* 
12.30* 
18.00* 
1.60 
3.50 
2.00 
3.50 
18.67* 
61.00* 
Aberration/ 
cell ± SE 
0.07 + 0.02 
0.09 + 0.02 
0.18 ±0.02 
0.20 ± 0.01 
0.12 ±0.02 
0.18 ±0.02 
0.02 ± 0.01 
0.04 ± 0.01 
0.02 ± 0.00 
0.04 ± 0.01 
0.19 ±0.03 
0.61 ± 0.07 
CP: Cyclophosphamide; DMSO: dimethyl sulphoxide; SE: standard error. 
* Significant at ;»<0.05. 
50 (Ag/ml of concentration the maximum frequency 
of SCE per cell was found to be 4.34 + 1.22. This 
value was highly significant compared to the mean 
SCE value of normal control, i.e., 1.74 ± 0.14. 
In the presence of S, mix, both doses (25 and 50 
fjLg/ml) enhanced the SCE frequency significantly, 
i.e., 4.58 + 0.41 and 6.08 ± 1.31, respectively (Table 
4). Both these values were significantly higher than 
Table 3 
Sister chromatid exchange (SCE) in human lymphocytes after estradiol-17(3 exposure in vitro 
Treatment 
((jig/ml) 
Estradiol-17P 
10 
25 
50 
Controls 
Normal 
DMSO (5 )xg/ml) 
(— ve control) 
CP(1 X lO^'M) 
(-1- ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No. of 
metaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
76 
171 
217 
87 
96 
340 
Range 
0-6 
1-9 
2-11 
0-5 
0-6 
2-11 
SCEs/ 
cell ± SE 
1.52 ±0.14 
3.42 ± 0.52* 
4.34 ± 1.22* 
1.74 ±0.14 
1.92 ±0.12 
6.80 ± 1.29* 
CP: Cyclophosphamide; DMSO: dimethylsulphoxide; SE: standard error. 
'Significant at p < 0.05. 
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Table 4 
Sister chromatid exchange (SCE) in human lymphocytes after estradiol-17p with metabolic activation 
Treatment 
(jig/ml) 
Estradiol-17fi 
10 
25 
50 
Controls 
Normal 
DMSO (5 ixg/ml) 
( - ve control) 
c p ( i X 10" • 'M) 
( + ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No. of 
metaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
97 
229 
304 
78 
89 
380 
Range 
0-5 
1-11 
2-12 
0-5 
0-6 
4-12 
SCEs/ 
cell ± SE 
1.94 ±0.50 
4.58 ±0.41* 
6.08 ±1.31* 
1.56 ±0.12 
1.78 ±0.11 
7.60 ±1.34* 
CP: Cyclophosphamide; DMSO: dimethylsulphoxide; SE: standard error. 
* Significant at p < 0.05. 
the mean SCE value of 1.56 ±0.12 observed in 
normal controls ip < 0.05). 
4. Discussion 
The results of the present investigation demon-
strate that the use of estradiol-173 is associated with 
clastogenicity. A significant increase in the incidence 
of chromosomal abnormalities per cell as well as an 
increase in the number of abnormal cells were ob-
served when compared with normal control. At 10 
(i,g/ml of concentration, the results were insignifi-
cant for all treatment duration (24, 48 and 72 h). 
However, at 25 p-g/ml concentration a significant 
increase in aberration frequency was observed. But 
the maximal effect was observed at the highest con-
centration, an observation in line with the majority of 
clastogens. Of the various chromosomal aberrations 
induced by estradiol-17p, chromatid and chromo-
some fragments and breaks were more frequent than 
other types of aberrations, such as ring and bridge 
formation, acentric fragments, etc. 
The increased clastogenicity by estradiol-17p at 
the longest treatment duration as compared to the 
shorter treatment duration could be attributable to the 
inherent ability of the human lymphocytes to metab-
olize certain compounds per se [22]. The common 
effects of steroid hormone on chromosomes are 
stickiness in diakinesis and metaphase, and bridges 
and sometimes lagging chromosomes in the anaphase 
[23]. Similar observations were made in Anovlar (a 
steroid) treated plant chromosomes [24]. Chromatid 
breaks were seen more frequently than chromosome 
breaks in the metaphase plates analyzed. This indi-
cates that the drug introduces replication errors or 
breaks replicated chromatids. Estradiol-173 induced 
reversible mitotic delay in HeLa cells, which were 
localized at the beginning of mitosis. The duration of 
mitotic lag was dose dependent [25]. The present 
data on the time-response analysis revealed a signif-
icant increase in chromosomal aberration at 72 h of 
treatment [26]. 
In the presence of S, microsomal activation sys-
tem, the clastogenic effects of estradiol-17p were 
more prominent. In the absence of S9 mix, the 
chromosomal aberrations observed were also signifi-
cant but slightly less. The time-response analysis in 
the presence of S, revealed significant increase at 48 
h of incubation and decreased later on [27]. The 
maximum frequency of chromosomal aberration was 
found at 48 h long treatment on mouse bone marrow 
cells, while it decreased later on and gave no signifi-
cant result. This suggests that the drug and/or its 
metabolites were active during this (48th h) period. 
The decline in the frequency of aberrations observed 
at the later time intervals may be due to some or all 
of the following reasons: (i) repairs of damaged 
genetic material, (ii) elimination of the drug and its 
metabolites, (iii) elimination of cells/chromosomes 
with damaged genetic material, (iv) or due to cell 
114 Md.E. Ahmad et al./Mutation Research 466 (2000) 109-115 
cycle delay and cell killing effect, and (v) inactiva-
tion of drug or its metabolites. The results obtained 
from the SCE analyses indicated the drug has strong 
SCE inducing potential. The frequency of SCE fur-
ther increases if the drug is treated in the presence of 
Sy mix. There exists a relationship between in-
creased SCE rates and altered mutation frequency 
[28]. Therefore, it can be concluded that estradiol-17p 
is capable of attacking the genetic material directly 
in its unmetabolized as well as metabolized state. 
Because of the apparent relationship among chro-
mosome abnormalities, mutagenesis and carcino-
genesis [29], in vivo and in vitro screening for 
chromosome aberrations is an established tool in the 
evaluation of the potential hazards to the genetic 
material due to environmental agents. The theoretical 
possibility of genetic damage during post-natal life 
will apply directly to the health of the drug user. Any 
mutational effect on adult somatic cells could lead to 
cancer [30]. People should, therefore, be careful and 
aware of the potential hazards of such drugs, espe-
cially if they are continuously exposed to for such 
long periods. 
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ABSTRACT : Dexamethasone, a steroidal hormone has potential application in pharmacology. This drug possesses anti-
inflammatory, immunosuppressive, antibacterial, antimicrobial and antiviral activity. The cytogenetic effects of this drug 
was studied on human chromosomes in lymphocyte cultures in vitro and in vivo. There was no increase in the 
chromosomal aberration and sister chromatid exchange (SCE) frequency with dexamethasone at any concentration which 
was equivalent to plasma level and slightly higher than the plasma level in vitro. However, a significant increase in the 
frequency of chromosome aberration as well as SCE was seen in patients given tlierapeutic doses of dexamethasone 
when compared to the control of two types—(a) Arthritis patients before starting the drug therapy, and (b) the normal 
healthy individuals from the general population. The most frequently observed abberrations were chromatid gaps and 
breaks. Therefore, our study indicates that dexamethasone is clastogenic in vivo but not in vitro. 
Key words : Dexamethasone - Chromosome aberration - Sister chromatid exchanges - Human lymphocytes - Arthritis 
patients. 
Introduction 
Hormonal steroids are being widely used 
therapeutically. They form steroid-DNA complex 
after entering the cells, alter the gene expression 
and ultimately alter the expression of many 
cellular processes including enzyme synthesis. 
Quite a large number of hormonal steroids have 
been studied for their teratogenic (Joshi et al., 
1983), carcinogenic (Lang and Redman, 1979) 
mutagenic and clastogenic (Wheeler et al., 1986) 
potentiaUties. However, most of the work has been 
concentrated on the sex hormones, while very 
li t t le at tention has been paid to the other 
members being extensively used as steroidal drug. 
Dexamethasone is one of the corticosteroidal drugs 
which is primari ly used for curing severe 
inflammations, allergic reactions, shock, neoplasia 
and adrenal insufficiencies. 
Reports on the mutagenic effects of 
corticosteroids are controversial. It could not 
exhibit mutagenicity in the Ames/Salmonella test 
system (Bah et al., 1990). 
It has been reported that the administration 
of low dose of dexamethasone to rapidly dividing 
cells results in an inhibition on DNA synthesis in 
the liver cells in vitro (Loeb et al., 1973). Tlie 
clastogenic effect of corticosteroid hormones on 
human Ismaphocytes is evident (Azfer and Afzal, 
1996; Ilinskikh, 1979). The frequencies of sister 
chromatid exchanges (SCEs) and micronuclei also 
increase with dose, and thereby indicates the dose 
related clEistogeniciiy of the drug in the in vivo 
system (Bah etal., 1990; Singh et al., 1994). A 
negative result was obtained by Dhillon (1990) 
that corticosteroids could not induce clastogenicity 
in human chromosomes. In the present study we 
investigated the effect of dexamethasone on 
human chromosomes in lymphocjrte culttires in 
vitro and in vivo in the Indian population. 
Materials and Methods 
Chromosomal aberration analysis : 
Peripheral blood samples were obtained from 
healthy adults who were not exposed to mutagen. 
0.5 ml of blood (lymphocyte) was cultured into 4.5 
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ml of TC-199 medium supplemented with 20% 
foetal calf serum, phytohaemagglutinin and 
antibiotics. Dexamethasone (Wyeth Lab. India), at 
a final concentration of 20, 40 and 60 jig/ml, was 
added at the 24, 48 and 72 h old cultures. Cultures 
without the drug served as controls. 
In vivo studies were conducted in Arthritis 
patients from Jawaharlal Nehru Medical College, 
A.M.U., Aligarh. Patients who were on therapeutic 
doses of dexamethasone for over 4 weeks were 
examined. Two types of controls were taken : (i) 
Arthritis patients before taking any treatment and 
(ii) normal healthy individuals from the general 
population. 
Whole blood was cultured by the method of 
Moorehead et al., (1960) and were prepared by 
flame drying method and stained with giemsa 
(10%) and screened for the presence of 
chromosomal aberrations. 
Sister chromat id exchange (SCE) 
analysis : SCE analysis was performed using the 
fluorescent plus giemsa techniques of Perry and 
Wolff (1974). Bromodeoxyuridine (5' BrdU) was 
added to a concentration of 3 |Ag/ml. 
Simultaneously 20, 40 and 60 |ig/ml doses of 
examethasone were added in respective cultures 
at the 24 h.. The cultures were prepared by air 
drying. One day old slides were stained with 5.0 
^g/ml Hoechst 33258 in the dark for 30 min. They 
were further washed with distilled water, 
mounted in 2x SSC with cover slip, and exposed 
to sunlight for 2 h. They were again washed and 
stained in 5% giemsa. SCE were scored blindly in 
50 M2 cells per concentration. 
Stat ist ical analys is : The differences 
between the data of control and the experimental 
groups were statistically evaluated with Student's 
't' test. 
Results and Discussion 
The concentrations tested were not cytotoxic 
to the lymphocytes. Very high and cytotoxic 
concentrations were not tested. No significant 
increase in the chromosomal aberration frequency 
could be observed in any of the treated cultures 
as compared to the normal cultures (Table 1). 
Time-dose relationship could not prove the 
genotoxicity of dexamethasone. The aberrations 
commonly observed were breaks, gaps, exchange 
and fragments at all concentration and duration 
of treatment. ! 
Results obtained in the in vivo study of the 
effect of dexamethasone are summarised in Table 
2. The difference between the values of general 
control and pat ient control in regard to 
chromosomal aberrat ions (3.00 + 0,60 and 
3,38 ± 0,62) was not significant. This indicates 
that Arthritis disorder per se does not exert any 
influence on the chromosomal aberrat ion 
frequency. The frequency of chromosomal 
aberrations was significantly increased in patients 
under dexamethasone therapy as compared to the 
two types of controls (P < 0.05). The frequency of 
SCE analysis in human lymphocyte after 
dexamethasone exposure in vitro is presented in 
Table 3. The mean SCE frequency of the drug at 
20, 40 and 60 ug/ml of doses were not significant 
as compared to the normal controls. 
The results of in vivo SCE frequencies in 
human lymphocjrtes is described in Table 4. The 
difference between the mean SCE of the general 
control and patient control was statistically not 
significant. The mean SCE frequency of the 
patient exposed to dexamethasone on the other 
hand was found to be significantly higher than the 
mean SCE value observed in both the controls. 
The results of the present investigation 
showed that dexamethasone did not induce 
chromosomal aberration in vitro but significantly 
increased the aberration frequency in vivo. The 
differences in the in vivo and in vitro studies can 
be explained on the basis of the fact that some 
chemicals and drugs are not mutagenic and 
clastogenic by themselves but require metabolic 
activation (Wright, 1980). It is probable that the 
products of dexamethasone metabolism could be 
clastogenic (Iskandar and Vijayalaxmi, 1981), The 
possibility that the increase in the aberrations in 
the cells of patients on dexamethasone therapy 
could be due to their Arthritis disorder is ruled 
out by the fact that there was no significant 
difference in the chromosomal aberration 
frequency between-the unt rea ted Arthri t is 
patients and the normal healthy individuals from 
the general population. A predominance of 
chromatid gaps and breaks was observed 
suggesting, that the drug acts mostly in the late 
S or G2 phase of cell-cycle. The chromosomal 
aberration observed mainly in groups of A, B and 
C chromosomes are probably due to their larger 
size and more DNA contents. Similar observations 
were also made by Madhuri et al. (1981) in the 
case of combined chemotherapy with isoniazid and 
para-aminosalicylic acid in vivo, while Manjula et 
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Figs 1-4. 1. Analysis of human Ijrmphocyte chromosomes treated with dexamethasone in vitro. 2. Chromosomal 
aberration analysis of patients exposed to dexamethasone. 3. Sister chromatid exchange in human lymphocyte 
after dexamethasone exposure in vitro. 4. Sister chromatid exchange in human lymphocyte of the patients exposed 
to dexamethasone. (CD-Control dexamethasone; GC-General control; PC-Patient control; PED-Patient exposed to 
dexamethasone). 
al., (1982) studied the effect of cephaloridine in 
vitro. 
It has been reported that glucocorticoids 
induce clastogenicity in huni£in lymphocytes (Bali 
et al., 1990). The higher doses of the drug exhibit 
clfistogenicily but with a lesser magnitude. The 
reduction could be attributed to their toxic effect 
at the highest concentration and the cells with 
increased aberrations could have been eliminated 
as a result of apoptosis (Thompson, 1994) and got 
replaced wi th normal cel ls perhaps due to 
compensatory division in the remaining healthy 
cells. Our findings are further corroborated by the 
reports of Loeb et al., (1973) and Rubin (1982) 
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Table 1 : Analysis of human lymphocyte chromosomes treated with dexamethasone in vitro. 
Treatment 
(ng/ml) 
No. of 
metaphases 
No. of breaks No. of gaps 
Chrohnatid Isochromatid Chromatid Isochromatid 
Others %Total ± SE 
Control 
20 ng 
40 ng 
60 ng 
24h 
48h 
72h 
24h 
48h 
72h 
24h 
48h 
72h 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
3 
3 
3 
2 
3 
3 
2 
4 
3 
3 
3 
2 
3 
3 
3 
4 
4 
2 
4 
3 
-
2 
1 
2 
3 
2 
1 
2 
3 
4 
3.00 ± 0.93 
3.67 ±1.09 
4.00±1.13 
4.67 ±1.22 
4.33 ±1.16 
4.00±1.13 
4.00±1.13 
4.67 ±1.22 
5.00 ±1.26 
5.33 ±1.30 
SE=Standard error. 
Table 2 : Chromosomal aben-ation analysis of patients exposed to dexamethasone. 
No. of No. of breaks No. of gaps 
metaphases chromatid Isochromatid Chromatid Isochromatid 
Others %Total ± SE 
General control 800 
Patient control 850 
Patient exposed 1000 
to dexamethasone 
15 
12 
60 
5 
5 
10 
3.00 ± 0.60 
3 (Ex2, F2) 3.38 ± 0.62 
3 (Ex1,F4) 10.63 ±0.97* 
SE=Standard error; Ex=Exchange; F=Fragment; "Significant at P<0.05. 
Table 3 : Sister chromatid exchange in human lymphocyte after dexamethasone exposure in vitro. 
Treatment Duration (h) No. of metaphases Total SCE Range SCE/cell ± SE 
Control 
Dexamethasone 
20 ng/ml 
40 Jig/ml 
60 ng/ml 
48 
48 
48 
48 
50 
50 
50 
50 
114 
135 
135 
120 
0-4 
0-7 
0-7 
0-4 
2.28 ±0.14 
2.70 ±0.30 
2.70 ±0.30 
2.40 ±0.20 
S*E=Standard error; SCE=sister chromatid exchange. 
Table 4 : Sister chromatid exchange in human lymphocytes of the patients exposed to dexamethasone. 
General control 
Patient Control 
Patient exposed to 
dexamethasone 
Duration (h) 
48 
48 
48 
No. of 
metaphases 
50 
50 
50 
Total SCE 
125 
139 
239 
Range 
0-5 
1-8 
2-12 
SCE/cell ±SE 
2.50 ±0.16 
2.78 ±0.40 
4.68 ± 0.85* 
SE=Standard error; "Significant at P<0.05, SCE=sister chromatid exchange. 
indicating that the continuous presence of the 
steroidal drug inhibits DNA synthesis, prevention 
of protein binding of the drug causes reduction in 
mitotic cell population and produce induction of 
genetic damage following the treatment of the 
glucocorticoid drugs in both animals and humans. 
The non-mutagenicity of dexamethasone in the in 
vitro system has been reported by Singh et al., 
(1994). 
The increased frequency of chromosomal 
aberrations in vivo in patients continuously 
exposed to dexamethasone may be attributed to 
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the inherent ability of the human lymphocytes to 
metabolize certain compounds. Moreover, as 
dexamethasone has a longer biologiced half-life 
(36-54 h) tium other corticosteroids, patients using 
dexametlitttone had continuous presence of the 
drug whidi affected DNA and spindle forming 
miorartuboles (Banduhn and Obe, 1985). In the 
case of in vivo study it is clear that in arthritis 
patients adverse effect of dexamethasone in the 
lymphocytes did not give sufBcient time for the 
possible repair of induced lesions in the DNA. 
The frequency of SCE were enhanced in the 
patient who were under the regime of therapy. 
SCE eirise from the DNA breaks and the reunion 
of broken and exchanged fragments at the 
homologous loci (Latt et al., 1981). The observed 
rise in the frequency of SCE could be attributed 
to the dexamethasone's influence on increasing 
the number of DNA lesions. The present study is 
in line with Naumova (1977) and Ihnskikh (1979) 
who observed DNA suppression and bone marrow 
deterioration effects due to the glucocorticoids. 
From the present findings it appears tha t 
dexamethasone is a genotoxic drug. The 
theoretical possibiUty of genetic damage during 
post-natal life will apply directly to the health of 
the drug user. Any mutational effect on adult 
somatic cells could lead to cancer (Weiss, 1976). 
One should, therefore, be mindfril of the potential 
hazards of such drugs, especially if they are 
continuotisly used for such longer periods of time. 
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EFFECT OF HYDROCORTISONE ON H U M A N LYMPHOCYTE 
C H R O M O S O M E S IN VITRO 
G. G. H. A. Shadab, Md. Equebal Ahmed and Mohaminad Afzai* 
Section of Genetics, Deptt. of Zoology. Aligarh l\/luslim University 
Aligarfi-202 002, U.P. India 
Abstract 
Hydrocortisone is a potent steroidal 
drug used therapeutically for a number of 
reasons. Hormonal steroids have been 
reported to cause damage to human chro-
mosomes, l o test genotoxicity. human 
lymphocytes were cultured in TC-199 
medium suppli irented with 20% fetal calt 
serum, phytohaemagglutinin and antibio-
tics. Hydrocortisone (Wyeth Lab India) 
at a final concentration of 10,25 and 50 
/^g/ml, was added at the 24.48 £r 72 hrs old 
culture. Moorehead et al. ( i960) & flame 
drying method were used for in vitro 
cu l tures ' stainmg was done wi th Giemsa 
<lU7o). Chromosome aberration analysis, 
Sisterchromatid exchange (SCE) analysis 
and Statistical analysis was done. Present 
study showed that hydrocortisone affects 
the lymphocytes in vitro and induce chro-
mosomal aberrations wi th increased fre-
quency in the presence of metabolic activa-
t ion, maximum aberration was recorded at 
25/Lig/ml concentration. SCEalso increased 
wi th higher dose but was less mutagenic 
at the highest concentration. Metabolic 
activation did not alter result in this case. 
It is concluded that this drug could inhibit 
the proliferation of human lymphocytes. 
I n t r o d u c t i o n 
Hormones are informational molecules 
secreted by endocrine glands in response 
to changes in the environment inside or 
out-side the body. Hormones may stimulate 
or inhibit specific biological processes in 
the target organs to modify their activities. 
They play vital role in metabolic regulation, 
growth and control of several body func-
tions. Natural Steroidal hormones ( e g . 
gonadal and adrenocortical hormones ) or 
their synthetic derivatives perform their 
functions by forming steroid-DNA com-
plexes that influence the gene expression 
( Rubin3^ Makin2«). Several naturally 
occuring as well as synthetic steroids have 
since long been widely used therapeutically 
(Azfer 96). Several steroids have been 
reported to possess anti inflammatory 
(Boltralik*). anesthetic (Evelyne efa/. '«), 
anabolic (Fennessey etal.^^), angiostatic 
(Larrian**), antiangiogenic (Judah etal^^), 
cardioactive (Karel & Thomas'*) and anti-
diabetic (Ryoji etal^), activities 
Address for correspondence : *Dr, Mohammad Afzal. Reader. Section of Genetics, Deptt. 
of Zoology. AM.U Afigarh-202 002, U.P. India. 
tightly capped culture vials were gently 
mixed and incubated at 37°C indark for 
72 hours. Colchicine (0,20ug/ml Microlab) 
was added 2 | hours prior to harvesting to 
arrest the calls at metaphase stage. 
(iv) Selection of doses— 
Only those doses, which do not reduce 
the Ml but yield sufficient number of 
scorable metaphases, were chosen for the 
experiment. On this basis the lower and 
the medium doses were selected and the 
highest dose selected was normally the 
maximum tolerated dose (MTD) beyond 
which the Ml showed a steep decline. 
Following these norms the different doses 
selected for hydrocosticse were 10. 25 and 
50|ug;ml 
(v) Studies with and without 59-mix.— 
Without &9mix the cultures were 
exposed to three different concentrations 
for 24, 48 and 72 hours. Positive ( CP, 
1 x 1 0 - ' m ) and negative (DMSO, 5 ul/ml) 
control cultures were also simultaneously 
set for all treatment durations For studying 
result with metabolic activation, 30 hours 
old cultures were given 5 hours treatment 
with different concentration of hydrocosti-
sone in the presence of 59-mix. The 
parallel culture without 59 mix were done 
for comparison simultaneously. The DMSO 
(5 ul/ml; SRL, Bombay) were used as 
negative and positive controls respectively. 
(vi) Harvesting of the cultures-
After 72 hours the cultures were centri-
fuged ( lOmin, 1200 rmp) & the buttons 
of cells were saved by discarding the 
supernatant Hypotonic treatment (0.075 
Mkci) was carried out for 10-12 minutes 
at 37°C and the cells were recollected in 
5 ml freshly prepared chilled fixative before 
preparing the slides. 
(vii) Slide preparation and staining— 
After final washing in the fixative, the 
cells were resuspended in 0.2 ml of fresh 
fixative, Two to three drops of this cells 
suspension were dropped on clean, grease 
free, prechilled wet microscope slides which 
were then air dried. One day old slides 
were stained in carbol fuschin (Sigma) 
for 15 minutes and rinsed in 0.95% alcohol 
and finally in absolute alcohol for proper 
differentiation. After air drying, these 
slides were dipped in xylene for 5 minutes 
before mounting in depex (BDH). 
(viii) Analysis of the Ceils— 
To avoid mistakes in scoring of the 
chromosomal anomalies, all slides were 
coded prior to scoring. A total of 300 well 
spread metaphases were analysed for each 
concentration of the steroid testing and for 
each time duration to snalyse varicus 
chromosome and chromstid-type aberra 
tlons. Evans" method of analysis was 
followed. 
b) Analysis of Sister Chromatid Exchanges 
( S C E ) -
(i) SCE detection mechanism-
Sister chromatid exchange is a sensitive 
rapid and objective method of observing 
reciprocal exchanges between sister chro-
matids. In this 5-bromo-2-deoxyuridine 
(BrdU) incorporate with DNA in place of 
thymidine (Azfer and AfzaP). 
After two rounds of eel) division the 
chromatids are labelled with BrdU and 
consequently these differentiate with 
Hoechst stain. Due to BrdU incorporation 
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Students two tailed t' test was used for 
calculating the statistical significance in 
SCE and chromosomal aberrations by com-
paring the effects induced by different 
doses of steroids with the respective control. 
The following formula was used for this 
purpose-
t = 
Xi (control) — X^ (treated) 
(SE of control)^ + (SE of treated)^" 
Results 
a) Chromosomal aberrations—Table-! 
Summarises the data on the influence of 
chromosomal aberrations. At lO/ixg/mlof 
dose significant increase in the percentage 
of chromosomal aberrations was found 
when the drug was continued for 72 hours 
of incubation (7.3%). This value is higher 
than the normal control value (2.3%). At 
24 and 48 hours of incubation, this dose 
did not influence the chromosomal aberra-
tions (3.7% in 2.7%). 
At 25 /^g/ml of concentration the drug 
influenced the chromosomal aberration in 
all exposure times. The values were 18.0%, 
18 6% and 48.7% at 24 48 72 hrs. of 
incubation. Increased frequency at this 
dose showed the significant result compared 
to the normal control at P < 0.05. How-
ever at 50 jLig/ml of concentration some 
interesting observations were made. At 24 
hrs of incubation, the drug influenced the 
rate of chromosomal aberration significantly 
(33.0%) while at 24 and 48 hrs. of incuba-
tion the drug did not give any significant 
increase in the chromosomal abarration, 
4 5% and 4 3% respectively. The positive 
control (CP), being a potent mutagen, 
influences the rate of aberration at all 
exposure times. 
The effect of hydrocortisone on human 
lymphocytes in the presence of S9 mix has 
been summarised in Table-2. The mean 
percentage value at 10 /.ig/ml was 9 0 in the 
presence of S9 mix which was significantly 
higher than the mean percent of chrcmo-
somal aberration value of 2.3%, obsetved 
in normal control (P < 0.05). At 25 /ip/ml 
of concentration, the drug enhanced the 
rate of aberrations (20 0%), which gave a 
statistically significant value at P < 0 05 
At 50 nQlml of concentration no significert 
value were observed (4.0% 8 3 5%,). The 
decreased value may be attributed to the 
toxic effect at higher concentrations. 
b) Sister chromatid Exchange (SCE) — 
Table-3 Shows the effect of hydrocor-
tisone on the frequency of i:CE in human 
lymphocytes. The mean SCE frequency 
at 10 f^g/ml did not enhance it significantly 
( 2 . 4 6 ± 0 1 9 ) when this is compared with 
normal control value (2 .32±1 7). The 
concentration with 25 /^g/ml had a mean 
SCE frequency of 3 66±0 .28 which was 
significantly higher than the mean SCE 
value observed in normal control (P<0C5} . 
No significant value was observed at higher 
concentration i.e. 50 /^g/ml The meen 
SCE value was2.5±0.18, not found signi-
ficant at P < 0 05, The data of the 
mean SCE frequency value of the positive 
control d.ug (CP) was 4 6 0 ± 0 68 The 
value was highly significant compared to 
normal control. 
The data of SCE in human lymphocyte 
after hydrocortisone exposure in the pre-
sence of 59 mix has been described in 
Table-4. There was not any significant 
increase in SCE value observed at 10 /xg,ml 
(1 .78±0 16). Both the doses at 25 and 50 
/i^ g/ml of concentration in the presence of 
S9 mix enhanced the frequency of SCE. 
At 25 |Ltg/ml, the mean SCE frequency was 
3 94-1-0.37 which was significant at 
P < 0.05 when compared with that of the 
normal control SCE (1.56±0.18). A 
slightly decreased SCE frequency was 
observed and found significant with 50 
fj.g/m\ compared to normal control. The 
enhanced SCE at higher level of concentra-
tion of the drug may be due to the meta-
bolic activation by liver enzyme (S9 mix). 
An increased mean SCE frequency was 
observed byCP (6 50±1.30). 
Discussions 
Chromosome aberration assessment 
serves as a good indicator of the clastogenic 
effects of any genotoxic agent (Gebhart^ ,^ 
Buckton & Evans', Hsu*^). Present study 
very evidently established the clastogenic 
potential of hydrocortisone in human 
lymphocyte cultures, its effect was maxi-
mum at ^5 /xg/ml concentration. The 
highest concentration ( 50 /^ g/ml ) also 
caused clastogenicity but with a lesser 
magnitude This may be due to cell cycle 
delay and cell kilting effect caused by the 
drug at the highest concentration ( Bali 
etal.^). The present findings are further 
supported by the reports of Loeb et al.^^, 
Naumova^ and Rubin^ ) indicating the 
suppression of DNA snythesis, prevention 
of protein binding of the drug at its higher 
doses, reduction in mitotic cell population 
and induction of genetic damage after the 
hydrocortisone and other glucocorticoid 
treatment in man. 
Hydrocortisone also enhanced the 
frequency of chromosomal aberration in the 
presence of metabolic activation. 
SCE arise from DNA breaks and the 
reunion of broken exchanged fragments et 
almost homologous loci (Latt et al^^). We 
observed rise in the frequency of SCE with 
higher dose of hydrocortisone, but with 
lesser magnitude at the highest concentra-
tion. The effect was same even in the 
presence of metabolic activation. The rise 
may be due to the hydrocortisone's influ-
ence in increasing the number of DNA 
lesions. 
Because of the apparent relationship 
between chromosome abnormalities, muta-
genesis and carcinogenesis (Sendberg^^), 
in vivo and in vitro, screening for chromo-
some aberrations is an established tool in 
the evaluation of potential hazards to the 
genetic material due to environmental 
agents. The theoretical possibility of 
genetic damage during post-natal life will 
apply directly to the health of the drug 
user. Any mutational effect on adult 
Somatic calls could lead to cancer (Woiss 
era/.^*). People should, therefore be 
careful and aware of the potential hazards 
of such drugs, especially if they are conti-
nuously exposed to for such a long periods. 
Acknowledgements 
Authors express their gratitude to D|^  
Asim Azfer, Lecturer for his expert & 
valuable suggestions and incessant en-
couragement and the Chairman, Depart-
ment of Zoology for providing laboratory 
facilities. 
References 
1. Afzal, M. and M. A. Az/er, Chem. Env. Ret. 3 
(1&2) : 67-70 (1994). 
2. Azfer, M. A. and M Afzal, Bull Env. Sci XIII : 
35-37(1995). 
